EP4355782A1 - Anti canine cd20 antibodies - Google Patents
Anti canine cd20 antibodiesInfo
- Publication number
- EP4355782A1 EP4355782A1 EP22740459.7A EP22740459A EP4355782A1 EP 4355782 A1 EP4355782 A1 EP 4355782A1 EP 22740459 A EP22740459 A EP 22740459A EP 4355782 A1 EP4355782 A1 EP 4355782A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- sequence
- antibody
- variable region
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282465 Canis Species 0.000 title claims abstract description 164
- 238000009739 binding Methods 0.000 claims abstract description 227
- 230000027455 binding Effects 0.000 claims abstract description 226
- 108091007433 antigens Proteins 0.000 claims abstract description 207
- 102000036639 antigens Human genes 0.000 claims abstract description 207
- 239000000427 antigen Substances 0.000 claims abstract description 205
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 155
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 155
- 238000000034 method Methods 0.000 claims abstract description 63
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 47
- 230000001404 mediated effect Effects 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 203
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 203
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 201
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 199
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 199
- 210000004027 cell Anatomy 0.000 claims description 142
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 130
- 150000001413 amino acids Chemical class 0.000 claims description 90
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 39
- 150000007523 nucleic acids Chemical group 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 15
- 230000002147 killing effect Effects 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000011830 transgenic mouse model Methods 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 101710112752 Cytotoxin Proteins 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000336 radiotoxic Toxicity 0.000 claims description 2
- 230000001690 radiotoxic effect Effects 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 34
- 235000001014 amino acid Nutrition 0.000 description 108
- 229940024606 amino acid Drugs 0.000 description 97
- 239000002773 nucleotide Substances 0.000 description 61
- 125000003729 nucleotide group Chemical group 0.000 description 60
- 230000000875 corresponding effect Effects 0.000 description 57
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 43
- 241000282472 Canis lupus familiaris Species 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 210000004602 germ cell Anatomy 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 31
- 229940079593 drug Drugs 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000012634 fragment Substances 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 27
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 238000003556 assay Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 18
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 17
- 238000006206 glycosylation reaction Methods 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 241000283984 Rodentia Species 0.000 description 16
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 102100032768 Complement receptor type 2 Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000002998 immunogenetic effect Effects 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 7
- -1 FR3 Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000022534 cell killing Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 101100495231 Canis lupus familiaris MS4A1 gene Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 4
- 101150117115 V gene Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000003302 anti-idiotype Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 101150023212 fut8 gene Proteins 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000003720 plasmablast Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101150008942 J gene Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000012867 alanine scanning Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 102000011185 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 238000011493 immune profiling Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000948 non-nucleated cell Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150098873 MS4A1 gene Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108090000794 Streptopain Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- 239000000906 photoactive agent Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000027174 regulation of B cell differentiation Effects 0.000 description 1
- 230000021821 regulation of B cell proliferation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Canine lymphomas are among the most common cancers diagnosed in dogs, representing around 7-14% of all cancers. As in humans, there are many different types of canine lymphoma and vary from rapidly progressing cancer to chronic disease.
- CD20 is a cell-surface protein thought to be involved in regulation of B-cell proliferation and differentiation.
- the antigen comprises four transmembrane spanning regions and is present on the surface of almost all 13- cells, both normal and malignant.
- Human antibodies which recognise human CD20 are used to treat human diseases characterized by excessive numbers of B-cells, or overactive or dysfunctional B-cells. These antibodies destroy B-cells.
- Rituximab is viewed as a revolutionary advance in the treatment of B-cell lymphoma.
- the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 27, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 28, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No.
- LC CDR1 sequence comprising or consisting of SEQ ID No. 30 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 32.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR1 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR1 sequence comprising or consisting of SEQ ID No. 12.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22.
- the antibody has a HC CDR1 sequence comprising SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No. 41 and a LC CDR3 sequence comprising SEQ ID No. 42.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 82, a HC CDR2 sequence comprising or consisting of SEQ ID No. 83, a HC CDR3 sequence comprising or consisting of SEQ ID No. 84, a LC CDR1 sequence comprising or consisting of SEQ ID No. 85, a LC CDR2 sequence comprising or consisting of SEQ ID No. 86 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 87.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 92, a HC CDR2 sequence comprising or consisting of SEQ ID No. 93, a HC CDR3 sequence comprising or consisting of SEQ ID No. 94, a LC CDR1 sequence comprising or consisting of SEQ ID No. 95, a LC CDR2 sequence comprising or consisting of SEQ ID No. 96 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 97.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 102, a HC CDR2 sequence comprising or consisting of SEQ ID No. 103, a HC CDR3 sequence comprising or consisting of SEQ ID No. 104, a LC CDR1 sequence comprising or consisting of SEQ ID No. 105, a LC CDR2 sequence comprising or consisting of SEQ ID No. 106 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 107.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 112, a HC CDR2 sequence comprising or consisting of SEQ ID No. 113, a HC CDR3 sequence comprising or consisting of SEQ ID No. 114, a LC CDR1 sequence comprising or consisting of SEQ ID No. 115, a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 117.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 122, a HC CDR2 sequence comprising or consisting of
- SEQ ID No. 123 a HC CDR3 sequence comprising or consisting of SEQ ID No. 124, a LC CDR1 sequence comprising or consisting of SEQ ID No. 125, a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 127.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 132, a HC CDR2 sequence comprising or consisting of SEQ ID No. 133, a HC CDR3 sequence comprising or consisting of SEQ ID No. 134, a LC CDR1 sequence comprising or consisting of SEQ ID No. 135, a LC CDR2 sequence comprising or consisting of SEQ ID No. 136 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 137.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 142, a HC CDR2 sequence comprising or consisting of SEQ ID No. 143, a HC CDR3 sequence comprising or consisting of SEQ ID No. 144, a LC CDR1 sequence comprising or consisting of SEQ ID No. 145, a LC CDR2 sequence comprising or consisting of SEQ ID No. 146 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 147.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 152, a HC CDR2 sequence comprising or consisting of SEQ ID No. 153, a HC CDR3 sequence comprising or consisting of SEQ ID No. 154, a LC CDR1 sequence comprising or consisting of SEQ ID No. 155, a LC CDR2 sequence comprising or consisting of SEQ ID No. 156 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 157.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 162, a HC CDR2 sequence comprising or consisting of SEQ ID No. 163, a HC CDR3 sequence comprising or consisting of SEQ ID No. 164, a LC CDR1 sequence comprising or consisting of SEQ ID No. 165, a LC CDR2 sequence comprising or consisting of SEQ ID No. 166 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 167.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 172, a HC CDR2 sequence comprising or consisting of SEQ ID No. 173, a HC CDR3 sequence comprising or consisting of SEQ ID No. 174, a LC CDR1 sequence comprising or consisting of SEQ ID No. 175, a LC CDR2 sequence comprising or consisting of SEQ ID No. 176 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 177.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 182, a HC CDR2 sequence comprising or consisting of SEQ ID No. 183, a HC CDR3 sequence comprising or consisting of SEQ ID No. 184, a LC CDR1 sequence comprising or consisting of SEQ ID No. 185, a LC CDR2 sequence comprising or consisting of SEQ ID No. 186 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 187.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 192, a HC CDR2 sequence comprising or consisting of SEQ ID No. 193, a HC CDR3 sequence comprising or consisting of SEQ ID No. 194, a LC CDR1 sequence comprising or consisting of SEQ ID No. 195, a LC CDR2 sequence comprising or consisting of SEQ ID No. 196 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 197.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 202, a HC CDR2 sequence comprising or consisting of
- SEQ ID No. 203 a HC CDR3 sequence comprising or consisting of SEQ ID No. 204, a LC CDR1 sequence comprising or consisting of SEQ ID No. 205, a LC CDR2 sequence comprising or consisting of SEQ ID No. 206 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 207.
- the wherein said antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 212, a HC CDR2 sequence comprising or consisting of SEQ ID No. 213, a HC CDR3 sequence comprising or consisting of SEQ ID No. 214, a LC CDR1 sequence comprising or consisting of SEQ ID No. 215, a LC CDR2 sequence comprising or consisting of SEQ ID No. 216 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 217.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 222, a HC CDR2 sequence comprising or consisting of SEQ ID No. 223, a HC CDR3 sequence comprising or consisting of SEQ ID No. 224, a LC CDR1 sequence comprising or consisting of SEQ ID No. 225, a LC CDR2 sequence comprising or consisting of SEQ ID No. 226 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 227.
- the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 232, a HC CDR2 sequence comprising or consisting of SEQ ID No. 233, a HC CDR3 sequence comprising or consisting of SEQ ID No. 234, a LC CDR1 sequence comprising or consisting of SEQ ID No. 235, a LC CDR2 sequence comprising or consisting of SEQ ID No. 236 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 237.
- the antibody or antigen-binding portion thereof comprises a HC variable region sequence comprising SEQ ID NO. 24 or a sequence with at least 75%, 80%, 85% or 90% sequence identity thereto and a LC variable region sequence comprising SEQ ID NO. 26 or a sequence with at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity thereto.
- the antibody or antigen-binding portion thereof has a) a HC variable region sequence comprising SEQ ID NO. 4 and a LC variable region sequence comprising SEQ ID NO. 6; b) a HC variable region sequence comprising SEQ ID NO. 14 and a LC variable region sequence comprising SEQ ID NO. 16; c) a HC variable region sequence comprising SEQ ID NO. 34 and a LC variable region sequence comprising SEQ ID NO. 36; d) a HC variable region sequence comprising SEQ ID NO. 44 and a LC variable region sequence comprising SEQ ID NO. 46; e) a HC variable region sequence comprising SEQ ID NO. 79 and a LC variable region sequence comprising SEQ ID NO.
- LC variable region sequence comprising SEQ ID NO. 238; f) a HC variable region sequence comprising SEQ ID NO. 89 and a LC variable region sequence comprising SEQ ID NO. 91 or a LC variable region sequence comprising SEQ ID NO. 239; g) a HC variable region sequence comprising SEQ ID NO. 99 and a LC variable region sequence comprising SEQ ID NO. 101 or a LC variable region sequence comprising SEQ ID NO. 240; h) a HC variable region sequence comprising SEQ ID NO. 109 and a LC variable region sequence comprising SEQ ID NO. 111 or a LC variable region sequence comprising SEQ ID NO.
- a HC variable region sequence comprising SEQ ID NO. 119 and a LC variable region sequence comprising SEQ ID NO. 121 ; j) a HC variable region sequence comprising SEQ ID NO. 129 and a LC variable region sequence comprising SEQ ID NO. 131 or a LC variable region sequence comprising SEQ ID NO. 242; k) a HC variable region sequence comprising SEQ ID NO. 139 and a LC variable region sequence comprising SEQ ID NO. 141 or a LC variable region sequence comprising SEQ ID NO. 243;
- a HC variable region sequence comprising SEQ ID NO. 149 and a LC variable region sequence comprising SEQ ID NO. 151 or a LC variable region sequence comprising SEQ ID NO. 244; m) a HC variable region sequence comprising SEQ ID NO. 159 and a LC variable region sequence comprising SEQ ID NO. 161 or a LC variable region sequence comprising SEQ ID NO. 245; n) a HC variable region sequence comprising SEQ ID NO. 169 and a LC variable region sequence comprising SEQ ID NO. 171 ; o) a HC variable region sequence comprising SEQ ID NO. 179 and a LC variable region sequence comprising SEQ ID NO.
- LC variable region sequence comprising SEQ ID NO. 246; p) a HC variable region sequence comprising SEQ ID NO. 189 and a LC variable region sequence comprising SEQ ID NO. 191 or a LC variable region sequence comprising SEQ ID NO. 247; q) a HC variable region sequence comprising SEQ ID NO. 199 and a LC variable region sequence comprising SEQ ID NO. 201 a LC variable region sequence comprising SEQ ID NO. 248; r) a HC variable region sequence comprising SEQ ID NO. 209 and a LC variable region sequence comprising SEQ ID NO. 211 a LC variable region sequence comprising SEQ ID NO.
- HC variable region sequence comprising SEQ ID NO. 219 and a LC variable region sequence comprising SEQ ID NO. 221 ; or t) a HC variable region sequence comprising SEQ ID NO. 229 and a LC variable region sequence comprising SEQ ID NO. 231 a LC variable region sequence comprising SEQ ID NO. 250.
- the antigen-binding portion thereof is an scFv, Fv, heavy chain or single domain antibody.
- the invention also relates to an isolated canine antibody or antigen-binding portion thereof that binds to canine CD20 competing with an antibody or antigen-binding portion thereof as described above.
- the antibody or antigen-binding portion thereof is conjugated to a therapeutic moiety.
- the therapeutic moiety is a second antibody or antigen-binding portion thereof.
- the second antibody or antigen-binding portion thereof binds to a different target.
- the antibody or antigen-binding portion thereof is conjugated to a further moiety selected from a half life extending moiety, label, cytotoxin, liposome, nanoparticle or radioisotope.
- the said antibody or antigen-binding portion thereof is a-fucosylated.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising an antibody or antigen-binding portion thereof as described above.
- the invention also relates to a method of treating a condition mediated by B-cells in a canine subject in need thereof comprising administering an effective amount of the antibody or antigen-binding portion thereof as described above or a pharmaceutical composition as described above.
- condition mediated by B-cells is a B cell lymphoma or leukaemia.
- condition mediated by B-cells is an immune mediated disease.
- the immune mediated disease is an autoimmune disease.
- another therapeutic agent can be separately administered to the subject.
- the therapeutic agent is a cytotoxic agent or a radiotoxic agent.
- the therapeutic agent is an immunosuppressant.
- the therapeutic agent is an immunological modulating agent, such as a cytokine or a chemokine.
- the invention also relates to the antibody or antigen-binding portion as described above or the pharmaceutical composition as described above for use in the treatment of disease.
- the disease is a disease mediated by B-cells.
- the disease mediated by B-cells is a B cell lymphoma or leukaemia.
- the disease mediated by B-cells is an immune mediated disease.
- the immune mediated disease is an autoimmune disease.
- the invention also relates to a method of inhibiting tumor growth or metastasis comprising contacting a tumor cell with an effective amount of the antibody or antigen-binding portion thereof as described above or pharmaceutical composition as described above.
- the invention also relates to a method of killing a tumor cell expressing CD20, comprising contacting the cell with the antibody of as described above or a pharmaceutical composition as described above, such that killing of the cell expressing CD20 occurs.
- the tumor cell is a canine tumor cell.
- the invention also relates to a nucleic acid sequence that encodes an antibody or antibody antigen-binding portion thereof as described above.
- the nucleic acid sequence comprises a sequence selected from SEQ ID NOs. 3, 5, 13, 15, 23, 25, 33, 35, 43, 45, 78, 80, 88, 90, 98, 100, 108, 110, 118, 120, 128, 130, 138, 140, 148, 150, 158, 160, 168, 170, 178, 180, 188, 190, 198, 200, 208, 210, 218, 220, 228, 230, 251 , 252, 253, 254, 255, 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, 266, 267, 268, 269, 270,271 , 272, 273, 274, 275, 276, 277, 278, 279, 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, 290, 291 , 292, 293, 294, 295, 296, 297, 298, 299, 300 or 301.
- the invention also relates to a vector comprising a nucleic acid sequence as described above.
- the invention also relates to a host cell comprising the nucleic acid sequence as described above or a vector of as described above.
- the invention also relates to a kit comprising an antibody or antigen-binding portion thereof as described above or a pharmaceutical composition as described above.
- the invention also relates to a method for making a canine antibody that binds CD20 comprising culturing the isolated host cell as described above and recovering said antibody.
- the invention also relates to a method for making a canine antibody that binds CD20 comprising the steps of a) immunising a transgenic mouse that expresses a nucleic acid construct comprising canine heavy chain V genes and canine light chain V genes with CD20 antigen, b) generating a library of antibodies from said mouse and c) isolating an antibody from said library.
- the invention also relates to a method for detecting a CD20 protein or an extracellular domain of a CD20 protein in a biological sample from a canine subject, comprising contacting a biological sample with the antibody or antigen-binding portion thereof as described above wherein said antibody or antigen-binding portion thereof is linked to a detectable label.
- the biological sample is a biopsy, tissue, blood, serum, plasma, or lymphatic fluid sample.
- the invention also relates to an antibody or antigen binding portion thereof that binds canine at an epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. ISO- 159 in Seq ID NO: 2).
- FIG. 1 Antibody titre of canine CD20 immunised Ky9 mice. Post-immunisation sera were serially diluted (as shown) and added to canine CD20-expressing cells. Subsequently, the cells were incubated with fluorophore-conjugated anti-mouse lgG1 , lgG2a, lgG2b secondary antibodies and the samples were assessed on a flow cytometer. Binding of pre-immunisation sera to canine CD20-expressing cells is presented as the background line in the plot.
- FIG. 1 Amino acid sequence alignment of variable regions of PMX001 , PMX002, PMX003, PMX004 and PMX005 mAbs. The shading indicates the CDR1 , CDR2 and CDR3 regions in both heavy chain (HC) and light chain (LC) sequences of the mAbs.
- FIG. 3 Binding assessment of anti-canine CD20 mAbs using flow cytometry.
- ADCC activity of anti-canine CD20 antibodies Both native and a-fucosylated format of antibodies were analysed at a range of concentrations (as shown) in the ADCC assay.
- Rituximab-cIGGB chimeric antibody was used as the “isotype contro”l.
- F refers to the a-fucosylated format of the antibodies.
- EC50 values are also presented for each antibody.
- FIG. 6 B cell depletion efficiency of anti-canine CD20 mAbs in whole canine blood.
- Freshly drawn dog whole blood was diluted with culture media and incubated with 10 pg/ml of PMX001 , PMX003, 1 E4-clGGB, 4E1-7-CIGGB (see A), native or a-fucosylated format of PMX003 and 4E1-7-CIGGB antibodies, (see B), PMX003, PMX006, PMX007, PMX008, PMX009, PMX010, PMX011 (see C), or no antibody, for 24h.
- Rituximab-cIGGB was used as the “isotype control” (Iso Ctrl).
- “F” refers to the a-fucosylated format of the antibodies.
- FIG. 7 The B cell depletion efficiency of anti-canine CD20 mAbs in healthy Beagles.
- A-B Three healthy beagles for each test group were given the following antibodies by intravenous administration: Isotype control (rituximab-clgGB, 2.5 mg/kg), low dose of PMX003 (0.5 mg/kg), high dose of PMX003 (2.5 mg/kg) and low dose of a-fucosyslated PMX003 (0.5 mg/kg).
- “F” refers to a-fucosylated format of antibodies.
- the data shown here is representative of four technical repeats.
- C Three healthy beagles for each test group were given the following antibodies by intravenous administration: Isotype control (rituximab-clgGB, 2 mg/kg), low dose of PMX115 (0.5 mg/kg), high dose of PMX115 (2 mg/kg), low dose of PMX070 (0.5 mg/kg) and high dose of PMX070 (2 mg/kg).
- Isotype control rituximab-clgGB, 2 mg/kg
- PMX115 0.5 mg/kg
- PMX070 0.5 mg/kg
- HP dose of PMX070 0.5 mg/kg
- the percentage of CD21+ B cells in lymphocytes was analysed using flow cytometry on day 0, 1 , 4, 7, 14, 21 and 28.
- the data shown here is representative of four technical repeats.
- Figure 8 Epitope mapping strategy for anti-CD20 antibodies.
- A The canine CD20 extracellular domain sequence was mutated to the human CD20 sequence at equivalent locations in vectors DH01 -DH09.
- B The canine CD20 extracellular domain sequence was mutated to the murine CD20 sequence at equivalent locations in vectors DM01 -DM09.
- C Every residue in the small loop and every other residue in the large loop of canine CD20 extracellular domain was mutated to alanine, giving rise to vectors S01 -S09 and L01- L25. Mutated residues are highlighted in bold.
- Figure 9 Binding of PMX003, PMX115 and PMX070 mAbs to MDCK cells expressing dog-human chimeric CD20 or dog-mouse chimeric CD20 was evaluated by flow cytometry. Black bars of 01-09 in the figure represent binding to DH01-DH09 sequences shown in figure 8A and grey bars of 01-09 in the figure represent binding to DM01 -DM09 sequences shown in figure 8B. MDCK cells expressing wildtype canine CD20 were applied as positive controls and wildtype MDCK cells were used as negative controls.
- Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein.
- the nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
- the inventors have developed fully canine antibodies that bind specifically to canine CD20. These antibodies were generated in transgenic rodents expressing canine V, D, J genes. Therefore, the antibodies are less likely to be immunogenic for administration to canine subjects than caninized antibodies or chimeric antibodies. Furthermore, as these antibodies can be used directly, with no further modifications to their variable regions, there is no risk of reducing the affinity or otherwise compromising the antibody. Other technologies risk introducing development or efficacy liabilities through the ex vivo combination of antibody sequences of canine origin with that from another species, typically rodent. Thus, the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20.
- CD20 refers to the B-lymphocyte antigen CD20.
- the antibodies and antigen binding portions thereof bind specifically to wild type canine CD20 as defined in SEQ ID No. 1 (nucleotide sequence) and SEQ ID No. 2 (amino acid sequence).
- CD20 as used herein refers to canine CD20.
- B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans and canines, CD20 is encoded by the MS4A1 gene.
- CD20 binding molecule/protein/polypeptide/agent/moiety refers to a molecule capable of specifically binding to the canine CD20 antigen.
- the binding reaction may be shown by standard methods, for example with reference to a negative control test using an antibody of unrelated specificity.
- An antibody or antigen binding portion thereof of the invention including a multispecific, e.g. bispecific or trispecific, binding agent described herein, "which binds” or is “capable of binding” an antigen of interest, that is canine CD20, is one that binds the antigen with sufficient affinity such that the antibody or antigen binding portion thereof is useful as a therapeutic agent in targeting a cell or tissue expressing the antigen CD20 as described herein.
- the antibody or antigen binding portion thereof according to the invention bind specifically to canine CD20.
- binding to the CD20 antigen is measurably different from a non-specific interaction.
- the antibodies described herein do not cross react with mouse CD20.
- telomere binding or “specifically binds to” or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a KD for the target of at least about 10 -6 M, alternatively at least about 10 -7 M, alternatively at least about 10 -8 M, alternatively at least about 10 -9 M, alternatively at least about 10 _1 ° M, alternatively at least about 10 -11 M, alternatively at least about 10 -12 M, or lower.
- the KD is at least about 10 -8 M to about 10 _ 9 M, e.g. In one embodiment, the KD is in the nanomolar range.
- the term "specific binding” refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
- KD and KD are used interchangeably herein.
- antibody as used herein broadly refers to any immunoglobulin (Ig) molecule, or antigen binding portion thereof, comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule.
- Ig immunoglobulin
- each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as HCVR) and a heavy chain constant region.
- the heavy chain constant region is comprised of three domains, CH1 , CH2 and CH3.
- Each light chain is comprised of a light chain variable region or domain (abbreviated herein as LCVR) and a light chain constant region.
- the light chain constant region is comprised of one domain, CL.
- the heavy chain and light chain variable regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each heavy chain and light chain variable region is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
- Immunoglobulin molecules can generally be of any isotype, class or subclass.
- the CH3 domain according to the various aspects of the invention is a CH3 domain of the canine IgG subtype, for example IgG-A, IgG-B, IgG-C, and IgG-D.
- IgG heavy chains there are four IgG heavy chains referred to as A, B, C, and D. These heavy chains represent four different subclasses of dog IgG, which are referred to as IgG-A, IgG-B, IgG-C and IgG-D.
- the DNA and amino acid sequences of these four heavy chains were first identified by Tang et al. (Vet. Immunol. Immunopathol. 80: 259-270 (2001)).
- the amino acid and DNA sequences for these heavy chains are also available from the GenBank data bases (IgGA: accession number AAL35301 .1 , IgGB: accession number AAL35302.1 , IgGC: accession number AAL35303.1 , IgGD: accession number AAL35304.1).
- Canine antibodies also contain two types of light chains, kappa and lambda (GenBank accession number kappa light chain amino acid sequence ABY 57289.1 , GenBank accession number ABY 55569.1).
- the antibodies herein may have a lambda or kappa light chain. In one embodiment, the light chain is a lambda light chain.
- CDR refers to the complementarity-determining region within antibody variable sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1 , CDR2 and CDR3, for each of the variable regions.
- CDR set refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs can be defined differently according to different systems known in the art.
- the Kabat Complementarity Determining Regions are based on sequence variability and are the most commonly used (Kabat et al., (1971) Ann. NY Acad. Sci.
- a chimeric antibody is a recombinant protein that contains the variable domains including the complementarity determining regions (CDRs) of an antibody derived from one species, preferably a rodent or human antibody, while the constant domains of the antibody molecule are derived from those of a canine antibody.
- CDRs complementarity determining regions
- caninized antibody refers to forms of recombinant antibodies that contain sequences from both canine and non-canine (e.g., murine) antibodies.
- a caninized antibody will comprise substantially all of at least one or more typically, two variable domains in which all or substantially all of the hypervariable loops correspond to those of a non-canine immunoglobulin, and all or substantially all of the framework (FR) regions (and typically all or substantially all of the remaining frame) are those of a canine immunoglobulin sequence.
- a caninized antibody may comprise both the three heavy chain CDRs and the three light chain CDRS from a murine or human antibody together with a canine frame or a modified canine frame.
- a modified canine frame comprises one or more amino acids changes that can further optimize the effectiveness of the caninized antibody, e.g., to increase its binding to its target.
- the non-canine sequences e.g., of the hypervariable loops, may further be compared to canine sequences and as many residues changed to be as similar to authentic canine sequences as possible.
- fully canine antibodies of the present invention have canine variable regions and do not include full or partial CDRs orFRs from another species.
- fully canine antibodies as described herein have been obtained from transgenic mice comprising canine immunoglobulin sequences.
- Antibodies produced in these immunised mice are developed through in vivo B cell signalling and development to allow for natural affinity maturation including in vivo V(D)J recombination, in vivo junctional diversification, in vivo pairing of heavy and light chains and in vivo hypermutation.
- Fully canine antibodies produced in this way generate antibodies with optimal properties for developability, minimizing lengthy lead optimization prior to production at scale.
- fully canine antibodies present the lowest possible risk of immunogenicity when introduced into a patient animal which, in turn, facilitates a repeated dosing regime.
- fully canine antibodies of the present invention are, therefore, most likely to be efficacious therapies in a clinical context.
- the term canine antibody refers to a fully canine antibody.
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e.
- the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translation modifications (e.g., isomerizations, amidations, carbohydrate addition) that may be present in minor amounts.
- Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
- the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
- antigen binding site refers to the part of the antibody or antibody fragment that comprises the area that specifically binds to an antigen.
- An antigen binding site may be provided by one or more antibody variable domains.
- An antigen binding site is typically comprised within the associated VH and VL of an antibody or antibody fragment.
- epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or non-contiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope).
- Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
- An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14 or 15 amino acids in a unique spatial conformation.
- Methods for determining what epitopes are bound by a given antibody or antibody fragment i.e., epitope mapping by alanine-scanning mutagenesis or Pepscan) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides are tested for reactivity with a given antibody or antibody fragment.
- An antibody binds "essentially the same epitope" as a reference antibody, when the two antibodies recognize identical or sterically overlapping epitopes.
- the most widely used and rapid methods for determining whether two epitopes bind to identical or sterically overlapping epitopes are competition assays, which can be configured in different formats, using either labelled antigen or labelled antibody.
- the antibody or antigen binding portion thereof as described herein binds an epitope that comprises one or more amino residues, e.g. 1 to 19, e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18 or 19, of the following amino residues or consists of the following amino residues ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2).
- the epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO.
- the epitope is determined by site directed mutagenesis as shown in the examples, for example using alanine scanning.
- the epitope is a linear epitope.
- the epitope is a conformational epitope.
- the epitope includes a linear epitope in the large loop.
- the epitope further includes a conformational epitope in the small loop.
- the antibody is PMX003 or antigen binding portion thereof or an antibody with at least 80% sequence identity as described herein.
- the invention also relates to an antibody or antigen binding portion thereof binds an epitope that comprises one or more amino residues, e.g. 1 to 19, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9,10,11 , 12, 13, 14, 15, 16, 17, 18 or 19, of the following amino residues or consists of the following amino residues ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2).
- the epitope comprises one or more amino residues e.g. 1 to 10, e.g.
- the antibody or antigen binding portion thereof may have the sequences as described herein.
- the invention also relates to an antibody or antigen binding portion thereof that competes with an antibody or antigen binding portion thereof as described herein.
- Fv Framaizement variable
- Fab Fram antigen binding
- Fc Frament crystallisation
- the Fc fragment comprises the carboxy- terminal portions of both H chains held together by disulfides.
- the constant domains of the Fc fragment are responsible for mediating the effector functions of an antibody.
- the invention extends to antigen binding portions or antigen binding fragments of the antibody.
- binding portion and “fragment” are used interchangeably herein.
- An antibody fragment is a portion of an antibody, for example a F(ab')2, Fab, Fv, scFv, heavy chain, light chain, variable heavy (VH), variable light (VL) chain domain and the like.
- Functional fragments of a full-length antibody retain the target specificity of a full antibody.
- Recombinant functional antibody fragments such as Fab (Fragment, antibody), scFv (single chain variable chain fragments) and single domain antibodies (dAbs) have therefore been used to develop therapeutics as an alternative to therapeutics based on mAbs.
- the invention also extends to antibody mimetics that comprise a sequence as described herein.
- Fv is the minimum antibody fragment which contains a complete antigen- recognition and -binding site.
- This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non- covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
- Single-chain Fv also abbreviated as “sFv” or “scFv” are antibody fragments scFv fragments ( ⁇ 25kDa) that consist of the two variable domains, VH and VL connected into a single polypeptide chain.
- VH and VL domains are non-covalently associated via hydrophobic interactions and tend to dissociate.
- stable fragments can be engineered by linking the domains with a hydrophilic flexible linker to create a single chain Fv (scFv).
- the smallest antigen binding fragment is the single variable fragment, namely the variable heavy (VH) or variable light (VL) chain domain.
- VH and VL domains respectively are capable of binding to an antigen. Binding to a light chain/heavy chain partner respectively or indeed the presence of other parts of the full antibody is not required fortarget binding.
- the antigen-binding entity of an antibody reduced in size to one single domain (corresponding to the VH or VL domain), is generally referred to as a “single domain antibody” or “immunoglobulin single variable domain”.
- a single domain antibody ( ⁇ 12 to 15 kDa) has thus either the VH or VL domain, i.e. it does not have other parts of a full antibody.
- dAb for "domain antibodies” generally refers to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen.
- isolated refers to a moiety that is isolated from its natural environment.
- isolated refers to an antibody or fragment thereof that is substantially free of other antibodies, antibodies or antibody fragments.
- an isolated antibody may be substantially free of other cellular material and/or chemicals.
- the term "homology” or “identity” generally refers to the percentage of amino acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity.
- the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences.
- N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known.
- the percent identity between two amino acid sequences can be determined using well known mathematical algorithms.
- amino acid herein is meant one of the 20 naturally occurring amino acids or any non- natural analogues that may be present at a specific, defined position.
- Amino acid encompasses both naturally occurring and synthetic amino acids. Although in most cases, when the protein is to be produced recombinantly, only naturally occurring amino acids are used.
- a substitution of an amino acid residue with another amino acid residue in an amino acid sequence of heterodimeric protein or polypeptide as described herein (an antibody for example), is equivalent to "replacing an amino acid residue” with another amino acid residue and denotes that a particular amino acid residue at a specific position in the original (e.g.
- wild type / germline amino acid sequence has been replaced by (or substituted for) by a different amino acid residue. This can be done using standard techniques available to the skilled person, e.g. using recombinant DNA technology.
- the amino acids are changed relative to the native (wild type / germline) sequence as found in nature in the wild type (wt), but may be made in IgG molecules that contain other changes relative to the native sequence.
- wild type or WT or “native” herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations.
- a WT protein, polypeptide, antibody or immunoglobulin has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
- the antibody or antigen-binding portion thereof has one or more of the following properties: a) binds specifically to canine CD20; b) binds to canine CD20 with a KD as measured in the examples and for example as shown in the figures; c) shows cell killing, such as CDC and/or ADCC, in canine lymphoma cell lines expressing CD20, as measured in the examples; d) promotes antibody dependent cellular phagocytosis (ADCP); e) is capable of effectively depleting CD20 positive B cells in canine tissues; f) is capable of binding to cells expressing canine CD20; g) is capable of depleting cells expressing canine CD20, suitably by direct cell killing via apoptosis; h) provides good stability as shown in the examples; i) binds an epitope that comprises one or more amino residues e.g.
- ENLNLIKAPM SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO. 2
- ITISHFFKMENLNLIKAPM SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2
- j) has a stronger binding capacity (5-10 fold higher) to canine CD20 than benchmark test antibodies 1 E4 and 4E1-7, e.g. as shown in the examples
- k) has stronger ADCC and/or CDC activity than benchmark test antibodies 1 E4 and 4E1-7, e.g. as shown in the examples and in table 4 and/or
- the antibody or antigen-binding portion thereof according to the invention has one or more of the properties above and optionally one or more of the following properties: a) has CDC activity with an EC50 value of less than 20 nM; b) has ADCC activity with an EC50 value of less than 0.3 nM; c) has a transient expression yield more than 100 ug/ml; d) has a Tm1 as determined by Uncle higher than 58°C; e) provides in vivo cell killing in dog at a dose of about 0.5 mg/kg to 2.5 mg/kg; f) maintains B cell depletion in vivo in dog at a low level for at least 15 days and/or g) binds an epitope that comprises one or more amino residues e.g.
- ENLNLIKAPM SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO. 2
- ITISHFFKMENLNLIKAPM SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2.
- the inventors have found that the antibodies and antigen binding portions thereof show both CDC and ADCC activity, e.g. as demonstrated by the cell killing in canine lymphoma cell lines expressing CD20, as measured in the examples.
- the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a heavy chain (HC) CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto, c) a HC CDR3 sequence comprising or consisting of SEQ ID No.
- HC heavy chain
- LC CDR1 sequence comprising or consisting of SEQ ID No. 30 at least 60%, 70%, 80% or 90% sequence identity thereto
- LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto
- LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto.
- the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 27 b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an isolated canine antibody or antigen-binding portion thereof with CDRs as described above but which has one or more CDR which has 1 , 2, 3 or 4 amino acid substitutions compared to the CDR sequence mentioned above.
- the invention thus relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a heavy chain (HC) CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 27, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 28, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No.
- HC heavy chain
- LC CDR1 sequence comprising or consisting of SEQ ID No. 30 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 32.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR2 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 12.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No. 41 and a LC CDR3 sequence comprising SEQ ID No. 42.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 82, a HC CDR2 sequence comprising or consisting of SEQ ID No. 83, a HC CDR3 sequence comprising or consisting of SEQ ID No. 84, a LC CDR1 sequence comprising or consisting of SEQ ID No. 85, a LC CDR2 sequence comprising or consisting of SEQ ID No. 86 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 87.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 92, a HC CDR2 sequence comprising or consisting of SEQ ID No. 93, a HC CDR3 sequence comprising or consisting of SEQ ID No. 94, a LC CDR1 sequence comprising or consisting of SEQ ID No. 95, a LC CDR2 sequence comprising or consisting of SEQ ID No. 96 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 97.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 102, a HC CDR2 sequence comprising or consisting of SEQ ID No. 103, a HC CDR3 sequence comprising or consisting of SEQ ID No. 104, a LC CDR1 sequence comprising or consisting of SEQ ID No. 105, a LC CDR2 sequence comprising or consisting of SEQ ID No. 106 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 107.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 112, a HC CDR2 sequence comprising or consisting of SEQ ID No. 113, a HC CDR3 sequence comprising or consisting of SEQ ID No. 114, a LC CDR1 sequence comprising or consisting of SEQ ID No. 115, a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 117.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 122, a HC CDR2 sequence comprising or consisting of SEQ ID No. 123, a HC CDR3 sequence comprising or consisting of SEQ ID No. 124, a LC CDR1 sequence comprising or consisting of SEQ ID No. 125, a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 127.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 132, a HC CDR2 sequence comprising or consisting of SEQ ID No. 133, a HC CDR3 sequence comprising or consisting of SEQ ID No. 134, a LC CDR1 sequence comprising or consisting of SEQ ID No. 135, a LC CDR2 sequence comprising or consisting of SEQ ID No. 136 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 137.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No.
- a HC CDR2 sequence comprising or consisting of SEQ ID No. 143
- a HC CDR3 sequence comprising or consisting of SEQ ID No. 144
- a LC CDR1 sequence comprising or consisting of SEQ ID No. 145
- a LC CDR2 sequence comprising or consisting of SEQ ID No. 146
- a LC CDR3 sequence comprising or consisting of SEQ ID No. 147.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 152, a HC CDR2 sequence comprising or consisting of SEQ ID No. 153, a HC CDR3 sequence comprising or consisting of SEQ ID No. 154, a LC CDR1 sequence comprising or consisting of SEQ ID No. 155, a LC CDR2 sequence comprising or consisting of SEQ ID No. 156 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 157.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 162, a HC CDR2 sequence comprising or consisting of SEQ ID No. 163, a HC CDR3 sequence comprising or consisting of SEQ ID No. 164, a LC CDR1 sequence comprising or consisting of SEQ ID No. 165, a LC CDR2 sequence comprising or consisting of SEQ ID No. 166 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 167.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 172, a HC CDR2 sequence comprising or consisting of SEQ ID No. 173, a HC CDR3 sequence comprising or consisting of SEQ ID No. 174, a LC CDR1 sequence comprising or consisting of SEQ ID No. 175, a LC CDR2 sequence comprising or consisting of SEQ ID No. 176 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 177.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 182, a HC CDR2 sequence comprising or consisting of SEQ ID No. 183, a HC CDR3 sequence comprising or consisting of SEQ ID No. 184, a LC CDR1 sequence comprising or consisting of SEQ ID No. 185, a LC CDR2 sequence comprising or consisting of SEQ ID No. 186 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 187.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 192, a HC CDR2 sequence comprising or consisting of SEQ ID No. 193, a HC CDR3 sequence comprising or consisting of SEQ ID No. 194, a LC CDR1 sequence comprising or consisting of SEQ ID No. 195, a LC CDR2 sequence comprising or consisting of SEQ ID No. 196 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 197.
- the antibody or antigen-binding portion thereof a HC CDR1 sequence comprising or consisting of SEQ ID No. 202, a HC CDR2 sequence comprising or consisting of SEQ ID No. 203, a HC CDR3 sequence comprising or consisting of SEQ ID No. 204, a LC CDR1 sequence comprising or consisting of SEQ ID No. 205, a LC CDR2 sequence comprising or consisting of SEQ ID No. 206 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 207.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 212, a HC CDR2 sequence comprising or consisting of SEQ ID No. 213, a HC CDR3 sequence comprising or consisting of SEQ ID No. 214, a LC CDR1 sequence comprising or consisting of SEQ ID No. 215, a LC CDR2 sequence comprising or consisting of SEQ ID No. 216 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 217.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 222, a HC CDR2 sequence comprising or consisting of SEQ ID No. 223, a HC CDR3 sequence comprising or consisting of SEQ ID No. 224, a LC CDR1 sequence comprising or consisting of SEQ ID No. 225, a LC CDR2 sequence comprising or consisting of SEQ ID No. 226 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 227.
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 232, a HC CDR2 sequence comprising or consisting of SEQ ID No. 233, a HC CDR3 sequence comprising or consisting of SEQ ID No. 234, a LC CDR1 sequence comprising or consisting of SEQ ID No. 235, a LC CDR2 sequence comprising or consisting of SEQ ID No. 236 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 237.
- the antibody or antigen-binding portion thereof comprises a heavy chain (HC) variable region sequence comprising SEQ ID NO. 24 or a sequence with at least 75%, 80%, 85% or 90% sequence identity thereto and a light chain (LC) variable region sequence comprising SEQ ID NO. 26 or a sequence with at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity thereto.
- the antibody or antigen-binding portion thereof comprises a heavy chain (HC) variable region sequence comprising SEQ ID NO. 24 and a light chain (LC) variable region sequence comprising SEQ ID NO. 26 or a LC variable region sequence comprising SEQ ID NO.
- NVT sequence in FR1 of the LC variable region has been modified, for example an LC variable region with 1 , 2 or 3 amino acid modifications in FR1 , e.g. a LC variable region sequence comprising FR1 having SEQ ID NO. 60, 61 , 62, 63, 64 or 65 as described below or a LC variable region sequence comprising SEQ ID NO. 53, 54, 55, 56, 57 or 58.
- the antibody or antigen-binding portion thereof has a) a HC variable region sequence comprising or consisting of SEQ ID NO. 4 and a LC variable region sequence comprising or consisting of SEQ ID NO. 6; b) a HC variable region sequence comprising or consisting of SEQ ID NO. 14 and a LC variable region sequence comprising or consisting of SEQ ID NO. 16; c) a HC variable region sequence comprising SEQ ID NO. 34 and a LC variable region sequence comprising or consisting of SEQ ID NO. 36; d) a HC variable region sequence comprising or consisting of SEQ ID NO. 44 and a LC variable region sequence comprising or consisting of SEQ ID NO.
- a HC variable region sequence comprising SEQ ID NO. 79 and a LC variable region sequence comprising SEQ ID NO. 81 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 238; f) a HC variable region sequence comprising SEQ ID NO. 89 and a LC variable region sequence comprising SEQ ID NO. 91 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 239; g) a HC variable region sequence comprising SEQ ID NO. 99 and a LC variable region sequence comprising SEQ ID NO.
- LC variable region sequence comprising SEQ ID NO. 240; h) a HC variable region sequence comprising SEQ ID NO. 109 and a LC variable region sequence comprising SEQ ID NO. 111 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 241 ; i) a HC variable region sequence comprising SEQ ID NO. 119 and a LC variable region sequence comprising SEQ ID NO. 121 ; j) a HC variable region sequence comprising SEQ ID NO.
- LC variable region sequence comprising SEQ ID NO. 131 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 242; k) a HC variable region sequence comprising SEQ ID NO. 139 and a LC variable region sequence comprising SEQ ID NO. 141 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 243;
- a HC variable region sequence comprising SEQ ID NO. 149 and a LC variable region sequence comprising SEQ ID NO. 151 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 244; m) a HC variable region sequence comprising SEQ ID NO. 159 and a LC variable region sequence comprising SEQ ID NO. 161 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 245; n) a HC variable region sequence comprising SEQ ID NO. 169 and a LC variable region sequence comprising SEQ ID NO.
- a HC variable region sequence comprising SEQ ID NO. 179 and a LC variable region sequence comprising SEQ ID NO. 181 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 246; p) a HC variable region sequence comprising SEQ ID NO. 189 and a LC variable region sequence comprising SEQ ID NO. 191 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 247; q) a HC variable region sequence comprising SEQ ID NO.
- LC variable region sequence comprising SEQ ID NO. 201 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 248; r) a HC variable region sequence comprising SEQ ID NO. 209 and a LC variable region sequence comprising SEQ ID NO. 211 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 249; s) a HC variable region sequence comprising SEQ ID NO. 219 and a LC variable region sequence comprising SEQ ID NO.
- a HC variable region sequence comprising SEQ ID NO. 229 and a LC variable region sequence comprising SEQ ID NO. 231 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 250.
- the antigen-binding portion thereof is a F(ab')2, Fab, Fv, scFv, heavy chain, light chain, variable heavy (VH) domain or variable light (VL).
- the antibody or antigen-binding portion comprises a HC CDR1 sequence comprising or consisting of SEQ ID No. 27, a HC CDR2 sequence comprising or consisting of SEQ ID No. 28, a HC CDR3 sequence comprising or consisting of SEQ ID No. 29, a LCDR1 sequence comprising or consisting of SEQ ID No. 30, LC CDR2 sequence comprising or consisting of SEQ ID No. 31 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 32.
- the antibody or antigen-binding portion has framework regions which have 5 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 1 amino acid change in the light chain variable sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR2 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 12.
- the antibody or antigen-binding portion has framework regions which have 2 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 3 amino acid changes in light chain variable sequence as compared to the germline sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22.
- the antibody or antigen-binding portion has framework regions which have 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising
- the antibody or antigen-binding portion has framework regions which have 12 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52.
- the antibody or antigen-binding portion has framework regions which have 4 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in the light chain variable sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion has framework regions which have 1 to 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74).
- the antibody or antigen-binding portion has framework regions may have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74).
- the antibody or antigen-binding portion has framework regions which have 1 to 10 amino acid changes in the light chain variable sequence as compared to germline sequence (SEQ ID NO: 76).
- the antibody or antigen-binding portion has framework regions may have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid changes in the light chain variable sequence as compared to germline sequence (SEQ ID NO: 76).
- the invention also relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 112 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 112, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 113 or an amino acid sequence which has 1 , 2, 3, 4 or 5 amino acid differences compared to SEQ ID No. 113, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 114 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No.
- LC CDR1 sequence comprising or consisting of SEQ ID No. 115 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 124, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 116 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 117 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 117.
- the invention also relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 122 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 122, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 123 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 123, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 124 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No.
- LC CDR1 sequence comprising or consisting of SEQ ID No. 125 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 125
- LC CDR2 sequence comprising or consisting of SEQ ID No. 126 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 126
- LC CDR3 sequence comprising or consisting of SEQ ID No. 127 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 127.
- Amino acid changes as used herein are selected from amino acid substitutions, additions or deletions.
- an amino acid change is an amino acid substitution.
- the antibody is PMX001 , PMX002, PMX003, PMX004, PMX005, PMX 006, PMX 007, PMX 008, PMX 009, PMX 010, PMX 011 , PMX066, PMX067, PMX068, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078, PMX079, PMX080, PMX081 ,
- the antibody is selected from PMX001 , PMX002, PMX003, PMX004, PMX005, PMX066, PMX067, PMX068, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078, PMX079, PMX080 or PMX081.
- the antibody is selected from PMX003, PMX066, PMX069, PMX070, PMX078, or PMX081. In one embodiment, the antibody is selected from PMX010, PMX112, PMX115, PMX122 or PMX124. In one embodiment, the antibody is selected from PMX069, PMX070 or PMX115.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 3) that encodes for the corresponding amino acid sequence (SEQ ID NO: 4) and a light chain variable region nucleotide sequence (SEQ ID NO: 5) that encodes for the corresponding amino acid sequence (SEQ ID NO: 6).
- SEQ ID NO: 3 that encodes for the corresponding amino acid sequence
- SEQ ID NO: 5 that encodes for the corresponding amino acid sequence
- the CDR sequences are as follows: CDR1 (SEQ ID NO: 7), CDR2 (SEQ ID NO: 8) and CDR3 (SEQ ID NO: 9) of the heavy chain variable region and the CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 13) and a heavy chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15)
- the CDRs are: CDR1 (SEQ ID NO: 17), CDR2 (SEQ ID NO: 18) and CDR3 (SEQ ID NO: 19) of the heavy chain variable region and the CDR1 (SEQ ID NO: 20), CDR2 (SEQ ID NO: 21) and CDR3 (SEQ ID NO: 22) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 23) that encodes for the corresponding amino acid sequence (SEQ ID NO: 24) and a light chain variable region nucleotide sequence (SEQ ID NO: 25) that encodes for the corresponding amino acid sequence (SEQ ID NO: 26).
- SEQ ID NO: 23 a heavy chain variable region nucleotide sequence that encodes for the corresponding amino acid sequence
- SEQ ID NO: 25 a light chain variable region nucleotide sequence that encodes for the corresponding amino acid sequence
- the CDRs are: CDR1 (SEQ ID NO: 27), CDR2 (SEQ ID NO: 28) and CDR3 (SEQ ID NO: 29) of the heavy chain variable region and the CDR1 (SEQ ID NO: 30), CDR2 (SEQ ID NO: 31) and CDR3 (SEQ ID NO: 32) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 33) that encodes for the corresponding amino acid sequence (SEQ ID NO: 34) and a light chain variable region nucleotide sequence (SEQ ID NO: 35) that encodes for the corresponding amino acid sequence (SEQ ID NO: 36).
- SEQ ID NO: 33 a heavy chain variable region nucleotide sequence
- SEQ ID NO: 35 a light chain variable region nucleotide sequence that encodes for the corresponding amino acid sequence
- the CDRs are CDR1 (SEQ ID NO: 37), CDR2 (SEQ ID NO: 38) and CDR3 (SEQ ID NO: 39) of the heavy chain variable region and the CDR1 (SEQ ID NO: 40), CDR2 (SEQ ID NO: 41) and CDR3 (SEQ ID NO: 42) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 43) that encodes for the corresponding amino acid sequence (SEQ ID NO: 44) and a light chain variable region nucleotide sequence (SEQ ID NO: 45) that encodes for the corresponding amino acid sequence (SEQ ID NO: 46).
- SEQ ID NO: 43 heavy chain variable region nucleotide sequence
- SEQ ID NO: 45 light chain variable region nucleotide sequence
- the CDRs are CDR1 (SEQ ID NO: 47), CDR2 (SEQ ID NO: 48) and CDR3 (SEQ ID NO: 49) of the heavy chain variable region and the CDR1 (SEQ ID NO: 50), CDR2 (SEQ ID NO: 51) and CDR3 (SEQ ID NO: 52) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 78) that encodes for the corresponding amino acid sequence (SEQ ID NO: 79) and a light chain variable region nucleotide sequence (SEQ ID NO: 80) that encodes for the corresponding amino acid sequence (SEQ ID NO: 81).
- the CDRs are CDR1 (SEQ ID NO: 82), CDR2 (SEQ ID NO: 83) and CDR3 (SEQ ID NO: 84) of the heavy chain variable region and the CDR1 (SEQ ID NO: 85), CDR2 (SEQ ID NO: 86) and CDR3 (SEQ ID NO: 87) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 88) that encodes for the corresponding amino acid sequence (SEQ ID NO: 89) and a light chain variable region nucleotide sequence (SEQ ID NO: 90) that encodes for the corresponding amino acid sequence (SEQ ID NO: 91).
- the CDRs are CDR1 (SEQ ID NO: 92), CDR2 (SEQ ID NO: 93) and CDR3 (SEQ ID NO: 94) of the heavy chain variable region and the CDR1 (SEQ ID NO: 95), CDR2 (SEQ ID NO: 96) and CDR3 (SEQ ID NO: 97) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 98) that encodes for the corresponding amino acid sequence (SEQ ID NO: 99) and a light chain variable region nucleotide sequence (SEQ ID NO: 100) that encodes for the corresponding amino acid sequence (SEQ ID NO: 101).
- the CDRs are CDR1 (SEQ ID NO: 102), CDR2 (SEQ ID NO: 103) and CDR3 (SEQ ID NO: 104) of the heavy chain variable region and the CDR1 (SEQ ID NO: 105), CDR2 (SEQ ID NO: 106) and CDR3 (SEQ ID NO: 107) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 108) that encodes for the corresponding amino acid sequence (SEQ ID NO: 109) and a light chain variable region nucleotide sequence (SEQ ID NO: 110) that encodes for the corresponding amino acid sequence (SEQ ID NO: 111).
- the CDRs are CDR1 (SEQ ID NO: 112), CDR2 (SEQ ID NO: 113) and CDR3 (SEQ ID NO: 114) of the heavy chain variable region and the CDR1 (SEQ ID NO: 115), CDR2 (SEQ ID NO: 116) and CDR3 (SEQ ID NO: 117) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 118) that encodes for the corresponding amino acid sequence (SEQ ID NO: 119) and a light chain variable region nucleotide sequence (SEQ ID NO: 120) that encodes for the corresponding amino acid sequence (SEQ ID NO: 121).
- the CDRs are CDR1 (SEQ ID NO: 122), CDR2 (SEQ ID NO: 123) and CDR3 (SEQ ID NO: 124) of the heavy chain variable region and the CDR1 (SEQ ID NO: 125), CDR2 (SEQ ID NO: 126) and CDR3 (SEQ ID NO: 127) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 128) that encodes for the corresponding amino acid sequence (SEQ ID NO: 129) and a light chain variable region nucleotide sequence (SEQ ID NO: 130) that encodes for the corresponding amino acid sequence (SEQ ID NO: 131).
- the CDRs are CDR1 (SEQ ID NO: 132), CDR2 (SEQ ID NO: 133) and CDR3 (SEQ ID NO: 134) of the heavy chain variable region and the CDR1 (SEQ ID NO: 135), CDR2 (SEQ ID NO: 136) and CDR3 (SEQ ID NO: 137) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 138) that encodes for the corresponding amino acid sequence (SEQ ID NO: 139) and a light chain variable region nucleotide sequence (SEQ ID NO: 140) that encodes for the corresponding amino acid sequence (SEQ ID NO: 141).
- the CDRs are CDR1 (SEQ ID NO: 142), CDR2 (SEQ ID NO: 143) and CDR3 (SEQ ID NO: 144) of the heavy chain variable region and the CDR1 (SEQ ID NO: 145), CDR2 (SEQ ID NO: 146) and CDR3 (SEQ ID NO: 147) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 148) that encodes for the corresponding amino acid sequence (SEQ ID NO: 149) and a light chain variable region nucleotide sequence (SEQ ID NO: 150) that encodes for the corresponding amino acid sequence (SEQ ID NO: 151).
- the CDRs are CDR1 (SEQ ID NO: 152), CDR2 (SEQ ID NO: 153) and CDR3 (SEQ ID NO: 154) of the heavy chain variable region and the CDR1 (SEQ ID NO: 155), CDR2 (SEQ ID NO: 156) and CDR3 (SEQ ID NO: 157) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 158) that encodes for the corresponding amino acid sequence (SEQ ID NO: 159) and a light chain variable region nucleotide sequence (SEQ ID NO: 160) that encodes for the corresponding amino acid sequence (SEQ ID NO: 161).
- the CDRs are CDR1 (SEQ ID NO: 162), CDR2 (SEQ ID NO: 163) and CDR3 (SEQ ID NO: 164) of the heavy chain variable region and the CDR1 (SEQ ID NO: 165), CDR2 (SEQ ID NO: 166) and CDR3 (SEQ ID NO: 167) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 168) that encodes for the corresponding amino acid sequence (SEQ ID NO: 169) and a light chain variable region nucleotide sequence (SEQ ID NO: 170) that encodes for the corresponding amino acid sequence (SEQ ID NO: 171).
- the CDRs are CDR1 (SEQ ID NO: 172), CDR2 (SEQ ID NO: 173) and CDR3 (SEQ ID NO: 174) of the heavy chain variable region and the CDR1 (SEQ ID NO: 175), CDR2 (SEQ ID NO: 176) and CDR3 (SEQ ID NO: 177) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 178) that encodes for the corresponding amino acid sequence (SEQ ID NO: 179) and a light chain variable region nucleotide sequence (SEQ ID NO: 180) that encodes for the corresponding amino acid sequence (SEQ ID NO: 181).
- the CDRs are CDR1 (SEQ ID NO: 182), CDR2 (SEQ ID NO: 183) and CDR3 (SEQ ID NO: 184) of the heavy chain variable region and the CDR1 (SEQ ID NO: 185), CDR2 (SEQ ID NO: 186) and CDR3 (SEQ ID NO: 187) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 188) that encodes for the corresponding amino acid sequence (SEQ ID NO: 189) and a light chain variable region nucleotide sequence (SEQ ID NO: 190) that encodes for the corresponding amino acid sequence (SEQ ID NO: 191).
- the CDRs are CDR1 (SEQ ID NO: 192), CDR2 (SEQ ID NO: 193) and CDR3 (SEQ ID NO: 194) of the heavy chain variable region and the CDR1 (SEQ ID NO: 195), CDR2 (SEQ ID NO: 196) and CDR3 (SEQ ID NO: 197) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 198) that encodes for the corresponding amino acid sequence (SEQ ID NO: 199) and a light chain variable region nucleotide sequence (SEQ ID NO: 200) that encodes for the corresponding amino acid sequence (SEQ ID NO: 201).
- the CDRs are CDR1 (SEQ ID NO: 202), CDR2 (SEQ ID NO: 203) and CDR3 (SEQ ID NO: 204) of the heavy chain variable region and the CDR1 (SEQ ID NO: 205), CDR2 (SEQ ID NO: 206) and CDR3 (SEQ ID NO: 207) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 208) that encodes for the corresponding amino acid sequence (SEQ ID NO: 209) and a light chain variable region nucleotide sequence (SEQ ID NO: 210) that encodes for the corresponding amino acid sequence (SEQ ID NO: 211).
- the CDRs are CDR1 (SEQ ID NO: 212), CDR2 (SEQ ID NO: 213) and CDR3 (SEQ ID NO: 214) of the heavy chain variable region and the CDR1 (SEQ ID NO: 215), CDR2 (SEQ ID NO: 216) and CDR3 (SEQ ID NO: 217) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 218) that encodes for the corresponding amino acid sequence (SEQ ID NO: 219) and a light chain variable region nucleotide sequence (SEQ ID NO: 220) that encodes for the corresponding amino acid sequence (SEQ ID NO: 221).
- the CDRs are CDR1 (SEQ ID NO: 222), CDR2 (SEQ ID NO: 223) and CDR3 (SEQ ID NO: 224) of the heavy chain variable region and the CDR1 (SEQ ID NO: 225), CDR2 (SEQ ID NO: 226) and CDR3 (SEQ ID NO: 227) of the light chain variable region.
- the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 228) that encodes for the corresponding amino acid sequence (SEQ ID NO: 229) and a light chain variable region nucleotide sequence (SEQ ID NO: 230) that encodes for the corresponding amino acid sequence (SEQ ID NO: 231).
- the CDRs are CDR1 (SEQ ID NO: 232), CDR2 (SEQ ID NO: 233) and CDR3 (SEQ ID NO: 234) of the heavy chain variable region and the CDR1 (SEQ ID NO: 235), CDR2 (SEQ ID NO: 236) and CDR3 (SEQ ID NO: 237) of the light chain variable region.
- the antibody or antigen-binding portion thereof comprises an Fc region, for example a canine Fc region, for example a canine IgGB Fc region.
- variable region sequences described herein including but not limited to the amino acid and nucleotide sequences shown in Table 2 (and / or fragments thereof) may be used in combination with one or more amino acid sequences and / or nucleotide sequences encoding one or more constant chains (and / or a fragment thereof) of an antibody molecule.
- the variable region amino acid sequences shown in Table 2 may be joined to the constant regions of any antibody molecule of the same or a different species (e.g., human, goat, rat, sheep, chicken) of that from which the variable region amino acid sequence was derived.
- variable region amino acid sequences shown in Table 2 is joined to the constant regions of a canine antibody and may be the constant region from any of canine IgG A, B, C or D.
- the constant region is canine IgG B constant region.
- Dog IGGB (SEQ ID NO: 66), dog IGK (SEQ ID NO: 73) or dog IGLC5 (SEQ ID NO: 67) constant regions may be used. Also within the scope of the invention are variants of the antibodies and antigen binding portions as described above.
- a variant of an antibody or antigen binding portion thereof as described herein has at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the non-variant molecule.
- sequence identity is at least 95%.
- the modification is a conservative sequence modification.
- conservative sequence modifications is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody or antigen binding portion thereof of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- one or more amino acid residues within the CDR regions of an antibody of the invention can be replaced with other amino acid residues from the same side chain family and the altered antibody can be tested for retained function (i.e. , CD20 binding) using the functional assays described herein.
- amino acid changes can typically be made without altering the biological activity, function, or other desired property of the polypeptide, such as its affinity or its specificity for antigen.
- single amino acid substitutions in nonessential regions of a polypeptide do not substantially alter biological activity.
- substitutions of amino acids that are similar in structure or function are less likely to disrupt the polypeptides' biological activity.
- Abbreviations for the amino acid residues that comprise polypeptides and peptides described herein, and conservative substitutions for these amino acid residues are shown in Table 1 below.
- the invention provides an antibody or antigen binding portion thereof that is a variant of an antibody or antigen binding portion thereof compared to a sequence described herein, e.g. selected from SEQ ID NO. 3 to 65 or SEQ ID NO. 78 to 237 that comprises one or more sequence modification and has improvements in one or more of a property such as binding affinity, specificity, thermostability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility as compared to the unmodified antibody or fragment thereof.
- a property such as binding affinity, specificity, thermostability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility as compared to the unmodified antibody or fragment thereof.
- Suitable methods for measuring properties which may suggest that the antibody can be successfully developed at scale include first purification using chromatography, such as affinity chromatography chromatography (Protein A: MabSelect Sure LX), anion exchange chromatography (Capto Q), cation exchange chromatography (Capto S) and buffer exchange (G-25 Fine), followed by assessment of whether the antibody remains intact (e.g. using SDS PAGE analysis to determine molecular weight, HPLC-SEC to calculate % of monomers, assess aggregation, and thermostability (Tm) studies.
- chromatography such as affinity chromatography chromatography (Protein A: MabSelect Sure LX), anion exchange chromatography (Capto Q), cation exchange chromatography (Capto S) and buffer exchange (G-25 Fine)
- SDS PAGE analysis to determine molecular weight
- HPLC-SEC HPLC-SEC to calculate % of monomers
- Tm thermostability
- the framework region 1 (FR1) of the light chain of PMX003 contains the NVT sequon, which is a consensus sequence for asparagine-linked glycosylation of proteins.
- NVT sequon is a consensus sequence for asparagine-linked glycosylation of proteins.
- the NVT sequon in the FR1 of PMX003 mAb was mutated to QVT for PMX006 mAb, AVT for PMX007 mAb, EVT for PMX008 mAb, NVA for PMX009 mAb, SVT for PMX010 mAb and TVT for PMX011 mAb.
- modifications are within the scope of the invention.
- the resulted light chain variable region amino acid sequences of PMX006 mAb (SEQ ID NO: 53), PMX007 mAb (SEQ ID NO: 54), PMX008 mAb (SEQ ID NO: 55), PMX009 mAb (SEQ ID NO: 56), PMX010 mAb (SEQ ID NO: 57), PMX011 mAb (SEQ ID NO: 58) and the FR1 sequences of PMX003 (SEQ ID NO: 59), PMX006 mAb (SEQ ID NO: 60), PMX007 mAb (SEQ ID NO: 61), PMX008 mAb (SEQ ID NO: 62), PMX009 mAb (SEQ ID NO: 63), PMX010 mAb (SEQ ID NO: 64), PMX011 mAb (SEQ ID NO: 65) are within the scope of the invention and are listed in the Sequences Table 2.
- the LC FR1 sequence for PMX003 is shown in SEQ ID NO. 59, the modified LC FR1 sequences in SEQ ID Nos. 60, 61 , 62, 63, 64 and 65.
- the NVT sequon is found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 (SEQ ID NO:6, SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:36, SEQ ID NO:46) and PMX066 to PMX0081 (SEQ ID NO:81 , SEQ ID NO:91 , SEQ ID NO:101 , SEQ ID NO:111 , SEQ ID NO:121 , SEQ ID NO:131 , SEQ ID NO:141 , SEQ ID NO:151 , SEQ ID NO:161 , SEQ ID NO:171 , SEQ ID NO:181 , SEQ ID NO:191 , SEQ ID NO:201 , SEQ ID NO:211 , SEQ ID NO:221 , SEQ ID NO:231).
- the NVT sequon found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 or PMX066 to PMX081 may be mutated to a sequence selected from: QVT, AVT, EVT, NVA, SVT, TVT.
- the NVT sequon found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 or PMX066 to PMX081 is mutated to SVT.
- the light chain of these can be used with their respective heavy chain counterpart, e.g. the HC of PMX066 (SEQ ID NO: 79) may be used with the modified LC (SEQ ID NO: 238) and so forth.
- the resulting light chain variable region amino acid sequences of PMX112 mAb (SEQ ID NO: 238), PMX113 mAb (SEQ ID NO: 239), PMX114 mAb (SEQ ID NO: 240), PMX115 mAb (SEQ ID NO: 241), PMX116 mAb (SEQ ID NO: 242), PMX117 mAb (SEQ ID NO: 243), PMX118 mAb (SEQ ID NO: 244), PMX119 mAb (SEQ ID NO: 245), PMX120 mAb (SEQ ID NO: 246), PMX121 mAb (SEQ ID NO: 247), PMX122 mAb (SEQ ID NO: 248), PMX123 mAb (SEQ ID NO: 249) and PMX124 mAb (SEQ ID NO: 250) are within the scope of the invention and are listed in the Sequences Table.
- modifications can be made to decrease the immunogenicity of the antibody.
- one approach is to revert one or more framework residues to the corresponding canine germline sequence.
- an antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived. In one embodiment, all framework sequences are germline sequence.
- the somatic mutations can be "backmutated" to the germline sequence by, for example, site- directed mutagenesis or PCR-mediated mutagenesis.
- Another type of framework modification involves mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T cell epitopes to thereby reduce the potential immunogenicity of the antibody.
- the antigen-binding proteins, fragments and derivatives thereof, and fusion proteins of the present disclosure undergo post-translational modifications, for example but not limited to, a glutamine can be cyclized or converted to pyroglutamic acid; additionally, or alternatively, amino acids can undergo deamidation, isomerization, glycation and/or oxidation.
- the polypeptides of the present disclosure can undergo additional post-translational modification, including glycosylation, for example N- linked or O-linked glycosylation, at sites that are well-known in the art. Changes can be made in the amino acid sequence of a polypeptide to preclude or minimize such alterations, or to facilitate them in circumstances where such processing is beneficial.
- Polypeptides of the present disclosure include polypeptides that have been modified, for example, to: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties.
- glycosylation is modified.
- an aglycoslated antibody can be made (i.e. , the antibody lacks glycosylation).
- the light chain variable region amino acid sequences of the aglycosylated antibody comprises SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58.
- FR1 sequences are provided as SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61 , SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 , or SEQ ID NO: 65.
- Glycosylation can also be altered to, for example, increase the affinity of the antibody for antigen.
- Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site.
- Such aglycosylation may increase the affinity of the antibody for the antigen.
- the binding agents may bind canine CD20 but have altered ability to bind Fc receptors as compared to standard binding agents.
- the binding agents are antibodies that have modified glycosylation patterns.
- IgG molecules for example, typically contain N-linked oligosaccharides, for example fucose.
- the antibody or antigen-binding portion thereof is a-fucosylated.
- antibodies may rely on the Fc-mediated immune effector function, antibody-dependent cellular cytotoxicity (ADCC), as the major mode of action to deplete tumor cells.
- ADCC antibody-dependent cellular cytotoxicity
- this effector function is modulated by the N-linked glycosylation in the Fc region of the antibody.
- absence of core fucose on the Fc N-glycan has been shown to increase lgG1 Fc binding affinity to the FcyRIIIa present on immune effector cells such as natural killer cells and lead to enhanced ADCC activity.
- a-fucosylated antibodies may have advantageous to improve therapeutic efficacy and absence / removal of the fucose enhances the ability of the antibody to interact with Fc receptors.
- Antibodies of this type may be referred to as "a-fucosylated".
- Such antibodies may be produced using techniques described herein and / or that may be known in the art.
- a nucleic acid sequence encoding an antibody may be expressed in a cell line that has modified glycosylation abilities (e.g., deleted, modified or lesser amount of fucosyl transferase) and fail to add the typical fucose moieties.
- the antibody or antigen-binding portion thereof has a CDC activity with an EC50 value in the 0.9-4.5 ug/ml (6-30nM) range, e.g. less than 20 nM.
- the antibody or antigen-binding portion thereof has an ADCC activity with an EC50 value of less than 0.3 nM, e.g 0.013 ug/ml (0.09nM).
- the antibody or antigen-binding portion thereof according to the invention has one or more of the following properties: a) has CDC activity with an EC50 value of less than 20 nM; b) has ADCC activity with an EC50 value of less than 0.3 nM; c) has a transient expression yield more than 100 ug/ml; d) has a Tm1 as determined by Uncle higher than 58°C and/or e) provides in vivo cell killing in dog at a dose of about 0.5 mg/kg to 2.5 mg/kg f) maintains B cell depletion in vivo in dog at a low level for at least 15 days and/or g) binds an epitope that comprises one or more amino residues e.g.
- ENLNLIKAPM SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO: 2
- ITISHFFKMENLNLIKAPM SEQ ID NO. 302 amino acid No. 141-159 in Seq ID NO: 2.
- ADCC and CDC activity may be measured as described in the examples.
- the antibody and antigen binding portion thereof shows both CDC and ADCC activity, e.g. as demonstrated by the cell killing in canine lymphoma cell lines expressing CD20, as measured in the examples.
- the antibody or antigen-binding portion thereof has one or more of the properties as set out above and has the HC CDRs and LC CDRs and/or the HC and LC CDRS of PMX069, PMX115 or PMX070. In one embodiment, the antibody or antigen-binding portion thereof is selected from PMX069, PMX115 or PMX070.
- the antibody is the antibody described in Table 4 or an antigen-binding portion thereof and has an EC50 value for ADCC or CDC as shown in that table. EC50 values may be measured as described in the examples.
- the Fc portion of the antibody may be modified.
- the one or more substitution in the variant is in the CDR1 , 2 and/or 3 region.
- the one or more substitution is in the framework region.
- the antibodies of the invention preferably have KD, IC50 and/or EC50 values, e.g. a KD as further described herein in the examples.
- the KD value is sufficient for the antibodies to have the desired biological effect.
- the KD can be least about 10 pM to 100 uM, about 100 pM to 10 nM or higher.
- the EC50 value may be as in Table 4, for example 0.12 to 0.89 nM. KD, IC50 and/or EC50 values may be measured as described in the examples.
- KD refers to the "equilibrium dissociation constant” and refers to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (Koff) by the association rate constant (Kon).
- KA refers to the affinity constant.
- the association rate constant, the dissociation rate constant and the equilibrium dissociation constant are used to represent the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore® SPR assay can be used.
- the invention also relates to an isolated canine antibody or antigen-binding portion thereof that binds to canine CD20 competing with an antibody or antigen-binding portion thereof as described above.
- Antibodies, antibody fragments or antibody mimetics that bind at or near the same epitope or an overlapping epitope on canine CD20 as any of the CD20 antibodies of the invention have the ability to cross- compete for binding to CD20 with any of the antibodies of the invention.
- the antibodies of the invention can thus be used as a reference antibody to assess such cross-reactivity.
- Such cross-competing antibodies can be identified based on their ability to cross-compete with an antibody described herein in standard CD20 binding assays. For example, BIAcore® analysis, ELISA assays or flow cytometry may be used to demonstrate cross-competition with the antibodies.
- the invention also relates to a nucleic acid sequence that encodes an amino acid sequence of an antibody or antigen binding portion thereof as described herein, e.g. a HC variable region or LC variable region. Exemplary sequences are described in table 2.
- said nucleic acid is selected from SEQ ID NOs. 3, 5, 13, 15, 23, 25, 33, 35, 43, 45, 78, 80, 88, 90, 98, 100, 108, 110, 118, 120, 128, 130, 138, 140, 148, 150, 158, 160, 168, 170, 178, 180, 188, 190, 198, 200, 208, 210, 218, 220, 228, 230, 251 , 252, 253,
- nucleic acid sequence is linked with a linker to a second nucleic acid sequence.
- said second nucleic acid encodes an additional therapeutic moiety.
- linker is a nucleic acid linker.
- Codon optimised nucleotide sequences are also within the scope of the invention, including SEQ ID NOs. 68 and 69.
- a nucleic acid according to the present invention may comprise DNA or RNA and may be wholly or partially synthetic or recombinantly produced.
- Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.
- the invention relates to a nucleic acid construct comprising at least one nucleic acid as defined above.
- the construct may be in the form of a plasmid, vector, transcription or expression cassette.
- the invention also relates to a vector that comprises a nucleic acid encoding the CD20 binding molecules as described herein.
- the term “vector” refers to a nucleic acid molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, or vims, into which a nucleic acid sequence may be inserted or cloned.
- a vector preferably contains one or more unique restriction sites and may be capable of autonomous replication in a defined host cell including a target cell or tissue or a progenitor cell or tissue thereof, or be integrable with the genome of the defined host such that the cloned sequence is reproducible.
- the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
- the vector may contain any means for assuring self-replication.
- the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
- a vector system may comprise a single vector or plasmid, two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
- the choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.
- the vector may also include a selection marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. Examples of such resistance genes are well known to those of skill in the art.
- the vector is an adeno-associated virus (AAV) vector, such as those described in WO2021176362.
- AAV adeno-associated virus
- the nucleic acid may also comprise a leader sequence. In another embodiment, it does not comprise a leader sequence. Any suitable leader sequences may be used including the native immunoglobulin germline leader sequence, such as SEQ ID NO: 71 for heavy chain, SEQ ID NO: 72 for light chain of PMX001 to PMX005 and PMX066 to PMX081 mAbs, or others, such as the Campath leader sequence (SEQ ID NO: 70) (see US 8,362,208 B2), may be chosen to enhance protein expression.
- the native immunoglobulin germline leader sequence such as SEQ ID NO: 71 for heavy chain, SEQ ID NO: 72 for light chain of PMX001 to PMX005 and PMX066 to PMX081 mAbs, or others, such as the Campath leader sequence (SEQ ID NO: 70) (see US 8,362,208 B2), may be chosen to enhance protein expression.
- the nucleic acid may also comprise a signal peptide, i.e. a short amino acid sequence (13-36 amino acids) on the N-terminus of a secretory protein (like an immunoglobulin) that mediates the translocation of a protein destined for secretion through the first membrane of the secretory pathway.
- a signal peptide i.e. a short amino acid sequence (13-36 amino acids) on the N-terminus of a secretory protein (like an immunoglobulin) that mediates the translocation of a protein destined for secretion through the first membrane of the secretory pathway.
- This sequence is not present in the mature protein, being cleaved in a co-translational event, but mediates the secretion and correct expression of the protein.
- Suitable signal sequences can be used to optimize the expression of a recombinant protein.
- the invention also relates to an isolated recombinant host cell comprising one or more nucleic acid construct as described above.
- Host cells useful in the present invention are prokaryotic, yeast, or higher eukaryotic cells and include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g.
- Baculovirus containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).
- recombinant virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV
- plasmid expression vectors e.g., Ti plasmid
- mammalian cell systems e.g., COS
- Prokaryotes useful as host cells in the present invention include gram negative or gram-positive organisms such as E. coli, B. subtilis, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, Serratia, and Shigella, as well as Bacilli, Pseudomonas, and Streptomyces.
- One cloning host is E. coli 294 (ATCC 31 ,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31 ,537), and E. coli W3110 (ATCC 27,325) are suitable.
- a method of making an anti- CD20 antibody as described herein is provided, wherein the method comprises culturing the host cell under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
- Nucleic acids encoding antibodies can be used to administer an antibody to an individual in order to produce their encoded protein in vivo and mediate a therapeutic effect.
- Delivery of polynucleotides into a subject can be direct such that polynucleotides or expression vectors are administered to an individual e.g. through introduction of mRNA or DNA directly into cells e.g. muscle cells. Indirect introduction is also envisaged where polynucleotides are transformed into cells in vitro prior to administration. Viral vectors, such as defective or attenuated viruses, may also be used.
- a method of making an anti- CD20 antibody as described herein comprises culturing the host cell under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
- the invention also relates to a heterologous assay or expression system comprising a canine CD20 and a cell line derived from a different species, e.g. a human cell line such as HEK.
- a heterologous assay or expression system comprising a canine CD20 and a cell line derived from a different species, e.g. a human cell line such as HEK.
- the assay comprises contacting a canine CD20 with a cell line derived from a different species, e.g. a cell line from a different mammal, e.g. a rodent cell line or a human cell line such as HEK.
- a cell line derived from a different species, e.g. a cell line from a different mammal, e.g. a rodent cell line or a human cell line such as HEK.
- the cell line is transfected with canine CD20 such that it expresses canine CD20 in a stable or transient manner.
- the invention relates to immunoconjugates and other binding agents comprising the antibody or antigen binding portion thereof according to the invention.
- the antibody or antigen-binding portion thereof according to the invention may be conjugated to a therapeutic moiety or non-therapeutic moiety.
- the therapeutic moiety is a binding molecule that binds to a target antigen of interest, for example selected from an antibody or antibody fragment (e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment (scFv) or single domain antibody, for example a VH or VHH domain) or antibody mimetic protein.
- proteins or polypeptides that comprise the antibody or antigen binding portion thereof that binds to CD20 as described herein and a second moiety are fusion proteins. In one embodiment, the proteins or polypeptides that comprise the antibody or antigen binding portion thereof that binds to CD20 as described herein and a second moiety are drug conjugates.
- conjugate refers to a composition comprising the antibody that binds to CD20 as described herein that is bonded/conjugated to a drug.
- Such conjugates include “drug conjugates” which comprise antibody that binds to CD20 to which a drug is covalently bonded, and "non-covalent drug conjugates” which comprise the antibody that binds to CD20 min to which a drug is noncovalently bonded.
- drug conjugate refers to a composition comprising the antibody to which a drug is covalently bonded.
- the drug can be covalently bonded to the antibody fragment directly or indirectly through a suitable linker moiety.
- the drug can be bonded to the antibody at any suitable position, such as the amino- terminus, the carboxyl-terminus or through suitable amino acid side chains.
- the antibody is linked to the second moiety with a peptide linker or other suitable linker to connect the two moieties.
- peptide linker refers to a peptide comprising one or more amino acids.
- a peptide linker comprises 1 to 50, for example 1 to 20 amino acids.
- Peptide linkers are known in the art and non-limiting examples are described herein.
- Suitable, non-immunogenic linker peptides are, for example, linkers that include G and/or S residues, (G4S)n, (SG4)n or G4(SG4)n peptide linkers, wherein "n” is generally a number between 1 and 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- the binding agent may be multispecific, for example bispecific.
- the binding molecule is bispecific.
- the invention relates to a bispecific molecule comprising an antibody described herein linked to a second moiety having a different binding specificity than said antibody.
- the second antibody binds to a different target antigen, e.g. a target of interest.
- the binding molecule e.g. the protein or construct is multispecific and comprises a further, i.e. third, fourth, fifth etc moiety.
- the therapeutic moiety can also be selected from a half life extending moiety, cytotoxin, or radioisotope.
- the non-therapeutic moiety can be selected from a label, liposome or nanoparticle.
- the label is detectable or functional.
- a label can be any molecule that produces or can be induced to produce a signal, including but not limited to fluorophores, fluorescers, radiolabels, enzymes, chemiluminescers, a nuclear magnetic resonance active label or photosensitizers.
- the binding may be detected and/or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity or light absorbance.
- antibodies and antigen binding portion that is linked to one moiety may further be linked to another moiety.
- a may be linked to a therapeutic moiety and further linkage to a non- therapeutic moiety may be provided either via the antibody or the moiety.
- the binding agent or the antibody or antigen binding portion thereof according to the invention may comprise a half life extending moiety. This may be selected from an antibody or antigen binding portion thereof that binds canine serum albumin. Alternatively, extended half life may be conferred through PEGylation.
- half-life can generally refer to the time taken for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, in vivo, for example due to degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms.
- the in vivo half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art.
- the half-life can be expressed using parameters such as the tl/2- alpha, tl/2-beta and the area under the curve (AUC).
- Half-lives (t alpha and t beta) and AUC can be determined from a curve of serum concentration of conjugate or fusion against time.
- half-life refers to the tl/2-beta or terminal half-life (in which the tl/2-alpha and/or the AUC or both may be kept out of considerations).
- a first phase the drug composition (e. g., drug conjugate, noncovalent drug conjugate, drug fusion) is undergoing mainly distribution in the patient, with some elimination.
- a second phase (beta phase) is the terminal phase when the drug composition (e. g., drug conjugate, noncovalent drug conjugate, drug fusion) has been distributed and the serum concentration is decreasing as the drug composition is cleared from the patient.
- the t alpha half-life is the half-life of the first phase and the t beta half-life is the half-life of the second phase.
- a pharmaceutical composition comprising an antibody or fragment as described herein and optionally a pharmaceutically acceptable carrier.
- pharmaceutical composition as used herein refers to a composition that is used to treat a companion animal, that is for veterinary use, i.e. a veterinary composition. In preferred embodiments the animal that is treated is a dog.
- the pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier.
- Antibodies, protein or construct or the pharmaceutical composition can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitreal, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.
- Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical or subcutaneous administration.
- the compositions are administered parenterally.
- the pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form.
- carrier refers to a diluent, adjuvant or excipient, with which a drug antibody conjugate of the present invention is administered.
- Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- the carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like.
- auxiliary, stabilizing, thickening, lubricating and coloring agents can be used.
- the antibody of the present invention or compositions and pharmaceutically acceptable carriers are sterile.
- Water is a preferred carrier when the drug antibody conjugates of the present invention are administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the pharmaceutical composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension.
- the liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or sub-cutaneously.
- the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
- the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
- a solid composition typically contains one or more inert diluents.
- binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
- a liquid carrier such as polyethylene glycol
- the composition can be in the form of a liquid, e. g. an elixir, syrup, solution, emulsion or suspension.
- the liquid can be useful for oral administration or for delivery by injection.
- a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
- a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
- compositions can take the form of one or more dosage units. In specific embodiments, it can be desirable to administer the composition locally to the area in need of treatment, or by intravenous injection or infusion.
- the invention further extends to methods for the treatment of a disease, administration of a pharmaceutical composition or formulation described herein or the antibody or antigen binding portion of the invention. Also envisaged is a pharmaceutical composition or formulation described herein or a binding molecule or fusion protein that comprises an antibody or antigen binding portion thereof as described herein for use in the treatment of disease.
- the invention relates to a method of treating a condition mediated by B-cells in a canine subject in need thereof comprising administering an effective amount of the antibody or antigen-binding portion thereof as described herein.
- An aspect of the invention is also an antibody or antigen-binding portion thereof or the pharmaceutical composition as described herein for use in the treatment of a condition mediated by B-cells in a canine subject.
- the antibody or antigen-binding portion thereof may be used to deplete canine blood and / or tissues of B cell lymphoma cells.
- the condition mediated by B-cells is selected from a B cell lymphoma, (e.g., diffuse large cell B cell lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, follicular lymphoma, mucosa- associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantel cell lymphoma, Burkitt's lymphoma, mediastinal large B cell lymphoma, Waldenstrom macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis), leukemia or an immune mediated disease.
- the immune mediated disease may be an autoimmune disease.
- Example may include, but are not limited to, autoimmune hemolytic anemia, immune-mediated thrombocytopenia, autoimmune blistering diseases, immune- mediated arthritis and atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjogren's syndrome, vasculitis, multiple sclerosis, Graves' disease, idiopathic thrombocytopenia, dermatomyositis, immune mediated thrombocytopenia, polymyocytosis, pemphigus, immune mediated hemolytic anemia and bullous pemphigoid.
- the amount of the therapeutic that is effective/active in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
- the amount is at least about 0.01 % of an antibody or fragment thereof of the present invention by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1 % to about 80% by weight of the composition.
- Preferred oral compositions can comprise from about 4% to about 50% of the antibody or fragment thereof of the present invention by weight of the composition.
- compositions of the present invention are prepared so that a parenteral dosage unit contains from about 0.01 % to about 2% by weight of the antibody or fragment thereof of the present invention.
- the composition can comprise from about typically about 0.01 mg/kg to about 250 mg/kg, for example 0.1 mg/kg to about 250 mg/kg of the subject’s body weight, for example, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, and more preferably about 1 mg/kg to about 10 mg/kg of the animal's body weight, although less than 0.1 mg/kg is also envisaged.
- the composition is administered at a dose of about 0.5 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 0.5 to 5 mg/kg, about 0.5 to 2.5 mg/kg, about 0.5 to 2.0 mg/kg or about 2 or 3 mg/kg. In one embodiment, the composition is administered at a dose of 2 to 50mg/ml. In one embodiment, the composition is administered at a dose of 0.5mg/ml to 2.5 mg/ml, or 0.5mg/ml to 5mg/ml.
- the dosing schedule can vary from e.g., once a week to once every 2, 3, 4 weeks, or up to 8 weeks between doses.
- the composition is administered at a dose of 0.5mg/ml to 2.5 mg/ml every three to four weeks, e.g. 0.5 mg/ml or 2.5 mg/ml every three to four weeks.
- the dose is chosen so as to give prolonged depletion of CD20 positive cells to allow a three to four week interval between doses.
- Multiple doses may be administered, suitably up to about 6 or more repeat doses.
- post-treatment the subject has at least 7 days, or at least 14 days, or at least 21 days, or at least 28 days, or at least 40 days, or at least 50 days, or at least 60 days disease progression-free. In one embodiment, post-treatment, the subject has at least 7 days, or at least 14 days, or at least 21 days, or at least 28 days, or at least 40 days, or at least 50 days, or at least 60 days disease progression-free.
- the number of days of survival, the number of disease free days, or the number of disease-progression free days is at least 2 months, or at least 3 months, or at least 4 months, e.g. at least 5 months, such as at least 6 months.
- the number of days of survival, the number of disease free days, or the number of disease-progression free days is at least 9 months, 200 days, 300 days or 3 years or more. In one embodiment, it is least one, two, three or more years.
- the invention provides methods of treating or preventing CD20-mediated diseases or disorders in a companion animal, e.g., a dog, comprising administering an effective amount of an antibody or fragment of the present invention to the animal in need thereof.
- treat means inhibiting or relieving a disease or disorder.
- treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease.
- the terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms.
- the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., canine patients, being treated.
- Many medical treatments are effective for some, but not all, patients that undergo the treatment.
- ameliorating symptoms can be assessed by measuring lymph nodes after treatment and observing a reduction in lymph node size as an indication of successful treatment.
- subject or “patient” refers to a dog, which is the object of treatment, observation, or experiment. For the avoidance of doubt, the treatment of humans is excluded.
- the molecules or pharmaceutical composition of the invention may be administered as the sole active ingredient or in combination with one or more other therapeutic agent, for example a cancer therapy.
- a therapeutic agent is a compound or molecule which is useful in the treatment of a disease.
- therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, boron compounds, photoactive agents or dyes, radioisotopes, immunosuppressant or an immunological modulating agent, such as a cytokine or a chemokine.
- the molecules or pharmaceutical composition of the invention may be administered in combination with a multi-agent, CHOP-based chemotherapy protocol incorporating several injectable and oral drugs (Lasparaginase, vincristine, Cytoxan, prednisone, and doxorubicin), given on a more-or-less weekly basis for a period of several months. Administration may be at the same time, prior or after administration of the compound of the invention.
- the invention also relates to a method of inhibiting tumor growth or metastasis comprising contacting a tumor cell with an effective amount of the antibody or antigen-binding portion thereof or a pharmaceutical composition as described herein. The method can be in vitro, in vivo or ex vivo.
- the invention also relates to a method of killing a tumor cell expressing CD20, comprising contacting the cell with an antibody or pharmaceutical composition as described herein, such that killing of the cell expressing CD20 occurs.
- the tumor cell is a canine tumor cell.
- the method can be in vitro, in vivo or ex vivo.
- Methods for eliminating cells expressing canine CD20 using an antibody or pharmaceutical composition as described herein are also provided.
- the method can be in vitro, in vivo or ex vivo.
- the invention provides a kit for the treatment or prevention of a disease for example as listed herein or an immune response and/or for detecting CD20 for diagnosis, prognosis or monitoring disease comprising an antibody of the invention and optionally instructions for use.
- a kit may contain other components, packaging, instructions, or material to aid in the detection of CD20 protein.
- the kit may include a labelled antibody that binds to CD20 or a binding molecule comprising an antibody that binds to CD20 and one or more compounds for detecting the label.
- An antibody described herein can be obtained from a transgenic mammal, for example a rodent, that expresses canine antibodies upon stimulation with an CD20 antigen.
- rodents are described in W020018/189520 and W02020/074874.
- an antibody or fragment described herein can be obtained from a mammal, for example a rodent, for example a transgenic animal, that expresses antibodies upon stimulation with a canine CD20 antigen.
- the transgenic rodent for example a mouse, may have a reduced capacity to express endogenous antibody genes.
- the rodent has a reduced capacity to express endogenous light and/or heavy chain antibody genes.
- the rodent for example a mouse, may therefore comprise modifications to disrupt expression of endogenous kappa and lambda light and/or heavy chain antibody genes so that no functional mouse light and/or heavy chains are produced, for example as further explained below.
- Such transgenic rodents are described in the art and this is further explained in the examples below.
- a method for producing canine antibodies capable of binding CD20 comprising a) immunising a transgenic rodent, e.g. a mouse, with an CD20 antigen wherein said rodent expresses a nucleic acid construct comprising unrearranged canine V, D and J genes, b) isolating canine antibodies.
- a method for producing antibodies capable of binding canine CD20 said method comprising a) immunising a transgenic rodent, e.g.
- a mouse with an CD20 antigen wherein said rodent expresses a nucleic acid construct comprising unrearranged canine V, D and J genes, b) generating a library of sequences comprising heavy chain and light chain sequences from said rodent, e.g. a mouse and c) isolating antibodies comprising heavy chain and light chain sequences from said libraries.
- Further steps may include identifying an antibody that binds to CD20, for example by using functional assays as shown in the examples.
- Methods for preparing or generating the polypeptides, nucleic acids, host cells, products and compositions described herein using in vitro expression libraries can comprise the steps of: a) providing a set, collection or library of nucleic acid sequences encoding amino acid sequences; and b) screening said set, collection or library for amino acid sequences that can bind to / have affinity for CD20 and c) isolating the amino acid sequence(s) that can bind to / have affinity for CD20
- the set, collection or library of amino acid sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening.
- suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) amino acid sequences will be clear to the person skilled in the art (see for example Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press; 1st edition (October 28, 1996) Brian K. Kay, Jill Winter, John McCafferty).
- Libraries for example phage libraries, are generated by isolating a cell or tissue expressing an antigen-specific antibody or fragment thereof, cloning the sequence encoding the antibody or fragment thereof mRNA derived from the isolated cell or tissue and displaying the encoded protein using a library.
- the sequences can be expressed in bacterial, yeast or other expression systems.
- Another aspect also relates to an isolated antibody obtained or obtainable by a method described above.
- the antibody or antigen-binding portion thereof as described herein is used for non- therapeutic purposes, such as diagnostic tests and assays.
- the invention thus also relates to a method for detecting a canine cell expressing canine CD20 or detecting a canine CD20 protein in a biological sample from a canine subject, comprising contacting a biological sample with the antibody or antigen-binding portion thereof as described herein wherein said antibody or antigen-binding portion thereof is linked to a detectable label.
- the biological sample may be a biopsy, tissue, blood, serum, plasma, or lymphatic fluid sample.
- the method may include comparing the amount of binding in the test biological sample to the amount of binding in a control biological sample, wherein increased binding to the test biological sample relative to the control biological sample may indicate the presence of one or more lymphoma cells in the test biological sample.
- the biological sample is canine blood or a needle aspirate.
- antibodies for diagnostic purposes are well known in the art.
- antibodies may be modified with a ligand group such as biotin, or a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme.
- a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme.
- Compounds of the invention can be used for diagnostic purposes and e.g. labelled using conventional techniques. Suitable detectable labels include but are not limited to fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners.
- the antibody or antigen-binding portion thereof as described herein is used in the isolation and / or identification of cells expressing canine CD20 or cells that contain a cell surface protein that reacts with these binding agents (e.g., B cells, B lymphoma cells, canine CD20).
- the antibody or antigen-binding portion thereof as described herein can also be used in an assay to determine the level of CD20 expression.
- the level of expression may then be correlated with base (e.g., control) levels to determine whether a particular disease is present within the patient, the patient's prognosis, or whether a particular treatment regimen is effective.
- PBMCs were isolated using a Ficoll gradient. Briefly, 10 ml whole blood was diluted with 25 ml phosphate buffered saline (PBS) and layered onto 15 ml Ficoll Paque Plus (Sigma Aldrich) before centrifuging at 800rcffor 10 min, room temp, with slow acceleration and no brake. The interphase disk was collected into PBS. Total RNA was isolated from PBMCs with the QIAGEN RNeasy Mini Kit (Qiagen, Hilden, DE) and standard procedures, with an on- column DNAse digestion. cDNA generation was undertaken using the SuperscriptTM IV First-Strand Synthesis System following standard procedures and anchored oligo dT primers (ThermoFisher, Massachusetts, US).
- PBS phosphate buffered saline
- Ficoll Paque Plus Sigma Aldrich
- nucleotide and amino acid sequence of full length canine CD20 for cellular expression is shown below: NUCLEOTIDE:
- HEK 293 cells Human embryonic kidney (HEK) 293 cells were grown on 90 mm round tissue culture plates as monolayers in DMEM/F12 (Life Technologies) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich) at 37°C, with 5% CO2.
- HEK293 cells were co-transfected with CD20 cDNA and PiggyBac transposase using polyethyleneimine (PEI MAX: 40 kDa, Polysciences Inc., Eppelheim, Germany).
- Mouse embryonic fibroblasts were grown on 90 mm round tissue culture plates as monolayers in DMEM-high glucose (Life Technologies) supplemented with 10% FBS, 1 mM Sodium pyruvate (Sigma- Aldrich), 0.5mM b-mercaptoethanol (Gibco) and 1% MEM non-essential amino acids (Sigma-Aldrich) at 37°C, with 5% CO2.
- Cells were transfected with CD20 cDNA and PiggyBac transposase using Lipofectamine LTX with PLUSTM reagent (ThermoFisher Scientific) according to the manufacturer’s recommended instructions. Stably transfected cells were selected 48hrs later using a suitable antibiotic.
- MDCK II Mesarby canine kidney cells were grown on surface treated tissue culture flasks (T25/ T75/ T175) as monolayers in DMEM-high glucose (Life Technologies) supplemented with 10% FBS, and 1% MEM non-essential amino acids (Sigma-Aldrich) at 37°C, with 5% C02. MDCK II cells were co-transfected with wild-type or mutant canine CD20 cDNA and piggyBac transposase using LipofectamineTM LTX reagent with PLUSTM reagent (ThermoFisher Scientific) by following the recommended protocol.
- Ky9TM mice substantially as described in WO2018/189520 and W02020/074874, for example, were immunised.
- the transgenic mice have been modified by insertion of the dog immunoglobulin variable gene repertoire into the corresponding loci of the mouse genome. This allows for the production of antibodies that comprise a variable antibody region originating from the expression of canine DNA in the mouse, in combination with a mouse constant region (for heavy chain and kappa chain) or a dog constant region (for lambda chain).
- Information concerning, or the nucleic acid comprising, the variable region of such chimeric antibody chains may be used to generate fully canine antibodies.
- HTVI hydrodynamic tail vein injection
- mice were bled prior to immunisation and 10 days after each subsequent boost.
- Sera were separated from clotted blood by centrifugation in microvette 200 Z-gel tubes (Starstedt AG & Co. KG, Germany) and antibody titres against canine CD20 were evaluated by flow cytometry.
- Sera were serially diluted 1 :10 in FACS buffer (PBS + 3 % FBS) and added to cells stably-expressing canine CD20, or canine CD20 negative control cells.
- Mouse antibodies to canine CD20 were detected with either BB700 conjugated (BD Horizon BrilliantTM Blue 700, BD Biosciences) or FITC-conjugated secondary monoclonal antibodies against isotypes lgG1 , lgG2a, lgG2b (BD OptiBuildTM, Becton Dickinson). Data were acquired using a BD Accuri C6 Flow Cytometer (Becton Dickinson, NJ, USA) or Beckman Coulter CytoFLEX. The pre-immunisation sera were used to determine background. Antibody titres were determined as the highest dilution that showed positive signal above background. Figure 1 shows antibody titres of 5 immunised Ky9 mice.
- Example 4 Isolation of antibody producing cells, antibody sequencing, selection and sequence modification
- Spleens, lymph nodes and bone marrow were harvested from mice.
- Splenocytes were prepared by cutting the spleen into pieces and mashing them through a 40 pm cell strainer (Falcon) while rinsing with RPMI-1640 (Lonza, Basel, CH) + 10% FBS on ice.
- RPMI-1640 Longza, Basel, CH
- a similar process was used for lymphocytes from lymph nodes with spleen and lymph node cells generally being pooled.
- Bone marrow was collected from femur and tibia by flushing the marrow with RPMI-1640 using a 25-gauge needle, through a 40 pm cell strainer pre-wetted with RPMI-1640. All cell types were pelleted at 300g for 5 min and either directly used for flow sorting or resuspended in FBS + 10% dimethyl sulfoxide (DMSO) before being frozen at -150°C.
- DMSO dimethyl sulfox
- antigen-specific splenic B cells can be captured by labelled antigen protein probes (eg. extra cellular domain) or antigen-VLPs because they dominantly express transmembrane antibodies on the cell surface.
- antigen-specific plasmablast or plasma cells are thought to be less easily labelled by protein probes or VLPs because of their dominant expression of secreted antibodies. Therefore, plasmablasts and plasma cells isolated from the spleen lymph nodes sample or bone marrow were proceeded to the next step of antibody sequence recovery without using antigen probes to isolate the antigen- specific subset of these populations.
- Cell surface co-expression of CD138 and CD267 (TACI) was used to identify the population of plasmablasts and plasma cells.
- a CD138 plasma cell enrichment kit (Miltenyi biotech UK) was used to enrich these rare cells. Prior to antigen-specific cell sorting from spleen and lymph node cells, B cell enrichment was undertaken using a mouse pan-B cell isolation kit according to the manufacturer’s instructions (StemCell Technologies UK) or using an in-house biotinylated antibody cocktail and streptavidin rapidspheres (StemCell Technologies UK) according to the manufacturer’s instructions.
- VLPs are generated from HEK cells stably transfected with CD20, and the retrovirus gag protein fused to EGFP; the gag expression enables VLP budding from cells, and EGFP labels the VLPs for fluorescence-detection.
- VLPs are directly expressed from recombinant cells without any step of purification or modification, and are presented in a native form.
- Other mammalian cell lines such as Chinese Hamster Ovary cells (CHO) or mouse embryonic fibroblasts (MEF) can also be used for VLP production. Markers to identify unwanted cell populations and dead cells (F4/80; Ly-6C/G; CD8a; CD4; CD11 c; 7AAD or zombie-NIR/FVD EF780) are included in all staining panels to exclude these cells from the sorting procedure.
- Sorted cells are prepared for antibody profiling using the 10X Genomics Chromium Single Cell Immune Profiling system and the V(D)J Kit (10X Genomics) according to the manufacturer’s instructions.
- 10X various lllumina platform instruments are used according to the instructions from 10X Genomics.
- the sequences are analysed using custom tools based on the pRESTO /Change-O (Yale University) / IgBlast (NCBI, USA)/Enclone (10X Genomics) software to predict the germline sequence and hypermutation.
- variable immunoglobulin region comprises a VDJ region of an immunoglobulin nucleotide sequence for heavy genes and a VJ region of an immunoglobulin nucleotide sequence for IgK and IgA.
- V(D)J segments Within a clonal family there are subfamilies with shared mutations within their V(D)J segments that arise during immunoglobulin gene recombination and somatic hypermutation. Different clonal families that display unique V(D)J segment usage usually exhibit different binding characteristics.
- cells whose antibodies have a higher affinity for an antigen are selected. The affinity usually increases with further mutations; for example, a clustered family is shown in Figure 6 of WO2015/040401 .
- a clonal family is generally defined by related immunoglobulin heavy chain and light chain V(D)J sequences of two or more clonal cells.
- Related immunoglobulin V(D)J sequences can be identified by theirshared usage of V and J gene segments.
- An example of the analysis of antibody sequences of sorted Ag-specific single B- cells is shown in Figure 5 of WO2015/040401 , and shows antibody sequences that are arranged by heavy- chain V-gene family usage, and clustered to generate the displayed phylogenetic trees. From phylogenetic trees such as these, candidate clones are selected.
- anti-canine CD20 mAbs PMX001 , PMX002, PMX003, PMX004 and PMX005 are all encoded by the same heavy chain V-gene (CIGHV3-5), heavy chain J-gene (clGHJ4, with germline sequence given in SEQ ID NO: 75), light chain V-gene (clGLV3-3) and light chain J-gene (clGLJ3, with germline sequence given in SEQ ID NO: 77).
- PMX001 variable region sequences were first identified from a canine CD20 immunised Ky9 mouse.
- the CDR1 (SEQ ID NO: 7), CDR2 (SEQ ID NO: 8) and CDR3 (SEQ ID NO: 9) of the heavy chain variable region and the CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the light chain variable region are predicted using IMGT V-QUEST (http://www.imgt.org/IMGT_vquest/input).
- the CDR3 regions of the heavy chain and the light chain of PMX mAbs are 5aa and 9aa in length, respectively.
- PMX001 mAb Hit expansion of PMX001 mAb was later performed in all the canine CD20 immunised mice, and candidates that share the same VJ gene usage and CDR3 length for both heavy and light chains were selected for further screening. Further mutations may occur in the sequences compared to PMX001 mAb. For instance, PMX002, PMX003, PMX004 and PMX005 mAbs were selected from other immunisation cohorts and hence different mice from where PMX001 mAb was identified. It shows the convergent selection of successful gene rearrangement.
- PMX002 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 16).
- SEQ ID NO: 13 heavy chain variable region nucleotide sequence
- SEQ ID NO: 15 light chain variable region nucleotide sequence
- the CDR1 (SEQ ID NO: 17), CDR2 (SEQ ID NO: 18) and CDR3 (SEQ ID NO: 19) of the heavy chain variable region and the CDR1 (SEQ ID NO: 20), CDR2 (SEQ ID NO: 21) and CDR3 (SEQ ID NO: 22) of the light chain variable region are predicted using IMGT V-QUEST.
- PMX003mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 23) that encodes for the corresponding amino acid sequence (SEQ ID NO: 24) and a light chain variable region nucleotide sequence (SEQ ID NO: 25) that encodes for the corresponding amino acid sequence (SEQ ID NO: 26).
- SEQ ID NO: 23 a heavy chain variable region nucleotide sequence that encodes for the corresponding amino acid sequence
- SEQ ID NO: 25 a light chain variable region nucleotide sequence that encodes for the corresponding amino acid sequence
- the CDR1 (SEQ ID NO: 27), CDR2 (SEQ ID NO: 28) and CDR3 (SEQ ID NO: 29) of the heavy chain variable region and the CDR1 (SEQ ID NO: 30), CDR2 (SEQ ID NO: 31) and CDR3 (SEQ ID NO: 32) of the light chain variable region are predicted using IMGT V-QUEST.
- PMX004 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 33) that encodes for the corresponding amino acid sequence (SEQ ID NO: 34) and a light chain variable region nucleotide sequence (SEQ ID NO: 35) that encodes for the corresponding amino acid sequence (SEQ ID NO: 36).
- the CDR1 (SEQ ID NO: 37), CDR2 (SEQ ID NO: 38) and CDR3 (SEQ ID NO: 39) of the heavy chain variable region and the CDR1 (SEQ ID NO: 40), CDR2 (SEQ ID NO: 41) and CDR3 (SEQ ID NO: 42) of the light chain variable region are predicted using IMGT V-QUEST.
- PMX005 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 43) that encodes for the corresponding amino acid sequence (SEQ ID NO: 44) and a light chain variable region nucleotide sequence (SEQ ID NO: 45) that encodes for the corresponding amino acid sequence (SEQ ID NO: 46).
- SEQ ID NO: 43 heavy chain variable region nucleotide sequence
- SEQ ID NO: 45 light chain variable region nucleotide sequence
- the CDR1 (SEQ ID NO: 47), CDR2 (SEQ ID NO: 48) and CDR3 (SEQ ID NO: 49) of the heavy chain variable region and the CDR1 (SEQ ID NO: 50), CDR2 (SEQ ID NO: 51) and CDR3 (SEQ ID NO: 52) of the light chain variable region are predicted using IMGT V-QUEST.
- Figure 2 shows an alignment of PMX antibody sequences.
- the framework region 1 (FR1) of the light chain of PMX003 contains the NVT sequon, which is a consensus sequence for asparagine-linked glycosylation of proteins.
- NVT sequon is a consensus sequence for asparagine-linked glycosylation of proteins.
- the NVT sequon in the FR1 of PMX003 mAb was mutated to QVT for PMX006 mAb, AVT for PMX007 mAb, EVT for PMX008 mAb, NVA for PMX009 mAb, SVT for PMX010 mAb and TVT for PMX011 mAb.
- PMX070 and PMX075 comprise the sequence motif SVT in FR1 of the light chain
- PMX080 comprises the sequence motif TVT in FR1 of the light chain.
- the heavy chain and light chain V(D)J sequence of selected candidate clones are synthesised and cloned into expression vectors containing the genomic sequences of the dog IgG constant region, and the dog IGK or IGL constant regions, respectively.
- PMX001 to PMX005 variable sequences were cloned into the vectors that encode the dog IGGB (SEQ ID NO: 66) and dog IGLC5 constant regions (SEQ ID NO: 67).
- the expression vectors encoding the heavy chain and light chain were co-transfected into a suitable mammalian cell line such as CHO cells to obtain stable expression. Fully canine sequence antibodies were thus generated.
- codon-optimisation can be performed, for example, on the nucleotide sequences of the heavy chain variable region (SEQ ID NO: 68) and light chain variable region (SEQ ID NO: 69) of PMX003 mAb.
- Campath leader (SEQ ID NO: 70) (see US 8,362.208 B2)l can be introduced to replace the native leader (SEQ ID NO: 71 for heavy chain, SEQ ID NO: 72 for light chain) of PMX001 to PMX005 mAbs.
- Monoclonal antibodies 1 E4 and 4E1-7 were also expressed.
- 1 E4 nucleotide sequence was obtained from WO2013063186.
- 4E1-7 amino acid sequence was obtained from Mizuno et al. Scientific Reports, 10, Article 11476 (2020) (https://doi.org/10.1038/s41598-020-68470-9).
- the variable regions of both antibodies were cloned into vectors that encode the dog IGGB (SEQ ID NO: 66) and dog IGK (SEQ ID NO: 73) constant regions.
- Rituximab-cIGGB control mAb was generated by synthesizing the variable region sequences (see US 5,736,137) and cloned into vectors that encode dog IGGB (SEQ ID NO: 66) and dog IGLC5 (SEQ ID NO: 67) constant regions.
- the core fucose on the N-linked glycans bound to the Fc portion of antibodies could affect the binding of Fc receptors to the Fc region of the antibodies and therefore reduce the ADCC activities.
- Fut8 knockout (KO) CHO cells were generated in a pooled format, by deleting exon 2 of Fut8 coding gene as described in Yamane-Ohnuki et al., Biotechnol Bioeng. 2004 Sep 5;87(5):614- 22. https://pubmed.ncbi.nlm.nih.gov/15352059/).
- the KO cells were phenotypically selected using LCA staining.
- HEK293 cells or MDCK II cells were stably transfected with a vector encoding the full length of canine CD20 cDNA. Binding of antibodies to these cells were assessed using flow cytometry. In brief, 1-2 x10 5 canine CD20-expressing cells were incubated with candidate mAbs for 1 hour at +4°C, at a fixed concentration of 1 pg/ml or 10 pg/ml for binding assays and a range of concentrations (12-point 1 :2 serial dilution antibodies starting at 30 pg/ml i.e.
- the large loop of the extracellular domain (ECD) of canine CD20 protein is expressed in CHO cells and secreted into the extracellular media under the control of the CAG promoter, before purification using a protein A column.
- CD20 ECD protein is coated to the assay plate.
- Antibodies are added at a range of concentrations and the binding capacity determined using ELISA. SPR-based assay:
- Affinity (Kd) of anti-canine CD20 mAbs can be measured by SPR, using a recombinant mouse Fc tagged CD20 extracellular domain.
- the recombinant extracellular domain (ECD) (large loop) of CD20 named dCD20LL-Fc (see WO2013/063186, page 37, SEQ ID NO:62) is expressed in secreted form with a murine lgG2a Fc tag from stable CHO cells and purified from clarified supernatant using protein A chromatography.
- An apparent K corresponding to the bivalent avidity of the interaction is derived by amine coupling 100-150 RU of dCD20LL- Fc onto flow cell 2 of a CM5 chip with NHS/EDC activation/deactivation applied to flow cell 1 .
- Three-fold dilutions from 200 nM to 0.1 nM concentrations of candidate IgG are made in HBS-EP+ buffer and injected over the chip surface for 180 s at 30 pL/min. Dissociation is monitored for 600 s at 30 pL/min before regenerating the surface with a 60s pulse of 10 mM glycine-HCI pH 2.0.
- a monovalent Kd corresponding to the monovalent affinity is derived by repeating the protocol above using candidate antibody Fab fragment generated by papain (or SpeB) digestion of the full-length IgG.
- Experiments are conducted in HBS-EP+ running buffer at 25°C. All SPR experiments are carried out on a Biacore 8K instrument and data analysed by fitting the data to a 1 :1 binding model using Biacore Insight Evaluation software.
- CLBL-1 canine lymphoma tumour cell line (University of Veterinary Medicine Vienna) that natively expresses canine CD20 was used as the target cell line for a CDC assay.10,000 CLBL-1 cells per well of 96-well plate (white with clear bottom) were incubated with a titration (11 -point 1 :3 dilution starting at 10 pg/ml) of anticanine CD20 antibody and canine complement preserved serum (BiolVT) at a final dilution of 1 :4, for 2 hours at 37°C, 5% C02. The assay was set up using media (RPMI + 1% L-glutamine + 20% fetal bovine serum) made using heat inactivated serum so that canine complement preserved serum would be the only source of complement. Rituximab-cIGGB chimeric antibody was used as the negative, isotype control.
- Live cells were then quantified using CellTitre-Glo® Luminescent Cell Viability Assay (Promega) following the assay protocol. This assay uses the ATP content of live cells as an indication of cell viability. Luminescence was measured on a CLARIOstar (BMG Labtech). Data were analyzed using MARS software (BMG Labtech) and the number of live cells remaining was used to calculate the percentage of killing in the presence of antibodies using Microsoft Excel, using wells without antibody as baseline. Graphs were plotted in GraphPad Prism.
- FIG. 4 shows CDC activity was observed with PMX003 in both native and a-fucosylated form. No CDC activity was observed for the native and a-fucosylated form of 1 E4 and 4E1-7 test antibodies under the same experimental settings using canine complement preserved serum. Table 4 summarises the CDC activity for antibodies PMX066 to PMX081 .
- Canine cell line such as MDCK II cell line (ATCC) was stably transfected with a construct encoding for the canine CD20 protein and a construct expressing a fluorescent protein (e.g. GFP). Either MDCK II cell line expressing the fluorescent protein, but not antigen, or an isotype control antibody was used as negative control for the experiment.
- a fluorescent protein e.g. GFP
- PBMCs canine peripheral blood mononuclear cells
- Envigo Canine peripheral blood mononuclear cells
- PBMCs were isolated from freshly drawn whole blood, with sodium heparin anticoagulant, using Ficoll-Paque plus (Cytiva, GE17-1440-02) density gradient centrifugation by following the recommended protocol.
- PBMC media RPMI + 10% heat inactivated foetal bovine serum + 1% penicillin- streptomycin + 1% non-essential amino acids + 1% L-glutamine + 1% sodium pyruvate + 2% HEPES
- R&D systems canine IL-2
- MDCK II cells were co-cultured with PBMCs at an effector: target ratio of 35:1 and a titration of antibodies (11-point 1 :3 dilution starting at 10 pg/ml antibody), for 24 h at 37°C, in a 1 :1 mix of MDCK II media (DMEM + 1% L-glutamine + 10% fetal bovine serum) and PBMC media.
- Rituximab- cIGGB was used as the negative (isotype) control antibody.
- GFP signal which is proportional to the number of live cells per well, was used as a measure of the number of live cells remaining in the well at the end of the 24h incubation. GFP signal was measured on a CLARIOstar (BMG Labtech). Data was analysed using MARS software (BMG Labtech) and percentage of killing in the presence of antibodies was calculated using Microsoft Excel, using wells without antibody as baseline. Graphs were plotted with GraphPad Prism.
- FIG. 5 shows ADCC activity was observed in the presence of PMX antibodies.
- PMX003 antibody shows a stronger ADCC activity than test antibodies 1 E4 and 4E1-7, in both native and afucosylated form.
- Table 4 summarises the ADCC activity observed for antibodies PMX066 to PMX081 .
- ADCP Antibody Dependent Cellular Phagocytosis
- ADCP activity is described in Ito et al. Leuk Lymphoma. 2015 January; 56(1): 219-225.
- Direct killing may be measured as described in Mizuno et al. Scientific Reports, 10, Article 11476 (2020).
- Example 8 Ex vivo - whole blood assay To assess the B cell depletion efficiency in ex vivo dog models, 100 pi of freshly drawn dog whole blood was collected with heparin and diluted with 200 pi of RPMI1640 + 10% heat inactivated fetal bovine serum + 1% penicillin/streptomycin/L-glutamine + 1% non-essential amino acids + 1% sodium pyruvate + 2% HEPES buffer. The diluted blood was incubated with or without 10 pg/ml of anti-canine CD20 antibodies for 2 hours, 24 hours and 96 hours at 37°C.
- a syngeneic tumour mouse model is generated to evaluate the in vivo tumour killing efficiency of anti-canine CD20 antibodies.
- the genomic sequences of mouse 129Sv ES cells are modified to replace the mouse CD20 coding region with dog CD20 coding region by homologous recombineering.
- the targeting vector contains the genomic DNA sequence of dog CD20 coding region flanked by 4-4.5kb of mouse genomic sequences on both sides. After microinjection and germline transmission, the thus-generated mice are bred with Balb/c mice to produce mCD20/dCD20 heterozygous progenies of mixed genetic background.
- the mouse lymphoma cell line A20 of Balb/c genetic background is also modified to express dog CD20.
- the mouse CD20 coding region is replaced by dog CD20 coding sequence by transfecting the A20 cell line with linearized ES cell targeting vector.
- the cells were pelleted at 400g for 5 min, the cell pellets were resuspended in 0.5 ml buffer and 50 pi cells were used for staining of each technical replicate.
- cells were stained with AF647 conjugated anti-canine CD21 antibody (BioRad, 1 :10) and PE conjugated anti-canine CD8 antibody (BioRad, 1 :50).
- Data was acquired using Beckman Coulter CytoFLEX by setting the threshold on DAPI to exclude debris and non-nucleated cells. Percentage of CD21 + B cells and CD8+ T cells in the lymphocyte population was analysed using FlowJo software.
- B cell depletion was determined by comparing the percentage of CD21+ B cells on the day of assessment post antibody administration to the percentage on day 0 (baseline) for each dog. The percentage of CD8+ T cells was also evaluated and served as the internal control.
- Figure 7A-B shows the results of B cell depletion in healthy beagles administered PMX and control antibodies. Depletion was observed when PMX003 was administered in native and a-fucosylated form. The a-fucosylated form was more effective than the native form. PMX003 showed B cell killing at a much lower dose than that observed in a dog study using 1E4 (Rue et al. Veterinary Immunology and Immunopathology 164(2015), 148-159. In addition, B cell depletion was maintained at a low level for at least 15 days which is longer than observed in a dog study for 4E1-7 (Mizuno et al.).
- the percentage of CD21 + B cells was monitored and analysed on the following days post antibody administration: day 0 (pre-dose), 1 , 4, 7, 14, 21 and 28.
- 1 ml freshly drawn blood with K3EDTA anticoagulant was fixed with 2ml 1x RBC Lysis/ Fixation Solution (BioLegend) for 30 minutes at room temperature in the dark and then diluted with 12 ml of 1x PBS.
- the fixed and diluted blood samples were kept at +4°C throughout storage and shipping to the UK. Sample analysis was performed between 48-72 hours from blood draw. For each sample, the cells were pelleted at 400g for 5 min, the cell pellets were resuspended in 1 ml buffer and 50 pi cells were used for staining of each technical replicate.
- Figure 7C shows the results of B cell depletion in healthy beagles administered PMX and control antibodies. Depletion was observed for PMX070 and PMX115 at 0.5mg/kg and 2mg/kg doses, and was comparable to the depletion observed with the a-fucosylated form of PMX003.
- the plasma concentration of the mAb drug was monitored and analysed at the following times post antibody administration: Pre-dose, T2h, T6h, T24h, T48h, T72h, T120h, T168h, T360h, D27 and D43 in dog study 1 and pre-dose, T2h, T6h, T24h, D4, D7, D14, D21 and D28 in dog study 2.
- Fresh blood with lithium heparin anticoagulant was placed on ice immediately after blood draw. The blood tubes were centrifuged at 2500g for 10 min at +5°C. The plasma was collected into polypropylene tubes and kept on ice until storage at -20°C. The plasma was kept frozen till analysis by ELISA.
- the concentration of mAb is assessed by ELISA using anti-idiotype polyclonal antibodies against PMX mAb as capture antibodies and anti-canine Fc-HRP (Sigma) or anti-canine Fc-biotin (Sigma) plus streptavidin-HRP (BioLegend) as detection antibody.
- Anti-idiotype polyclonal or monoclonal antibodies against PMX mAb are raised at GenScript by immunisation of rabbits with PMX Fab fragments, hybridoma cell line generation and selection of anti-idiotype antibodies that bind to PMX mAb followed by removal of any cross-reactive antibodies that bind isotype control antibody.
- the concentration of anti-drug antibodies (ADA) in the frozen plasma is assessed by ELISA after acid dissociation of any preformed complexes between candidate PMX antibodies and anti-drug antibodies.
- Chimeric versions of candidate antibodies for example PMX-mouseFc or PMX- humanFc, are generated and a fraction is labelled with biotin.
- Presence and concentration of anti-drug antibodies is determined using a sandwich ELISA assay format where the unlabelled chimeric antibody is used as a capture reagent and the biotin labelled chimeric antibody along with streptavidin-HRP is used for detection.
- the anti-idiotype polyclonal antibodies generated for the pharmacokinetic assay above is used as a positive control and to generate a standard curve.
- the size of the antibodies was determined on non-reduced and reduced SDS-PAGE gel. HPLC-SEC indicated that each candidate product is made up of over 95% monomers. The diameter of the particles was detected using the UNcle machine which allowed us to detect potential issues of aggregation.
- NVT N-linked glycosylation motif
Abstract
The disclosure relates to antibodies and antigen binding portions thereof that binds canine CD20. The present disclosure also relates to compositions and methods for the treatment of a condition mediated by B-cells in a canine subject.
Description
ANTI CANINE CD20 ANTIBODIES
Introduction
Canine lymphomas are among the most common cancers diagnosed in dogs, representing around 7-14% of all cancers. As in humans, there are many different types of canine lymphoma and vary from rapidly progressing cancer to chronic disease.
CD20 is a cell-surface protein thought to be involved in regulation of B-cell proliferation and differentiation. The antigen comprises four transmembrane spanning regions and is present on the surface of almost all 13- cells, both normal and malignant.
Human antibodies which recognise human CD20, such as rituximab, are used to treat human diseases characterized by excessive numbers of B-cells, or overactive or dysfunctional B-cells. These antibodies destroy B-cells. Rituximab is viewed as a revolutionary advance in the treatment of B-cell lymphoma.
Since the development of antibodies such as rituximab for humans over two decades ago, a number of antibodies which recognise canine CD20 have been reported in the literature. However, at this point in time, none are in common clinical use. There therefore still remains a need for different therapies. The invention is aimed at addressing this need.
Summary
In a first aspect, the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 27, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 28, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 29, d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 30 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 32.
In another aspect of the invention or in an embodiment of the first aspect, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence
comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR1 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR1 sequence comprising or consisting of SEQ ID No. 12.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No. 41 and a LC CDR3 sequence comprising SEQ ID No. 42.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 82, a HC CDR2 sequence comprising or consisting of SEQ ID No. 83, a HC CDR3 sequence comprising or consisting of SEQ ID No. 84, a LC CDR1 sequence comprising or consisting of SEQ ID No. 85, a LC CDR2 sequence comprising or consisting of SEQ ID No. 86 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 87.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 92, a HC CDR2 sequence comprising or consisting of SEQ ID No. 93, a HC CDR3 sequence comprising or consisting of SEQ ID No. 94, a LC CDR1 sequence comprising or consisting of SEQ ID No. 95, a LC CDR2 sequence comprising or consisting of SEQ ID No. 96 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 97.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 102, a HC CDR2 sequence comprising or consisting of SEQ ID No. 103, a HC CDR3 sequence comprising or consisting of SEQ ID No. 104, a LC CDR1 sequence comprising or consisting of SEQ ID No. 105, a LC CDR2 sequence comprising or consisting of SEQ ID No. 106 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 107.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 112, a HC CDR2 sequence comprising or consisting of SEQ ID No. 113, a HC CDR3 sequence comprising or consisting of SEQ ID No. 114, a LC CDR1 sequence comprising or consisting of SEQ ID No. 115, a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 117.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 122, a HC CDR2 sequence comprising or consisting of
SEQ ID No. 123, a HC CDR3 sequence comprising or consisting of SEQ ID No. 124, a LC CDR1 sequence
comprising or consisting of SEQ ID No. 125, a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 127.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 132, a HC CDR2 sequence comprising or consisting of SEQ ID No. 133, a HC CDR3 sequence comprising or consisting of SEQ ID No. 134, a LC CDR1 sequence comprising or consisting of SEQ ID No. 135, a LC CDR2 sequence comprising or consisting of SEQ ID No. 136 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 137.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 142, a HC CDR2 sequence comprising or consisting of SEQ ID No. 143, a HC CDR3 sequence comprising or consisting of SEQ ID No. 144, a LC CDR1 sequence comprising or consisting of SEQ ID No. 145, a LC CDR2 sequence comprising or consisting of SEQ ID No. 146 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 147.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 152, a HC CDR2 sequence comprising or consisting of SEQ ID No. 153, a HC CDR3 sequence comprising or consisting of SEQ ID No. 154, a LC CDR1 sequence comprising or consisting of SEQ ID No. 155, a LC CDR2 sequence comprising or consisting of SEQ ID No. 156 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 157.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 162, a HC CDR2 sequence comprising or consisting of SEQ ID No. 163, a HC CDR3 sequence comprising or consisting of SEQ ID No. 164, a LC CDR1 sequence comprising or consisting of SEQ ID No. 165, a LC CDR2 sequence comprising or consisting of SEQ ID No. 166 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 167.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 172, a HC CDR2 sequence comprising or consisting of SEQ ID No. 173, a HC CDR3 sequence comprising or consisting of SEQ ID No. 174, a LC CDR1 sequence comprising or consisting of SEQ ID No. 175, a LC CDR2 sequence comprising or consisting of SEQ ID No. 176 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 177.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 182, a HC CDR2 sequence comprising or consisting of SEQ ID No. 183, a HC CDR3 sequence comprising or consisting of SEQ ID No. 184, a LC CDR1 sequence comprising or consisting of SEQ ID No. 185, a LC CDR2 sequence comprising or consisting of SEQ ID No. 186 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 187.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 192, a HC CDR2 sequence comprising or consisting of SEQ ID No. 193, a HC CDR3 sequence comprising or consisting of SEQ ID No. 194, a LC CDR1 sequence comprising or consisting of SEQ ID No. 195, a LC CDR2 sequence comprising or consisting of SEQ ID No. 196 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 197.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 202, a HC CDR2 sequence comprising or consisting of
SEQ ID No. 203, a HC CDR3 sequence comprising or consisting of SEQ ID No. 204, a LC CDR1 sequence
comprising or consisting of SEQ ID No. 205, a LC CDR2 sequence comprising or consisting of SEQ ID No. 206 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 207.
In another aspect of the invention or in an embodiment of the first aspect, the wherein said antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 212, a HC CDR2 sequence comprising or consisting of SEQ ID No. 213, a HC CDR3 sequence comprising or consisting of SEQ ID No. 214, a LC CDR1 sequence comprising or consisting of SEQ ID No. 215, a LC CDR2 sequence comprising or consisting of SEQ ID No. 216 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 217.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 222, a HC CDR2 sequence comprising or consisting of SEQ ID No. 223, a HC CDR3 sequence comprising or consisting of SEQ ID No. 224, a LC CDR1 sequence comprising or consisting of SEQ ID No. 225, a LC CDR2 sequence comprising or consisting of SEQ ID No. 226 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 227.
In another aspect of the invention or in an embodiment of the first aspect, the antibody has a HC CDR1 sequence comprising or consisting of SEQ ID No. 232, a HC CDR2 sequence comprising or consisting of SEQ ID No. 233, a HC CDR3 sequence comprising or consisting of SEQ ID No. 234, a LC CDR1 sequence comprising or consisting of SEQ ID No. 235, a LC CDR2 sequence comprising or consisting of SEQ ID No. 236 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 237.
In one embodiment, the antibody or antigen-binding portion thereof comprises a HC variable region sequence comprising SEQ ID NO. 24 or a sequence with at least 75%, 80%, 85% or 90% sequence identity thereto and a LC variable region sequence comprising SEQ ID NO. 26 or a sequence with at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity thereto.
For example, the antibody or antigen-binding portion thereof has a) a HC variable region sequence comprising SEQ ID NO. 4 and a LC variable region sequence comprising SEQ ID NO. 6; b) a HC variable region sequence comprising SEQ ID NO. 14 and a LC variable region sequence comprising SEQ ID NO. 16; c) a HC variable region sequence comprising SEQ ID NO. 34 and a LC variable region sequence comprising SEQ ID NO. 36; d) a HC variable region sequence comprising SEQ ID NO. 44 and a LC variable region sequence comprising SEQ ID NO. 46; e) a HC variable region sequence comprising SEQ ID NO. 79 and a LC variable region sequence comprising SEQ ID NO. 81 or a LC variable region sequence comprising SEQ ID NO. 238; f) a HC variable region sequence comprising SEQ ID NO. 89 and a LC variable region sequence comprising SEQ ID NO. 91 or a LC variable region sequence comprising SEQ ID NO. 239; g) a HC variable region sequence comprising SEQ ID NO. 99 and a LC variable region sequence comprising SEQ ID NO. 101 or a LC variable region sequence comprising SEQ ID NO. 240; h) a HC variable region sequence comprising SEQ ID NO. 109 and a LC variable region sequence comprising SEQ ID NO. 111 or a LC variable region sequence comprising SEQ ID NO. 241 ; i) a HC variable region sequence comprising SEQ ID NO. 119 and a LC variable region sequence comprising SEQ ID NO. 121 ;
j) a HC variable region sequence comprising SEQ ID NO. 129 and a LC variable region sequence comprising SEQ ID NO. 131 or a LC variable region sequence comprising SEQ ID NO. 242; k) a HC variable region sequence comprising SEQ ID NO. 139 and a LC variable region sequence comprising SEQ ID NO. 141 or a LC variable region sequence comprising SEQ ID NO. 243;
L) a HC variable region sequence comprising SEQ ID NO. 149 and a LC variable region sequence comprising SEQ ID NO. 151 or a LC variable region sequence comprising SEQ ID NO. 244; m) a HC variable region sequence comprising SEQ ID NO. 159 and a LC variable region sequence comprising SEQ ID NO. 161 or a LC variable region sequence comprising SEQ ID NO. 245; n) a HC variable region sequence comprising SEQ ID NO. 169 and a LC variable region sequence comprising SEQ ID NO. 171 ; o) a HC variable region sequence comprising SEQ ID NO. 179 and a LC variable region sequence comprising SEQ ID NO. 181 or a LC variable region sequence comprising SEQ ID NO. 246; p) a HC variable region sequence comprising SEQ ID NO. 189 and a LC variable region sequence comprising SEQ ID NO. 191 or a LC variable region sequence comprising SEQ ID NO. 247; q) a HC variable region sequence comprising SEQ ID NO. 199 and a LC variable region sequence comprising SEQ ID NO. 201 a LC variable region sequence comprising SEQ ID NO. 248; r) a HC variable region sequence comprising SEQ ID NO. 209 and a LC variable region sequence comprising SEQ ID NO. 211 a LC variable region sequence comprising SEQ ID NO. 249; s) a HC variable region sequence comprising SEQ ID NO. 219 and a LC variable region sequence comprising SEQ ID NO. 221 ; or t) a HC variable region sequence comprising SEQ ID NO. 229 and a LC variable region sequence comprising SEQ ID NO. 231 a LC variable region sequence comprising SEQ ID NO. 250.
For example, the antigen-binding portion thereof is an scFv, Fv, heavy chain or single domain antibody.
The invention also relates to an isolated canine antibody or antigen-binding portion thereof that binds to canine CD20 competing with an antibody or antigen-binding portion thereof as described above.
For example, the antibody or antigen-binding portion thereof is conjugated to a therapeutic moiety.
For example, the therapeutic moiety is a second antibody or antigen-binding portion thereof.
For example, the second antibody or antigen-binding portion thereof binds to a different target.
For example, the antibody or antigen-binding portion thereof is conjugated to a further moiety selected from a half life extending moiety, label, cytotoxin, liposome, nanoparticle or radioisotope.
For example, the said antibody or antigen-binding portion thereof is a-fucosylated.
The invention also relates to a pharmaceutical composition comprising an antibody or antigen-binding portion thereof as described above.
The invention also relates to a method of treating a condition mediated by B-cells in a canine subject in need thereof comprising administering an effective amount of the antibody or antigen-binding portion thereof as described above or a pharmaceutical composition as described above.
For example, the condition mediated by B-cells is a B cell lymphoma or leukaemia.
For example, the condition mediated by B-cells is an immune mediated disease.
For example, the immune mediated disease is an autoimmune disease.
For example, another therapeutic agent can be separately administered to the subject.
For example, the therapeutic agent is a cytotoxic agent or a radiotoxic agent.
For example, the therapeutic agent is an immunosuppressant.
For example, the therapeutic agent is an immunological modulating agent, such as a cytokine or a chemokine.
The invention also relates to the antibody or antigen-binding portion as described above or the pharmaceutical composition as described above for use in the treatment of disease.
For example, in the disease is a disease mediated by B-cells.
For example, the disease mediated by B-cells is a B cell lymphoma or leukaemia.
For example, the disease mediated by B-cells is an immune mediated disease.
For example, the immune mediated disease is an autoimmune disease.
The invention also relates to a method of inhibiting tumor growth or metastasis comprising contacting a tumor cell with an effective amount of the antibody or antigen-binding portion thereof as described above or pharmaceutical composition as described above.
The invention also relates to a method of killing a tumor cell expressing CD20, comprising contacting the cell with the antibody of as described above or a pharmaceutical composition as described above, such that killing of the cell expressing CD20 occurs.
For example, the tumor cell is a canine tumor cell.
The invention also relates to a nucleic acid sequence that encodes an antibody or antibody antigen-binding portion thereof as described above.
For example, the nucleic acid sequence comprises a sequence selected from SEQ ID NOs. 3, 5, 13, 15, 23, 25, 33, 35, 43, 45, 78, 80, 88, 90, 98, 100, 108, 110, 118, 120, 128, 130, 138, 140, 148, 150, 158, 160, 168, 170, 178, 180, 188, 190, 198, 200, 208, 210, 218, 220, 228, 230, 251 , 252, 253, 254, 255, 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, 266, 267, 268, 269, 270,271 , 272, 273, 274, 275, 276, 277, 278, 279, 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, 290, 291 , 292, 293, 294, 295, 296, 297, 298, 299, 300 or 301.
The invention also relates to a vector comprising a nucleic acid sequence as described above.
The invention also relates to a host cell comprising the nucleic acid sequence as described above or a vector of as described above.
The invention also relates to a kit comprising an antibody or antigen-binding portion thereof as described above or a pharmaceutical composition as described above.
For example, further comprises a reagent for the detection of the antibody or antigen-binding portion thereof. The invention also relates to a method for making a canine antibody that binds CD20 comprising culturing the isolated host cell as described above and recovering said antibody.
The invention also relates to a method for making a canine antibody that binds CD20 comprising the steps of a) immunising a transgenic mouse that expresses a nucleic acid construct comprising canine heavy chain V genes and canine light chain V genes with CD20 antigen, b) generating a library of antibodies from said mouse and c) isolating an antibody from said library.
The invention also relates to a method for detecting a CD20 protein or an extracellular domain of a CD20 protein in a biological sample from a canine subject, comprising contacting a biological sample with the antibody or antigen-binding portion thereof as described above wherein said antibody or antigen-binding portion thereof is linked to a detectable label.
For example, the biological sample is a biopsy, tissue, blood, serum, plasma, or lymphatic fluid sample.
The invention also relates to an antibody or antigen binding portion thereof that binds canine at an epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. ISO- 159 in Seq ID NO: 2).
Figures
The invention is further described in the following non-limiting figures.
Figure 1. Antibody titre of canine CD20 immunised Ky9 mice. Post-immunisation sera were serially diluted (as shown) and added to canine CD20-expressing cells. Subsequently, the cells were incubated with fluorophore-conjugated anti-mouse lgG1 , lgG2a, lgG2b secondary antibodies and the samples were assessed on a flow cytometer. Binding of pre-immunisation sera to canine CD20-expressing cells is presented as the background line in the plot.
Figure 2. (A) Amino acid sequence alignment of variable regions of PMX001 , PMX002, PMX003, PMX004 and PMX005 mAbs. The shading indicates the CDR1 , CDR2 and CDR3 regions in both heavy chain (HC) and light chain (LC) sequences of the mAbs. (B) Amino acid sequence alignment of HC and LC variable regions of the mAbs. The boxes indicate the CDR1 , CDR2 and CDR3 regions in both heavy chain (HC) and light chain (LC) sequences of the mAbs.
Figure 3. Binding assessment of anti-canine CD20 mAbs using flow cytometry. PMX001 , PMX002, PMX003, PMX004, PMX005, 1 E4-CIGGB, 4E1-7-CIGGB (see A) and PMX006, PMX007, PMX008, PMX009, PMX010, PMX011 (see B) and PMX003, PMX066, PMX067, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078, PMX079, PMX080, PMX081 , 1 E4-CIGGB, 4E1-7-CIGGB (see C) were applied to cCD20-expressing MDCK II cells at 10 pg/ml. Rituximab-cIGGB (grey shadow) was used as the isotype control and presented in each plot. (D) Affinity determination of PMX003, PMX115 and PMX070 mAbs. Binding of 1 :2 serially diluted antibodies to cCD20-expressing MDCK II cells was assessed in a binding assay and the mean values of the fluorophore signal was determined. The plot of mean fluorescence intensity (MFI) versus concentration was used to determine EC50 of binding, using non-linear regression, which is the apparent Kd of antibody binding to cell surface expressed canine CD20.
Figure 4. CDC activity of anti-canine CD20 antibodies. Both native and a-fucosylated format of antibodies were analysed at a range of concentrations (as shown) in the CDC assay. Rituximab-cIGGB chimeric antibody was used as the “isotype control”. “F” refers to the a-fucosylated format of the antibodies.
Figure 5. ADCC activity of anti-canine CD20 antibodies. Both native and a-fucosylated format of antibodies were analysed at a range of concentrations (as shown) in the ADCC assay. Rituximab-cIGGB chimeric antibody was used as the “isotype contro”l. “F” refers to the a-fucosylated format of the antibodies. EC50 values are also presented for each antibody.
Figure 6. B cell depletion efficiency of anti-canine CD20 mAbs in whole canine blood. Freshly drawn dog whole blood was diluted with culture media and incubated with 10 pg/ml of PMX001 , PMX003, 1 E4-clGGB, 4E1-7-CIGGB (see A), native or a-fucosylated format of PMX003 and 4E1-7-CIGGB antibodies, (see B), PMX003, PMX006, PMX007, PMX008, PMX009, PMX010, PMX011 (see C), or no antibody, for 24h. Rituximab-cIGGB was used as the “isotype control” (Iso Ctrl). “F” refers to the a-fucosylated format of the antibodies.
Figure 7. The B cell depletion efficiency of anti-canine CD20 mAbs in healthy Beagles. (A-B) Three healthy beagles for each test group were given the following antibodies by intravenous administration: Isotype control (rituximab-clgGB, 2.5 mg/kg), low dose of PMX003 (0.5 mg/kg), high dose of PMX003 (2.5 mg/kg) and low dose of a-fucosyslated PMX003 (0.5 mg/kg). “F” refers to a-fucosylated format of antibodies. The percentage of CD21 + B cells (A) and CD8+ T cells (B) in lymphocytes was analysed using flow cytometry on day 0, 1 , 2, 5, 7, 15, 27 and 43. The data shown here is representative of four technical repeats. (C) Three healthy beagles for each test group were given the following antibodies by intravenous administration: Isotype control (rituximab-clgGB, 2 mg/kg), low dose of PMX115 (0.5 mg/kg), high dose of PMX115 (2 mg/kg), low dose of PMX070 (0.5 mg/kg) and high dose of PMX070 (2 mg/kg). The percentage of CD21+ B cells in lymphocytes was analysed using flow cytometry on day 0, 1 , 4, 7, 14, 21 and 28. The data shown here is representative of four technical repeats.
Figure 8. Epitope mapping strategy for anti-CD20 antibodies. (A) The canine CD20 extracellular domain sequence was mutated to the human CD20 sequence at equivalent locations in vectors DH01 -DH09. (B) The canine CD20 extracellular domain sequence was mutated to the murine CD20 sequence at equivalent locations in vectors DM01 -DM09. (C) Every residue in the small loop and every other residue in the large loop of canine CD20 extracellular domain was mutated to alanine, giving rise to vectors S01 -S09 and L01- L25. Mutated residues are highlighted in bold.
Figure 9. Binding of PMX003, PMX115 and PMX070 mAbs to MDCK cells expressing dog-human chimeric CD20 or dog-mouse chimeric CD20 was evaluated by flow cytometry. Black bars of 01-09 in the figure represent binding to DH01-DH09 sequences shown in figure 8A and grey bars of 01-09 in the figure represent
binding to DM01 -DM09 sequences shown in figure 8B. MDCK cells expressing wildtype canine CD20 were applied as positive controls and wildtype MDCK cells were used as negative controls.
Table 1. Amino Acid Residues and Examples of Conservative Amino Acid Substitutions
Table 2. Sequences
Table 3. VH and VL gene usage
Table 4. Summary of functional data for antibodies
Table 5. Developability profile for antibodies
Detailed description
The embodiments of the invention will now be further described. In the following passages, different embodiments are described. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary.
Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Green and Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012); Therapeutic Monoclonal Antibodies: From Bench to Clinic, Zhiqiang An (Editor), Wiley, (2009); and Antibody Engineering, 2nd Ed., Vols 1 and 2, Ontermann and Dubel, eds., Springer-Verlag, Heidelberg (2010).
Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
The inventors have developed fully canine antibodies that bind specifically to canine CD20. These antibodies were generated in transgenic rodents expressing canine V, D, J genes. Therefore, the antibodies are less likely to be immunogenic for administration to canine subjects than caninized antibodies or chimeric
antibodies. Furthermore, as these antibodies can be used directly, with no further modifications to their variable regions, there is no risk of reducing the affinity or otherwise compromising the antibody. Other technologies risk introducing development or efficacy liabilities through the ex vivo combination of antibody sequences of canine origin with that from another species, typically rodent. Thus, the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20.
The properties of the antibodies and antigen binding portions thereof of the invention can be exploited in therapeutic methods and uses as well as in pharmaceutical formulations as described herein.
The term CD20 refers to the B-lymphocyte antigen CD20. The antibodies and antigen binding portions thereof bind specifically to wild type canine CD20 as defined in SEQ ID No. 1 (nucleotide sequence) and SEQ ID No. 2 (amino acid sequence). Unless otherwise stated, the term CD20 as used herein refers to canine CD20. B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans and canines, CD20 is encoded by the MS4A1 gene.
The terms "CD20 binding molecule/protein/polypeptide/agent/moiety”, "CD20 antigen binding molecule molecule/protein/polypeptide/agent/moiety”, “anti-CD20 antibody”, “anti-CD20 antibody or antigen binding portion thereof all referto a molecule capable of specifically binding to the canine CD20 antigen. The binding reaction may be shown by standard methods, for example with reference to a negative control test using an antibody of unrelated specificity.
An antibody or antigen binding portion thereof of the invention, including a multispecific, e.g. bispecific or trispecific, binding agent described herein, "which binds" or is “capable of binding” an antigen of interest, that is canine CD20, is one that binds the antigen with sufficient affinity such that the antibody or antigen binding portion thereof is useful as a therapeutic agent in targeting a cell or tissue expressing the antigen CD20 as described herein.
The antibody or antigen binding portion thereof according to the invention bind specifically to canine CD20. In other words, binding to the CD20 antigen is measurably different from a non-specific interaction. In particular, the antibodies described herein do not cross react with mouse CD20.
The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a KD for the target of at least about 10-6 M, alternatively at least about 10-7 M, alternatively at least about 10-8 M, alternatively at least about 10-9 M, alternatively at least about 10_1° M, alternatively at least about 10-11 M, alternatively at least about 10-12 M, or lower. In one embodiment, the KD is at least about 10-8 M to about 10_ 9 M, e.g. In one embodiment, the KD is in the nanomolar range. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular
polypeptide without substantially binding to any other polypeptide or polypeptide epitope. The terms KD and KD are used interchangeably herein.
The term "antibody" as used herein broadly refers to any immunoglobulin (Ig) molecule, or antigen binding portion thereof, comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule.
In a full-length antibody, each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as HCVR) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1 , CH2 and CH3. Each light chain is comprised of a light chain variable region or domain (abbreviated herein as LCVR) and a light chain constant region. The light chain constant region is comprised of one domain, CL.
The heavy chain and light chain variable regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each heavy chain and light chain variable region is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
Immunoglobulin molecules can generally be of any isotype, class or subclass. The CH3 domain according to the various aspects of the invention is a CH3 domain of the canine IgG subtype, for example IgG-A, IgG-B, IgG-C, and IgG-D.
In canine, there are four IgG heavy chains referred to as A, B, C, and D. These heavy chains represent four different subclasses of dog IgG, which are referred to as IgG-A, IgG-B, IgG-C and IgG-D. The DNA and amino acid sequences of these four heavy chains were first identified by Tang et al. (Vet. Immunol. Immunopathol. 80: 259-270 (2001)). The amino acid and DNA sequences for these heavy chains are also available from the GenBank data bases (IgGA: accession number AAL35301 .1 , IgGB: accession number AAL35302.1 , IgGC: accession number AAL35303.1 , IgGD: accession number AAL35304.1). Canine antibodies also contain two types of light chains, kappa and lambda (GenBank accession number kappa light chain amino acid sequence ABY 57289.1 , GenBank accession number ABY 55569.1). The antibodies herein may have a lambda or kappa light chain. In one embodiment, the light chain is a lambda light chain.
The term "CDR" refers to the complementarity-determining region within antibody variable sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1 , CDR2 and CDR3, for each of the variable regions. The term "CDR set" refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs can be defined differently according to different systems known in the art.
The Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., (1971) Ann. NY Acad. Sci. 190:382-391 and Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196:901 -917 (1987)). The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1 -113 of the heavy chain). Another system is the ImMunoGeneTics (IMGT) numbering scheme. The IMGT numbering scheme is described in Lefranc et al., Dev. Comp. Immunol., 29, 185-203 (2005). The IMGT numbering scheme is used herein unless otherwise specified.
A chimeric antibody is a recombinant protein that contains the variable domains including the complementarity determining regions (CDRs) of an antibody derived from one species, preferably a rodent or human antibody, while the constant domains of the antibody molecule are derived from those of a canine antibody.
As used herein, the term "caninized antibody" refers to forms of recombinant antibodies that contain sequences from both canine and non-canine (e.g., murine) antibodies. In general, a caninized antibody will comprise substantially all of at least one or more typically, two variable domains in which all or substantially all of the hypervariable loops correspond to those of a non-canine immunoglobulin, and all or substantially all of the framework (FR) regions (and typically all or substantially all of the remaining frame) are those of a canine immunoglobulin sequence. A caninized antibody may comprise both the three heavy chain CDRs and the three light chain CDRS from a murine or human antibody together with a canine frame or a modified canine frame. A modified canine frame comprises one or more amino acids changes that can further optimize the effectiveness of the caninized antibody, e.g., to increase its binding to its target. The non-canine sequences, e.g., of the hypervariable loops, may further be compared to canine sequences and as many residues changed to be as similar to authentic canine sequences as possible.
In contrast, fully canine antibodies of the present invention have canine variable regions and do not include full or partial CDRs orFRs from another species. Advantageously, fully canine antibodies as described herein have been obtained from transgenic mice comprising canine immunoglobulin sequences. Antibodies produced in these immunised mice are developed through in vivo B cell signalling and development to allow for natural affinity maturation including in vivo V(D)J recombination, in vivo junctional diversification, in vivo pairing of heavy and light chains and in vivo hypermutation. Fully canine antibodies produced in this way generate antibodies with optimal properties for developability, minimizing lengthy lead optimization prior to production at scale. Advantageously, such fully canine antibodies present the lowest possible risk of immunogenicity when introduced into a patient animal which, in turn, facilitates a repeated dosing regime. Given that ex vivo mAb engineering runs the risk of introducing development liabilities, immunogenicity, and reduced affinity (as outlined above), fully canine antibodies of the present invention are, therefore, most likely to be efficacious therapies in a clinical context. Thus, in an embodiment, the term canine antibody refers to a fully canine antibody.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translation modifications (e.g., isomerizations, amidations, carbohydrate addition) that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
The term "antigen binding site" refers to the part of the antibody or antibody fragment that comprises the area that specifically binds to an antigen. An antigen binding site may be provided by one or more antibody variable domains. An antigen binding site is typically comprised within the associated VH and VL of an antibody or antibody fragment.
The term “epitope” or “antigenic determinant” refers to a site on the surface of an antigen to which an immunoglobulin, antibody or antibody fragment, specifically binds. Generally, an antigen has several or many different epitopes and reacts with many different antibodies. The term specifically includes linear epitopes and conformational epitopes. Epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or non-contiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope). Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining what epitopes are bound by a given antibody or antibody fragment (i.e., epitope mapping by alanine-scanning mutagenesis or Pepscan) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides are tested for reactivity with a given antibody or antibody fragment. An antibody binds "essentially the same epitope" as a reference antibody, when the two antibodies recognize identical or sterically overlapping epitopes. The most widely used and rapid methods for determining whether two epitopes bind to identical or sterically overlapping epitopes are competition assays, which can be configured in different formats, using either labelled antigen or labelled antibody.
In one embodiment, the antibody or antigen binding portion thereof as described herein binds an epitope that comprises one or more amino residues, e.g. 1 to 19, e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18 or 19, of the following amino residues or consists of the following amino residues ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2). In one embodiment, the epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO: 2).
In one embodiment, the epitope is determined by site directed mutagenesis as shown in the examples, for example using alanine scanning. In one embodiment, the epitope is a linear epitope. In one embodiment, the epitope is a conformational epitope. In one embodiment, the epitope includes a linear epitope in the large loop. In one embodiment, the epitope further includes a conformational epitope in the small loop. In one embodiment, the antibody is PMX003 or antigen binding portion thereof or an antibody with at least 80% sequence identity as described herein.
In another aspect of the invention, the invention also relates to an antibody or antigen binding portion thereof binds an epitope that comprises one or more amino residues, e.g. 1 to 19, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9,10,11 , 12, 13, 14, 15, 16, 17, 18 or 19, of the following amino residues or consists of the following amino residues ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2). In one embodiment, the epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO. 2). For example, the antibody or antigen binding portion thereof may have the sequences as described herein.
The invention also relates to an antibody or antigen binding portion thereof that competes with an antibody or antigen binding portion thereof as described herein.
Proteolytic digestion of antibodies releases different fragments termed Fv (Fragment variable), Fab (Fragment antigen binding) and Fc (Fragment crystallisation). The Fc fragment comprises the carboxy- terminal portions of both H chains held together by disulfides. The constant domains of the Fc fragment are responsible for mediating the effector functions of an antibody.
The invention extends to antigen binding portions or antigen binding fragments of the antibody. The terms “binding portion” and “fragment” are used interchangeably herein. An antibody fragment is a portion of an antibody, for example a F(ab')2, Fab, Fv, scFv, heavy chain, light chain, variable heavy (VH), variable light (VL) chain domain and the like. Functional fragments of a full-length antibody retain the target specificity of a full antibody. Recombinant functional antibody fragments, such as Fab (Fragment, antibody), scFv (single chain variable chain fragments) and single domain antibodies (dAbs) have therefore been used to develop therapeutics as an alternative to therapeutics based on mAbs.
The invention also extends to antibody mimetics that comprise a sequence as described herein.
An “Fv" is the minimum antibody fragment which contains a complete antigen- recognition and -binding site.
This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non- covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three
HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
"Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments scFv fragments (~25kDa) that consist of the two variable domains, VH and VL connected into a single polypeptide chain. Naturally, VH and VL domains are non-covalently associated via hydrophobic interactions and tend to dissociate. However, stable fragments can be engineered by linking the domains with a hydrophilic flexible linker to create a single chain Fv (scFv).
The smallest antigen binding fragment is the single variable fragment, namely the variable heavy (VH) or variable light (VL) chain domain. VH and VL domains respectively are capable of binding to an antigen. Binding to a light chain/heavy chain partner respectively or indeed the presence of other parts of the full antibody is not required fortarget binding. The antigen-binding entity of an antibody, reduced in size to one single domain (corresponding to the VH or VL domain), is generally referred to as a “single domain antibody” or “immunoglobulin single variable domain”. A single domain antibody (~12 to 15 kDa) has thus either the VH or VL domain, i.e. it does not have other parts of a full antibody. The term "dAb" for "domain antibodies" generally refers to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen.
The term "isolated" refers to a moiety that is isolated from its natural environment. For example, the term "isolated" refers to an antibody or fragment thereof that is substantially free of other antibodies, antibodies or antibody fragments. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.
As used herein, the term "homology" or “identity” generally refers to the percentage of amino acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Thus, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. Neither N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known. The percent identity between two amino acid sequences can be determined using well known mathematical algorithms.
By "amino acid" herein is meant one of the 20 naturally occurring amino acids or any non- natural analogues that may be present at a specific, defined position. Amino acid encompasses both naturally occurring and synthetic amino acids. Although in most cases, when the protein is to be produced recombinantly, only naturally occurring amino acids are used.
As used herein, a "substitution of an amino acid residue" with another amino acid residue in an amino acid sequence of heterodimeric protein or polypeptide as described herein (an antibody for example), is equivalent to "replacing an amino acid residue" with another amino acid residue and denotes that a particular amino acid residue at a specific position in the original (e.g. wild type / germline) amino acid sequence has been replaced by (or substituted for) by a different amino acid residue. This can be done using standard techniques available to the skilled person, e.g. using recombinant DNA technology. The amino acids are changed relative to the native (wild type / germline) sequence as found in nature in the wild type (wt), but may be made in IgG molecules that contain other changes relative to the native sequence. By "wild type" or "WT" or "native" herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. A WT protein, polypeptide, antibody or immunoglobulin has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
The antibody or antigen-binding portion thereof according to the invention has one or more of the following properties: a) binds specifically to canine CD20; b) binds to canine CD20 with a KD as measured in the examples and for example as shown in the figures; c) shows cell killing, such as CDC and/or ADCC, in canine lymphoma cell lines expressing CD20, as measured in the examples; d) promotes antibody dependent cellular phagocytosis (ADCP); e) is capable of effectively depleting CD20 positive B cells in canine tissues; f) is capable of binding to cells expressing canine CD20; g) is capable of depleting cells expressing canine CD20, suitably by direct cell killing via apoptosis; h) provides good stability as shown in the examples; i) binds an epitope that comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO. 2), for example ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2); j) has a stronger binding capacity (5-10 fold higher) to canine CD20 than benchmark test antibodies 1 E4 and 4E1-7, e.g. as shown in the examples; k) has stronger ADCC and/or CDC activity than benchmark test antibodies 1 E4 and 4E1-7, e.g. as shown in the examples and in table 4 and/or
L) a more efficient killing of B cells in whole canine blood as compared to benchmark test antibodies 1 E4 and 4E1-7 mAbs, e.g. as shown in e.g. as shown in.
In one embodiment, the antibody or antigen-binding portion thereof according to the invention has one or more of the properties above and optionally one or more of the following properties: a) has CDC activity with an EC50 value of less than 20 nM; b) has ADCC activity with an EC50 value of less than 0.3 nM;
c) has a transient expression yield more than 100 ug/ml; d) has a Tm1 as determined by Uncle higher than 58°C; e) provides in vivo cell killing in dog at a dose of about 0.5 mg/kg to 2.5 mg/kg; f) maintains B cell depletion in vivo in dog at a low level for at least 15 days and/or g) binds an epitope that comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO. 2), for example ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO. 2).
These properties can be measured by methods known in the art, such the methods disclosed in the examples, including in vivo studies in mouse models or in dogs.
In particular, the inventors have found that the antibodies and antigen binding portions thereof show both CDC and ADCC activity, e.g. as demonstrated by the cell killing in canine lymphoma cell lines expressing CD20, as measured in the examples.
In one aspect, the invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a heavy chain (HC) CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto, d) a light chain (LC) CDR1 sequence comprising or consisting of SEQ ID No. 30 at least 60%, 70%, 80% or 90% sequence identity thereto, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has at least 60%, 70%, 80% or 90% sequence identity thereto.
The invention relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 27 b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32
or an isolated canine antibody or antigen-binding portion thereof with CDRs as described above but which has one or more CDR which has 1 , 2, 3 or 4 amino acid substitutions compared to the CDR sequence mentioned above.
The invention thus relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a heavy chain (HC) CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 27, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 28, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 29, d) a light chain (LC) CDR1 sequence comprising or consisting of SEQ ID No. 30 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 32.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR2 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 12.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No. 41 and a LC CDR3 sequence comprising SEQ ID No. 42.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting
of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 82, a HC CDR2 sequence comprising or consisting of SEQ ID No. 83, a HC CDR3 sequence comprising or consisting of SEQ ID No. 84, a LC CDR1 sequence comprising or consisting of SEQ ID No. 85, a LC CDR2 sequence comprising or consisting of SEQ ID No. 86 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 87.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 92, a HC CDR2 sequence comprising or consisting of SEQ ID No. 93, a HC CDR3 sequence comprising or consisting of SEQ ID No. 94, a LC CDR1 sequence comprising or consisting of SEQ ID No. 95, a LC CDR2 sequence comprising or consisting of SEQ ID No. 96 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 97.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 102, a HC CDR2 sequence comprising or consisting of SEQ ID No. 103, a HC CDR3 sequence comprising or consisting of SEQ ID No. 104, a LC CDR1 sequence comprising or consisting of SEQ ID No. 105, a LC CDR2 sequence comprising or consisting of SEQ ID No. 106 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 107.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 112, a HC CDR2 sequence comprising or consisting of SEQ ID No. 113, a HC CDR3 sequence comprising or consisting of SEQ ID No. 114, a LC CDR1 sequence comprising or consisting of SEQ ID No. 115, a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 117.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 122, a HC CDR2 sequence comprising or consisting of SEQ ID No. 123, a HC CDR3 sequence comprising or consisting of SEQ ID No. 124, a LC CDR1 sequence comprising or consisting of SEQ ID No. 125, a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 127.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 132, a HC CDR2 sequence comprising or consisting of SEQ ID No. 133, a HC CDR3 sequence comprising or consisting of SEQ ID No. 134, a LC CDR1 sequence comprising or consisting of SEQ ID No. 135, a LC CDR2 sequence comprising or consisting of SEQ ID No. 136 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 137.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 142, a HC CDR2 sequence comprising or consisting of SEQ ID No. 143, a HC CDR3 sequence comprising or consisting of SEQ ID No. 144, a LC CDR1 sequence comprising or consisting of SEQ ID No. 145, a LC CDR2 sequence comprising or consisting of SEQ ID No. 146 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 147.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 152, a HC CDR2 sequence comprising or consisting of SEQ ID No. 153, a HC CDR3 sequence comprising or consisting of SEQ ID No. 154, a LC CDR1 sequence comprising or consisting of SEQ ID No. 155, a LC CDR2 sequence comprising or consisting of SEQ ID No. 156 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 157.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 162, a HC CDR2 sequence comprising or consisting of SEQ ID No. 163, a HC CDR3 sequence comprising or consisting of SEQ ID No. 164, a LC CDR1 sequence comprising or consisting of SEQ ID No. 165, a LC CDR2 sequence comprising or consisting of SEQ ID No. 166 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 167.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 172, a HC CDR2 sequence comprising or consisting of SEQ ID No. 173, a HC CDR3 sequence comprising or consisting of SEQ ID No. 174, a LC CDR1 sequence comprising or consisting of SEQ ID No. 175, a LC CDR2 sequence comprising or consisting of SEQ ID No. 176 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 177.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 182, a HC CDR2 sequence comprising or consisting of SEQ ID No. 183, a HC CDR3 sequence comprising or consisting of SEQ ID No. 184, a LC CDR1 sequence comprising or consisting of SEQ ID No. 185, a LC CDR2 sequence comprising or consisting of SEQ ID No. 186 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 187.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 192, a HC CDR2 sequence comprising or consisting of SEQ ID No. 193, a HC CDR3 sequence comprising or consisting of SEQ ID No. 194, a LC CDR1 sequence comprising or consisting of SEQ ID No. 195, a LC CDR2 sequence comprising or consisting of SEQ ID No. 196 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 197.
In one embodiment, the antibody or antigen-binding portion thereof a HC CDR1 sequence comprising or consisting of SEQ ID No. 202, a HC CDR2 sequence comprising or consisting of SEQ ID No. 203, a HC CDR3 sequence comprising or consisting of SEQ ID No. 204, a LC CDR1 sequence comprising or consisting
of SEQ ID No. 205, a LC CDR2 sequence comprising or consisting of SEQ ID No. 206 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 207.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 212, a HC CDR2 sequence comprising or consisting of SEQ ID No. 213, a HC CDR3 sequence comprising or consisting of SEQ ID No. 214, a LC CDR1 sequence comprising or consisting of SEQ ID No. 215, a LC CDR2 sequence comprising or consisting of SEQ ID No. 216 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 217.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 222, a HC CDR2 sequence comprising or consisting of SEQ ID No. 223, a HC CDR3 sequence comprising or consisting of SEQ ID No. 224, a LC CDR1 sequence comprising or consisting of SEQ ID No. 225, a LC CDR2 sequence comprising or consisting of SEQ ID No. 226 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 227.
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 232, a HC CDR2 sequence comprising or consisting of SEQ ID No. 233, a HC CDR3 sequence comprising or consisting of SEQ ID No. 234, a LC CDR1 sequence comprising or consisting of SEQ ID No. 235, a LC CDR2 sequence comprising or consisting of SEQ ID No. 236 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 237.
In one embodiment, the antibody or antigen-binding portion thereof comprises a heavy chain (HC) variable region sequence comprising SEQ ID NO. 24 or a sequence with at least 75%, 80%, 85% or 90% sequence identity thereto and a light chain (LC) variable region sequence comprising SEQ ID NO. 26 or a sequence with at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity thereto. In one embodiment, the antibody or antigen-binding portion thereof comprises a heavy chain (HC) variable region sequence comprising SEQ ID NO. 24 and a light chain (LC) variable region sequence comprising SEQ ID NO. 26 or a LC variable region sequence comprising SEQ ID NO. 26 where the NVT sequence in FR1 of the LC variable region has been modified, for example an LC variable region with 1 , 2 or 3 amino acid modifications in FR1 , e.g. a LC variable region sequence comprising FR1 having SEQ ID NO. 60, 61 , 62, 63, 64 or 65 as described below or a LC variable region sequence comprising SEQ ID NO. 53, 54, 55, 56, 57 or 58.
For example, the antibody or antigen-binding portion thereof has a) a HC variable region sequence comprising or consisting of SEQ ID NO. 4 and a LC variable region sequence comprising or consisting of SEQ ID NO. 6; b) a HC variable region sequence comprising or consisting of SEQ ID NO. 14 and a LC variable region sequence comprising or consisting of SEQ ID NO. 16; c) a HC variable region sequence comprising SEQ ID NO. 34 and a LC variable region sequence comprising or consisting of SEQ ID NO. 36;
d) a HC variable region sequence comprising or consisting of SEQ ID NO. 44 and a LC variable region sequence comprising or consisting of SEQ ID NO. 46; e) a HC variable region sequence comprising SEQ ID NO. 79 and a LC variable region sequence comprising SEQ ID NO. 81 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 238; f) a HC variable region sequence comprising SEQ ID NO. 89 and a LC variable region sequence comprising SEQ ID NO. 91 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 239; g) a HC variable region sequence comprising SEQ ID NO. 99 and a LC variable region sequence comprising SEQ ID NO. 101 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 240; h) a HC variable region sequence comprising SEQ ID NO. 109 and a LC variable region sequence comprising SEQ ID NO. 111 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 241 ; i) a HC variable region sequence comprising SEQ ID NO. 119 and a LC variable region sequence comprising SEQ ID NO. 121 ; j) a HC variable region sequence comprising SEQ ID NO. 129 and a LC variable region sequence comprising SEQ ID NO. 131 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 242; k) a HC variable region sequence comprising SEQ ID NO. 139 and a LC variable region sequence comprising SEQ ID NO. 141 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 243;
L) a HC variable region sequence comprising SEQ ID NO. 149 and a LC variable region sequence comprising SEQ ID NO. 151 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 244; m) a HC variable region sequence comprising SEQ ID NO. 159 and a LC variable region sequence comprising SEQ ID NO. 161 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 245; n) a HC variable region sequence comprising SEQ ID NO. 169 and a LC variable region sequence comprising SEQ ID NO. 171 ; o) a HC variable region sequence comprising SEQ ID NO. 179 and a LC variable region sequence comprising SEQ ID NO. 181 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 246; p) a HC variable region sequence comprising SEQ ID NO. 189 and a LC variable region sequence comprising SEQ ID NO. 191 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 247; q) a HC variable region sequence comprising SEQ ID NO. 199 and a LC variable region sequence comprising SEQ ID NO. 201 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 248;
r) a HC variable region sequence comprising SEQ ID NO. 209 and a LC variable region sequence comprising SEQ ID NO. 211 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 249; s) a HC variable region sequence comprising SEQ ID NO. 219 and a LC variable region sequence comprising SEQ ID NO. 221 ; or t) a HC variable region sequence comprising SEQ ID NO. 229 and a LC variable region sequence comprising SEQ ID NO. 231 or a LC variable region sequence where the NVT sequence as described below has been modified, e.g. a LC variable region sequence comprising SEQ ID NO. 250.
In one embodiment, the antigen-binding portion thereof is a F(ab')2, Fab, Fv, scFv, heavy chain, light chain, variable heavy (VH) domain or variable light (VL).
In another embodiment, the antibody or antigen-binding portion comprises a HC CDR1 sequence comprising or consisting of SEQ ID No. 27, a HC CDR2 sequence comprising or consisting of SEQ ID No. 28, a HC CDR3 sequence comprising or consisting of SEQ ID No. 29, a LCDR1 sequence comprising or consisting of SEQ ID No. 30, LC CDR2 sequence comprising or consisting of SEQ ID No. 31 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 32. The antibody or antigen-binding portion has framework regions which have 5 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 1 amino acid change in the light chain variable sequence (SEQ ID NO: 76).
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR2 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 12. The antibody or antigen-binding portion has framework regions which have 2 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 3 amino acid changes in light chain variable sequence as compared to the germline sequence (SEQ ID NO: 76).
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22. The antibody or antigen-binding portion has framework regions which have 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76).
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising
SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ
ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No.
41 and a LC CDR3 sequence comprising SEQ ID No. 42. The antibody or antigen-binding portion has framework regions which have 12 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76).
In one embodiment, the antibody or antigen-binding portion thereof has a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2 sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52. The antibody or antigen-binding portion has framework regions which have 4 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in the light chain variable sequence (SEQ ID NO: 76).
In an embodiment the antibody or antigen-binding portion has framework regions which have 1 to 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74). For example, the antibody or antigen-binding portion has framework regions may have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74). In an embodiment the antibody or antigen-binding portion has framework regions which have 1 to 10 amino acid changes in the light chain variable sequence as compared to germline sequence (SEQ ID NO: 76). For example, the antibody or antigen-binding portion has framework regions may have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid changes in the light chain variable sequence as compared to germline sequence (SEQ ID NO: 76).
The invention also relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 112 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 112, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 113 or an amino acid sequence which has 1 , 2, 3, 4 or 5 amino acid differences compared to SEQ ID No. 113, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 114 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 114, d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 115 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 124, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 116 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 117 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 117.
The invention also relates to an isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises
a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 122 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 122, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 123 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 123, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 124 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 124, d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 125 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 125, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 126 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 127 or an amino acid sequence which has 1 , 2 or 3 amino acid differences compared to SEQ ID No. 127.
Amino acid changes as used herein are selected from amino acid substitutions, additions or deletions. In one embodiment, an amino acid change is an amino acid substitution.
In one embodiment, the antibody is PMX001 , PMX002, PMX003, PMX004, PMX005, PMX 006, PMX 007, PMX 008, PMX 009, PMX 010, PMX 011 , PMX066, PMX067, PMX068, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078, PMX079, PMX080, PMX081 ,
PMX112, PMX113, PMX114, PMX115, PMX116, PMX117, PMX118, PMX119, PMX120, PMX121 , PMX122, PMX123 or PMX 124 as shown in the examples and sequence information. In one embodiment, the antibody is selected from PMX001 , PMX002, PMX003, PMX004, PMX005, PMX066, PMX067, PMX068, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078, PMX079, PMX080 or PMX081. In one embodiment, the antibody is selected from PMX003, PMX066, PMX069, PMX070, PMX078, or PMX081. In one embodiment, the antibody is selected from PMX010, PMX112, PMX115, PMX122 or PMX124. In one embodiment, the antibody is selected from PMX069, PMX070 or PMX115.
Thus, in one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 3) that encodes for the corresponding amino acid sequence (SEQ ID NO: 4) and a light chain variable region nucleotide sequence (SEQ ID NO: 5) that encodes for the corresponding amino acid sequence (SEQ ID NO: 6). There are 2 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 3 amino acid changes in light chain variable sequence as compared to the germline sequence (SEQ ID NO: 76). The CDR sequences are as follows: CDR1 (SEQ ID NO: 7), CDR2 (SEQ ID NO: 8) and CDR3 (SEQ ID NO: 9) of the heavy chain variable region and the CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID
NO: 16). There are 10 amino acid changes in the heavy chain variable sequence as compared to germline
sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDRs are: CDR1 (SEQ ID NO: 17), CDR2 (SEQ ID NO: 18) and CDR3 (SEQ ID NO: 19) of the heavy chain variable region and the CDR1 (SEQ ID NO: 20), CDR2 (SEQ ID NO: 21) and CDR3 (SEQ ID NO: 22) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 23) that encodes for the corresponding amino acid sequence (SEQ ID NO: 24) and a light chain variable region nucleotide sequence (SEQ ID NO: 25) that encodes for the corresponding amino acid sequence (SEQ ID NO: 26). There are 5 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 1 amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDRs are: CDR1 (SEQ ID NO: 27), CDR2 (SEQ ID NO: 28) and CDR3 (SEQ ID NO: 29) of the heavy chain variable region and the CDR1 (SEQ ID NO: 30), CDR2 (SEQ ID NO: 31) and CDR3 (SEQ ID NO: 32) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 33) that encodes for the corresponding amino acid sequence (SEQ ID NO: 34) and a light chain variable region nucleotide sequence (SEQ ID NO: 35) that encodes for the corresponding amino acid sequence (SEQ ID NO: 36). There are 12 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDRs are CDR1 (SEQ ID NO: 37), CDR2 (SEQ ID NO: 38) and CDR3 (SEQ ID NO: 39) of the heavy chain variable region and the CDR1 (SEQ ID NO: 40), CDR2 (SEQ ID NO: 41) and CDR3 (SEQ ID NO: 42) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 43) that encodes for the corresponding amino acid sequence (SEQ ID NO: 44) and a light chain variable region nucleotide sequence (SEQ ID NO: 45) that encodes for the corresponding amino acid sequence (SEQ ID NO: 46). There are 4 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDRs are CDR1 (SEQ ID NO: 47), CDR2 (SEQ ID NO: 48) and CDR3 (SEQ ID NO: 49) of the heavy chain variable region and the CDR1 (SEQ ID NO: 50), CDR2 (SEQ ID NO: 51) and CDR3 (SEQ ID NO: 52) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 78) that encodes for the corresponding amino acid sequence (SEQ ID NO: 79) and a light chain variable region nucleotide sequence (SEQ ID NO: 80) that encodes for the corresponding amino acid sequence (SEQ ID NO: 81). The CDRs are CDR1 (SEQ ID NO: 82), CDR2 (SEQ ID NO: 83) and CDR3 (SEQ ID NO: 84) of the heavy chain variable region and the CDR1 (SEQ ID NO: 85), CDR2 (SEQ ID NO: 86) and CDR3 (SEQ ID NO: 87) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 88) that encodes for the corresponding amino acid sequence (SEQ ID NO: 89) and a light chain variable region nucleotide sequence (SEQ ID NO: 90) that encodes for the corresponding amino acid sequence (SEQ ID NO: 91). The CDRs are CDR1 (SEQ ID NO: 92), CDR2 (SEQ ID NO: 93) and CDR3 (SEQ ID NO: 94) of the heavy chain variable region and the CDR1 (SEQ ID NO: 95), CDR2 (SEQ ID NO: 96) and CDR3 (SEQ ID NO: 97) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 98) that encodes for the corresponding amino acid sequence (SEQ ID NO: 99) and a light chain variable region nucleotide sequence (SEQ ID NO: 100) that encodes for the corresponding amino acid sequence (SEQ ID NO: 101). The CDRs are CDR1 (SEQ ID NO: 102), CDR2 (SEQ ID NO: 103) and CDR3 (SEQ ID NO: 104) of the heavy chain variable region and the CDR1 (SEQ ID NO: 105), CDR2 (SEQ ID NO: 106) and CDR3 (SEQ ID NO: 107) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 108) that encodes for the corresponding amino acid sequence (SEQ ID NO: 109) and a light chain variable region nucleotide sequence (SEQ ID NO: 110) that encodes for the corresponding amino acid sequence (SEQ ID NO: 111). The CDRs are CDR1 (SEQ ID NO: 112), CDR2 (SEQ ID NO: 113) and CDR3 (SEQ ID NO: 114) of the heavy chain variable region and the CDR1 (SEQ ID NO: 115), CDR2 (SEQ ID NO: 116) and CDR3 (SEQ ID NO: 117) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 118) that encodes for the corresponding amino acid sequence (SEQ ID NO: 119) and a light chain variable region nucleotide sequence (SEQ ID NO: 120) that encodes for the corresponding amino acid sequence (SEQ ID NO: 121). The CDRs are CDR1 (SEQ ID NO: 122), CDR2 (SEQ ID NO: 123) and CDR3 (SEQ ID NO: 124) of the heavy chain variable region and the CDR1 (SEQ ID NO: 125), CDR2 (SEQ ID NO: 126) and CDR3 (SEQ ID NO: 127) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 128) that encodes for the corresponding amino acid sequence (SEQ ID NO: 129) and a light chain variable region nucleotide sequence (SEQ ID NO: 130) that encodes for the corresponding amino acid sequence (SEQ ID NO: 131). The CDRs are CDR1 (SEQ ID NO: 132), CDR2 (SEQ ID NO: 133) and CDR3 (SEQ ID NO: 134) of the heavy chain variable region and the CDR1 (SEQ ID NO: 135), CDR2 (SEQ ID NO: 136) and CDR3 (SEQ ID NO: 137) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 138) that encodes for the corresponding amino acid sequence (SEQ ID NO: 139) and a light chain variable region nucleotide sequence (SEQ ID NO: 140) that encodes for the corresponding amino acid sequence (SEQ ID NO: 141). The CDRs are CDR1 (SEQ ID NO: 142), CDR2 (SEQ ID NO: 143) and CDR3 (SEQ ID NO: 144)
of the heavy chain variable region and the CDR1 (SEQ ID NO: 145), CDR2 (SEQ ID NO: 146) and CDR3 (SEQ ID NO: 147) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 148) that encodes for the corresponding amino acid sequence (SEQ ID NO: 149) and a light chain variable region nucleotide sequence (SEQ ID NO: 150) that encodes for the corresponding amino acid sequence (SEQ ID NO: 151). The CDRs are CDR1 (SEQ ID NO: 152), CDR2 (SEQ ID NO: 153) and CDR3 (SEQ ID NO: 154) of the heavy chain variable region and the CDR1 (SEQ ID NO: 155), CDR2 (SEQ ID NO: 156) and CDR3 (SEQ ID NO: 157) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 158) that encodes for the corresponding amino acid sequence (SEQ ID NO: 159) and a light chain variable region nucleotide sequence (SEQ ID NO: 160) that encodes for the corresponding amino acid sequence (SEQ ID NO: 161). The CDRs are CDR1 (SEQ ID NO: 162), CDR2 (SEQ ID NO: 163) and CDR3 (SEQ ID NO: 164) of the heavy chain variable region and the CDR1 (SEQ ID NO: 165), CDR2 (SEQ ID NO: 166) and CDR3 (SEQ ID NO: 167) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 168) that encodes for the corresponding amino acid sequence (SEQ ID NO: 169) and a light chain variable region nucleotide sequence (SEQ ID NO: 170) that encodes for the corresponding amino acid sequence (SEQ ID NO: 171). The CDRs are CDR1 (SEQ ID NO: 172), CDR2 (SEQ ID NO: 173) and CDR3 (SEQ ID NO: 174) of the heavy chain variable region and the CDR1 (SEQ ID NO: 175), CDR2 (SEQ ID NO: 176) and CDR3 (SEQ ID NO: 177) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 178) that encodes for the corresponding amino acid sequence (SEQ ID NO: 179) and a light chain variable region nucleotide sequence (SEQ ID NO: 180) that encodes for the corresponding amino acid sequence (SEQ ID NO: 181). The CDRs are CDR1 (SEQ ID NO: 182), CDR2 (SEQ ID NO: 183) and CDR3 (SEQ ID NO: 184) of the heavy chain variable region and the CDR1 (SEQ ID NO: 185), CDR2 (SEQ ID NO: 186) and CDR3 (SEQ ID NO: 187) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 188) that encodes for the corresponding amino acid sequence (SEQ ID NO: 189) and a light chain variable region nucleotide sequence (SEQ ID NO: 190) that encodes for the corresponding amino acid sequence (SEQ ID NO: 191). The CDRs are CDR1 (SEQ ID NO: 192), CDR2 (SEQ ID NO: 193) and CDR3 (SEQ ID NO: 194) of the heavy chain variable region and the CDR1 (SEQ ID NO: 195), CDR2 (SEQ ID NO: 196) and CDR3 (SEQ ID NO: 197) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 198) that encodes for the corresponding amino acid sequence (SEQ ID NO: 199) and a light chain variable region
nucleotide sequence (SEQ ID NO: 200) that encodes for the corresponding amino acid sequence (SEQ ID NO: 201). The CDRs are CDR1 (SEQ ID NO: 202), CDR2 (SEQ ID NO: 203) and CDR3 (SEQ ID NO: 204) of the heavy chain variable region and the CDR1 (SEQ ID NO: 205), CDR2 (SEQ ID NO: 206) and CDR3 (SEQ ID NO: 207) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 208) that encodes for the corresponding amino acid sequence (SEQ ID NO: 209) and a light chain variable region nucleotide sequence (SEQ ID NO: 210) that encodes for the corresponding amino acid sequence (SEQ ID NO: 211). The CDRs are CDR1 (SEQ ID NO: 212), CDR2 (SEQ ID NO: 213) and CDR3 (SEQ ID NO: 214) of the heavy chain variable region and the CDR1 (SEQ ID NO: 215), CDR2 (SEQ ID NO: 216) and CDR3 (SEQ ID NO: 217) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 218) that encodes for the corresponding amino acid sequence (SEQ ID NO: 219) and a light chain variable region nucleotide sequence (SEQ ID NO: 220) that encodes for the corresponding amino acid sequence (SEQ ID NO: 221). The CDRs are CDR1 (SEQ ID NO: 222), CDR2 (SEQ ID NO: 223) and CDR3 (SEQ ID NO: 224) of the heavy chain variable region and the CDR1 (SEQ ID NO: 225), CDR2 (SEQ ID NO: 226) and CDR3 (SEQ ID NO: 227) of the light chain variable region.
In one embodiment, the antibody has a heavy chain variable region nucleotide sequence (SEQ ID NO: 228) that encodes for the corresponding amino acid sequence (SEQ ID NO: 229) and a light chain variable region nucleotide sequence (SEQ ID NO: 230) that encodes for the corresponding amino acid sequence (SEQ ID NO: 231). The CDRs are CDR1 (SEQ ID NO: 232), CDR2 (SEQ ID NO: 233) and CDR3 (SEQ ID NO: 234) of the heavy chain variable region and the CDR1 (SEQ ID NO: 235), CDR2 (SEQ ID NO: 236) and CDR3 (SEQ ID NO: 237) of the light chain variable region.
In one embodiment, the antibody or antigen-binding portion thereof comprises an Fc region, for example a canine Fc region, for example a canine IgGB Fc region.
The variable region sequences described herein, including but not limited to the amino acid and nucleotide sequences shown in Table 2 (and / or fragments thereof) may be used in combination with one or more amino acid sequences and / or nucleotide sequences encoding one or more constant chains (and / or a fragment thereof) of an antibody molecule. For instance, the variable region amino acid sequences shown in Table 2 may be joined to the constant regions of any antibody molecule of the same or a different species (e.g., human, goat, rat, sheep, chicken) of that from which the variable region amino acid sequence was derived. Preferably, the variable region amino acid sequences shown in Table 2 is joined to the constant regions of a canine antibody and may be the constant region from any of canine IgG A, B, C or D. In one embodiment, the constant region is canine IgG B constant region. Dog IGGB (SEQ ID NO: 66), dog IGK (SEQ ID NO: 73) or dog IGLC5 (SEQ ID NO: 67) constant regions may be used.
Also within the scope of the invention are variants of the antibodies and antigen binding portions as described above.
A variant of an antibody or antigen binding portion thereof as described herein has at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the non-variant molecule. In one embodiment, sequence identity is at least 95%. In one embodiment, the modification is a conservative sequence modification.
As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody or antigen binding portion thereof of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CDR regions of an antibody of the invention can be replaced with other amino acid residues from the same side chain family and the altered antibody can be tested for retained function (i.e. , CD20 binding) using the functional assays described herein.
Thus, these amino acid changes can typically be made without altering the biological activity, function, or other desired property of the polypeptide, such as its affinity or its specificity for antigen. In general, single amino acid substitutions in nonessential regions of a polypeptide do not substantially alter biological activity. Furthermore, substitutions of amino acids that are similar in structure or function are less likely to disrupt the polypeptides' biological activity. Abbreviations for the amino acid residues that comprise polypeptides and peptides described herein, and conservative substitutions for these amino acid residues are shown in Table 1 below.
Table 1. Amino Acid Residues and Examples of Conservative Amino Acid Substitutions
In some embodiments, the invention provides an antibody or antigen binding portion thereof that is a variant of an antibody or antigen binding portion thereof compared to a sequence described herein, e.g. selected from SEQ ID NO. 3 to 65 or SEQ ID NO. 78 to 237 that comprises one or more sequence modification and has improvements in one or more of a property such as binding affinity, specificity, thermostability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility as compared to the unmodified antibody or fragment thereof.
Suitable methods for measuring properties which may suggest that the antibody can be successfully developed at scale include first purification using chromatography, such as affinity chromatography chromatography (Protein A: MabSelect Sure LX), anion exchange chromatography (Capto Q), cation exchange chromatography (Capto S) and buffer exchange (G-25 Fine), followed by assessment of whether the antibody remains intact (e.g. using SDS PAGE analysis to determine molecular weight, HPLC-SEC to calculate % of monomers, assess aggregation, and thermostability (Tm) studies.
For example, consensus sequence for asparagine-linked glycosylation of proteins can be removed. The framework region 1 (FR1) of the light chain of PMX003 (SEQ ID NO: 26) contains the NVT sequon, which is a consensus sequence for asparagine-linked glycosylation of proteins. To remove the glycans bound to this site, the NVT sequon in the FR1 of PMX003 mAb was mutated to QVT for PMX006 mAb, AVT for PMX007 mAb, EVT for PMX008 mAb, NVA for PMX009 mAb, SVT for PMX010 mAb and TVT for PMX011 mAb. Such modifications are within the scope of the invention.
The resulted light chain variable region amino acid sequences of PMX006 mAb (SEQ ID NO: 53), PMX007 mAb (SEQ ID NO: 54), PMX008 mAb (SEQ ID NO: 55), PMX009 mAb (SEQ ID NO: 56), PMX010 mAb (SEQ ID NO: 57), PMX011 mAb (SEQ ID NO: 58) and the FR1 sequences of PMX003 (SEQ ID NO: 59), PMX006 mAb (SEQ ID NO: 60), PMX007 mAb (SEQ ID NO: 61), PMX008 mAb (SEQ ID NO: 62), PMX009 mAb (SEQ ID NO: 63), PMX010 mAb (SEQ ID NO: 64), PMX011 mAb (SEQ ID NO: 65) are within the scope of the invention and are listed in the Sequences Table 2. These may be used with the PMX003 heavy chain instead of SEQ ID NO: 26. The LC FR1 sequence for PMX003 is shown in SEQ ID NO. 59, the modified LC FR1 sequences in SEQ ID Nos. 60, 61 , 62, 63, 64 and 65.
The NVT sequon is found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 (SEQ ID NO:6, SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:36, SEQ ID NO:46) and PMX066 to PMX0081 (SEQ ID NO:81 , SEQ ID NO:91 , SEQ ID NO:101 , SEQ ID NO:111 , SEQ ID NO:121 , SEQ ID NO:131 , SEQ ID NO:141 , SEQ ID NO:151 , SEQ ID NO:161 , SEQ ID NO:171 , SEQ ID NO:181 , SEQ ID NO:191 , SEQ ID NO:201 , SEQ ID NO:211 , SEQ ID NO:221 , SEQ ID NO:231). The NVT sequon found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 or PMX066 to PMX081 may be mutated to a sequence selected from: QVT, AVT, EVT, NVA, SVT, TVT. In an embodiment the NVT sequon found at residue position 11 to 13 of FR1 of the light chain of PMX001 to PMX005 or PMX066 to PMX081 is mutated to SVT.
The framework region 1 (FR1) of the light chain of PMX066 (SEQ ID NO: 81), PMX067 (SEQ ID NO: 91), PMX068 (SEQ ID NO: 101), PMX069 (SEQ ID NO: 111), PMX071 (SEQ ID NO: 131), PMX072 (SEQ ID NO: 141), PMX073 (SEQ ID NO: 151), PMX074 (SEQ ID NO: 161), PMX076 (SEQ ID NO: 181), PMX077 (SEQ ID NO: 191), PMX078 (SEQ ID NO: 201), PMX079 (SEQ ID NO: 211), PMX081 (SEQ ID NO: 231) contain the NVT sequon, which is a consensus sequence for asparagine-linked glycosylation of proteins. To remove the glycans bound to this site, the NVT sequons in the FR1 of PMX066, PMX067, PMX068, PMX069, PMX071 , PMX072, PMX073, PMX074, PMX076, PMX077, PMX078, PMX079 and PMX081 mAbs were mutated to SVT to produce PMX112 (SEQ ID NO: 238), PMX113 (SEQ ID NO: 239), PMX114 (SEQ ID NO: 240), PMX115 (SEQ ID NO: 241), PMX116 (SEQ ID NO: 242), PMX117 (SEQ ID NO: 243), PMX118 (SEQ ID NO: 244), PMX119 (SEQ ID NO: 245), PMX120 (SEQ ID NO: 246), PMX121 (SEQ ID NO: 247), PMX122 (SEQ ID NO: 248), PMX123 (SEQ ID NO: 249) and PMX124 (SEQ ID NO: 250) respectively. Such modifications are within the scope of the invention the light chain of these can be used with their respective heavy chain counterpart, e.g. the HC of PMX066 (SEQ ID NO: 79) may be used with the modified LC (SEQ ID NO: 238) and so forth.
The resulting light chain variable region amino acid sequences of PMX112 mAb (SEQ ID NO: 238), PMX113 mAb (SEQ ID NO: 239), PMX114 mAb (SEQ ID NO: 240), PMX115 mAb (SEQ ID NO: 241), PMX116 mAb (SEQ ID NO: 242), PMX117 mAb (SEQ ID NO: 243), PMX118 mAb (SEQ ID NO: 244), PMX119 mAb (SEQ ID NO: 245), PMX120 mAb (SEQ ID NO: 246), PMX121 mAb (SEQ ID NO: 247), PMX122 mAb (SEQ ID NO: 248), PMX123 mAb (SEQ ID NO: 249) and PMX124 mAb (SEQ ID NO: 250) are within the scope of the invention and are listed in the Sequences Table.
A skilled person will know that there are different ways to identify, obtain and optimise the antigen binding molecules as described herein, including in vitro and in vivo expression libraries. This is further described in the examples. Optimisation techniques known in the art, such as display (e.g., ribosome and/or phage display) and / or mutagenesis (e.g., error-prone mutagenesis) can be used. The invention therefore also comprises sequence optimised variants of the antibodies described herein.
In one embodiment, modifications can be made to decrease the immunogenicity of the antibody. For example, one approach is to revert one or more framework residues to the corresponding canine germline sequence. More specifically, an antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived. In one embodiment, all framework sequences are germline sequence.
To return one or more of the amino acid residues in the framework region sequences to their germline configuration, the somatic mutations can be "backmutated" to the germline sequence by, for example, site- directed mutagenesis or PCR-mediated mutagenesis.
Another type of framework modification involves mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T cell epitopes to thereby reduce the potential immunogenicity of the antibody.
In some embodiments, the antigen-binding proteins, fragments and derivatives thereof, and fusion proteins of the present disclosure undergo post-translational modifications, for example but not limited to, a glutamine can be cyclized or converted to pyroglutamic acid; additionally, or alternatively, amino acids can undergo deamidation, isomerization, glycation and/or oxidation. The polypeptides of the present disclosure can undergo additional post-translational modification, including glycosylation, for example N- linked or O-linked glycosylation, at sites that are well-known in the art. Changes can be made in the amino acid sequence of a polypeptide to preclude or minimize such alterations, or to facilitate them in circumstances where such processing is beneficial. Polypeptides of the present disclosure include polypeptides that have been modified, for example, to: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties.
Thus, in still another embodiment, glycosylation is modified. For example, an aglycoslated antibody can be made (i.e. , the antibody lacks glycosylation). In one embodiment, the light chain variable region amino acid sequences of the aglycosylated antibody comprises SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58. SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241 , SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID
NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250. FR1 sequences are provided as SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61 , SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 , or SEQ ID NO: 65.
Glycosylation can also be altered to, for example, increase the affinity of the antibody for antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation may increase the affinity of the antibody for the antigen.
In some applications, the binding agents may bind canine CD20 but have altered ability to bind Fc receptors as compared to standard binding agents. In one example, the binding agents are antibodies that have modified glycosylation patterns. IgG molecules, for example, typically contain N-linked oligosaccharides, for example fucose.
In one embodiment, the antibody or antigen-binding portion thereof is a-fucosylated. In cancer immunotherapy, antibodies may rely on the Fc-mediated immune effector function, antibody-dependent cellular cytotoxicity (ADCC), as the major mode of action to deplete tumor cells. It is well-known that this effector function is modulated by the N-linked glycosylation in the Fc region of the antibody. In particular, absence of core fucose on the Fc N-glycan has been shown to increase lgG1 Fc binding affinity to the FcyRIIIa present on immune effector cells such as natural killer cells and lead to enhanced ADCC activity. Therefore, a-fucosylated antibodies may have advantageous to improve therapeutic efficacy and absence / removal of the fucose enhances the ability of the antibody to interact with Fc receptors. Antibodies of this type may be referred to as "a-fucosylated". Such antibodies may be produced using techniques described herein and / or that may be known in the art. In some embodiments, a nucleic acid sequence encoding an antibody may be expressed in a cell line that has modified glycosylation abilities (e.g., deleted, modified or lesser amount of fucosyl transferase) and fail to add the typical fucose moieties.
In one embodiment, the antibody or antigen-binding portion thereof has a CDC activity with an EC50 value in the 0.9-4.5 ug/ml (6-30nM) range, e.g. less than 20 nM.
In one embodiment, the antibody or antigen-binding portion thereof has an ADCC activity with an EC50 value of less than 0.3 nM, e.g 0.013 ug/ml (0.09nM).
In one embodiment, the antibody or antigen-binding portion thereof according to the invention has one or more of the following properties: a) has CDC activity with an EC50 value of less than 20 nM; b) has ADCC activity with an EC50 value of less than 0.3 nM; c) has a transient expression yield more than 100 ug/ml; d) has a Tm1 as determined by Uncle higher than 58°C and/or
e) provides in vivo cell killing in dog at a dose of about 0.5 mg/kg to 2.5 mg/kg f) maintains B cell depletion in vivo in dog at a low level for at least 15 days and/or g) binds an epitope that comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO: 2), for example ITISHFFKMENLNLIKAPM (SEQ ID NO. 302 amino acid No. 141-159 in Seq ID NO: 2).
ADCC and CDC activity may be measured as described in the examples.
In one embodiment, the antibody and antigen binding portion thereof shows both CDC and ADCC activity, e.g. as demonstrated by the cell killing in canine lymphoma cell lines expressing CD20, as measured in the examples.
In one embodiment, the antibody or antigen-binding portion thereof has one or more of the properties as set out above and has the HC CDRs and LC CDRs and/or the HC and LC CDRS of PMX069, PMX115 or PMX070. In one embodiment, the antibody or antigen-binding portion thereof is selected from PMX069, PMX115 or PMX070.
In one embodiment, the antibody is the antibody described in Table 4 or an antigen-binding portion thereof and has an EC50 value for ADCC or CDC as shown in that table. EC50 values may be measured as described in the examples.
In one embodiment, the Fc portion of the antibody may be modified.
In one embodiment, the one or more substitution in the variant is in the CDR1 , 2 and/or 3 region. For example, there may be 1 , 2, 3, 4, 5 or more amino acid substitutions in the CDR1 , 2 and/or 3 region. In another example, there may be 1 or 2 amino acid deletions.
In one embodiment, the one or more substitution is in the framework region. For example, there may be 1 to 20, e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10, amino acid substitutions in the HC variable region and/or LC variable region framework region.
The antibodies of the invention preferably have KD, IC50 and/or EC50 values, e.g. a KD as further described herein in the examples. Suitably, the KD value is sufficient for the antibodies to have the desired biological effect. For example, the KD can be least about 10 pM to 100 uM, about 100 pM to 10 nM or higher. The EC50 value may be as in Table 4, for example 0.12 to 0.89 nM. KD, IC50 and/or EC50 values may be measured as described in the examples.
The term "KD" refers to the "equilibrium dissociation constant" and refers to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (Koff) by the association rate constant (Kon). “KA” refers to the affinity constant. The association rate constant, the dissociation rate constant and the equilibrium dissociation constant are used to represent the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore® SPR assay can be used. The invention also relates to an isolated canine antibody or antigen-binding portion thereof that binds to canine CD20 competing with an antibody or antigen-binding portion thereof as described above. Antibodies, antibody fragments or antibody mimetics that bind at or near the same epitope or an overlapping epitope on canine CD20 as any of the CD20 antibodies of the invention have the ability to cross- compete for binding to CD20 with any of the antibodies of the invention. The antibodies of the invention can thus be used as a reference antibody to assess such cross-reactivity. Such cross-competing antibodies can be identified based on their ability to cross-compete with an antibody described herein in standard CD20 binding assays. For example, BIAcore® analysis, ELISA assays or flow cytometry may be used to demonstrate cross-competition with the antibodies.
Nucleic acid sequences, vectors and host cells
The invention also relates to a nucleic acid sequence that encodes an amino acid sequence of an antibody or antigen binding portion thereof as described herein, e.g. a HC variable region or LC variable region. Exemplary sequences are described in table 2. In one embodiment, said nucleic acid is selected from SEQ ID NOs. 3, 5, 13, 15, 23, 25, 33, 35, 43, 45, 78, 80, 88, 90, 98, 100, 108, 110, 118, 120, 128, 130, 138, 140, 148, 150, 158, 160, 168, 170, 178, 180, 188, 190, 198, 200, 208, 210, 218, 220, 228, 230, 251 , 252, 253,
254, 255, 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, 266, 267, 268, 269, 270,271 , 272, 273, 274,
275, 276, 277, 278, 279, 280, 281 , 282, 283, 284, 285, 286, 287, 288, 289, 290, 291 , 292, 293, 294, 295,
296, 297, 298, 299, 300 or 301 or a nucleic acid having at least 75%, 80% or 90% sequence homology thereto. In one embodiment, said nucleic acid sequence is linked with a linker to a second nucleic acid sequence. In one embodiment, said second nucleic acid encodes an additional therapeutic moiety. In one embodiment, said linker is a nucleic acid linker. An exemplary nucleic acid is shown below. However, a skilled person will understand that due to the degeneracy of the genetic code, other sequences are envisaged.
Codon optimised nucleotide sequences are also within the scope of the invention, including SEQ ID NOs. 68 and 69.
A nucleic acid according to the present invention may comprise DNA or RNA and may be wholly or partially synthetic or recombinantly produced. Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.
Furthermore, the invention relates to a nucleic acid construct comprising at least one nucleic acid as defined above. The construct may be in the form of a plasmid, vector, transcription or expression cassette.
The invention also relates to a vector that comprises a nucleic acid encoding the CD20 binding molecules as described herein. The term “vector" refers to a nucleic acid molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, or vims, into which a nucleic acid sequence may be inserted or cloned. A vector preferably contains one or more unique restriction sites and may be capable of autonomous replication in a defined host cell including a target cell or tissue or a progenitor cell or tissue thereof, or be integrable with the genome of the defined host such that the cloned sequence is reproducible. Accordingly, the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. A vector system may comprise a single vector or plasmid, two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may also include a selection marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. Examples of such resistance genes are well known to those of skill in the art. In an embodiment the vector is an adeno-associated virus (AAV) vector, such as those described in WO2021176362.
In some embodiments, the nucleic acid may also comprise a leader sequence. In another embodiment, it does not comprise a leader sequence. Any suitable leader sequences may be used including the native immunoglobulin germline leader sequence, such as SEQ ID NO: 71 for heavy chain, SEQ ID NO: 72 for light chain of PMX001 to PMX005 and PMX066 to PMX081 mAbs, or others, such as the Campath leader sequence (SEQ ID NO: 70) (see US 8,362,208 B2), may be chosen to enhance protein expression.
In some embodiments, the nucleic acid may also comprise a signal peptide, i.e. a short amino acid sequence (13-36 amino acids) on the N-terminus of a secretory protein (like an immunoglobulin) that mediates the translocation of a protein destined for secretion through the first membrane of the secretory pathway. This sequence is not present in the mature protein, being cleaved in a co-translational event, but mediates the secretion and correct expression of the protein. Suitable signal sequences can be used to optimize the expression of a recombinant protein.
The invention also relates to an isolated recombinant host cell comprising one or more nucleic acid construct as described above. Host cells useful in the present invention are prokaryotic, yeast, or higher eukaryotic cells and include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression
vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g. Baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).
Prokaryotes useful as host cells in the present invention include gram negative or gram-positive organisms such as E. coli, B. subtilis, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, Serratia, and Shigella, as well as Bacilli, Pseudomonas, and Streptomyces. One cloning host is E. coli 294 (ATCC 31 ,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31 ,537), and E. coli W3110 (ATCC 27,325) are suitable. In one embodiment, a method of making an anti- CD20 antibody as described herein is provided, wherein the method comprises culturing the host cell under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
Nucleic acids encoding antibodies can be used to administer an antibody to an individual in order to produce their encoded protein in vivo and mediate a therapeutic effect. Delivery of polynucleotides into a subject can be direct such that polynucleotides or expression vectors are administered to an individual e.g. through introduction of mRNA or DNA directly into cells e.g. muscle cells. Indirect introduction is also envisaged where polynucleotides are transformed into cells in vitro prior to administration. Viral vectors, such as defective or attenuated viruses, may also be used.
In one embodiment, a method of making an anti- CD20 antibody as described herein is provided, wherein the method comprises culturing the host cell under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
The invention also relates to a heterologous assay or expression system comprising a canine CD20 and a cell line derived from a different species, e.g. a human cell line such as HEK.
The assay comprises contacting a canine CD20 with a cell line derived from a different species, e.g. a cell line from a different mammal, e.g. a rodent cell line or a human cell line such as HEK. For example, the cell line is transfected with canine CD20 such that it expresses canine CD20 in a stable or transient manner.
Immunoconjugates and other binding agents
The invention relates to immunoconjugates and other binding agents comprising the antibody or antigen binding portion thereof according to the invention. For example, the antibody or antigen-binding portion thereof according to the invention may be conjugated to a therapeutic moiety or non-therapeutic moiety.
In one embodiment, the therapeutic moiety is a binding molecule that binds to a target antigen of interest, for example selected from an antibody or antibody fragment (e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment (scFv) or single domain antibody, for example a VH or VHH domain) or antibody mimetic protein.
In one embodiment, the proteins or polypeptides that comprise the antibody or antigen binding portion thereof that binds to CD20 as described herein and a second moiety are fusion proteins. In one embodiment, the proteins or polypeptides that comprise the antibody or antigen binding portion thereof that binds to CD20 as described herein and a second moiety are drug conjugates.
As used herein "conjugate" refers to a composition comprising the antibody that binds to CD20 as described herein that is bonded/conjugated to a drug.
Such conjugates include "drug conjugates" which comprise antibody that binds to CD20 to which a drug is covalently bonded, and "non-covalent drug conjugates" which comprise the antibody that binds to CD20 min to which a drug is noncovalently bonded.
As used herein, "drug conjugate" refers to a composition comprising the antibody to which a drug is covalently bonded. The drug can be covalently bonded to the antibody fragment directly or indirectly through a suitable linker moiety. The drug can be bonded to the antibody at any suitable position, such as the amino- terminus, the carboxyl-terminus or through suitable amino acid side chains.
In one embodiment, the antibody is linked to the second moiety with a peptide linker or other suitable linker to connect the two moieties.
The term "peptide linker" refers to a peptide comprising one or more amino acids. A peptide linker comprises 1 to 50, for example 1 to 20 amino acids. Peptide linkers are known in the art and non-limiting examples are described herein. Suitable, non-immunogenic linker peptides are, for example, linkers that include G and/or S residues, (G4S)n, (SG4)n or G4(SG4)n peptide linkers, wherein "n" is generally a number between 1 and 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
The binding agent may be multispecific, for example bispecific.
In one embodiment, the binding molecule is bispecific. Thus, in one aspect, the invention relates to a bispecific molecule comprising an antibody described herein linked to a second moiety having a different binding specificity than said antibody. Thus, the second antibody binds to a different target antigen, e.g. a target of interest.
In one embodiment the binding molecule, e.g. the protein or construct is multispecific and comprises a further, i.e. third, fourth, fifth etc moiety.
The therapeutic moiety can also be selected from a half life extending moiety, cytotoxin, or radioisotope.
The non-therapeutic moiety can be selected from a label, liposome or nanoparticle. The label is detectable or functional. A label can be any molecule that produces or can be induced to produce a signal, including but not limited to fluorophores, fluorescers, radiolabels, enzymes, chemiluminescers, a nuclear magnetic resonance active label or photosensitizers. Thus, the binding may be detected and/or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity or light absorbance.
According to the invention, antibodies and antigen binding portion that is linked to one moiety may further be linked to another moiety. For example, a may be linked to a therapeutic moiety and further linkage to a non- therapeutic moiety may be provided either via the antibody or the moiety.
In one embodiment, the binding agent or the antibody or antigen binding portion thereof according to the invention may comprise a half life extending moiety. This may be selected from an antibody or antigen binding portion thereof that binds canine serum albumin. Alternatively, extended half life may be conferred through PEGylation.
The term "half-life" as used can generally refer to the time taken for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, in vivo, for example due to degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms. The in vivo half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art. The half-life can be expressed using parameters such as the tl/2- alpha, tl/2-beta and the area under the curve (AUC). Half-lives (t alpha and t beta) and AUC can be determined from a curve of serum concentration of conjugate or fusion against time. Thus, the term "half-life" as used herein in particular refers to the tl/2-beta or terminal half-life (in which the tl/2-alpha and/or the AUC or both may be kept out of considerations).
For example, in a first phase (the alpha phase) the drug composition (e. g., drug conjugate, noncovalent drug conjugate, drug fusion) is undergoing mainly distribution in the patient, with some elimination. A second phase (beta phase) is the terminal phase when the drug composition (e. g., drug conjugate, noncovalent drug conjugate, drug fusion) has been distributed and the serum concentration is decreasing as the drug composition is cleared from the patient. The t alpha half-life is the half-life of the first phase and the t beta half-life is the half-life of the second phase.
Pharmaceutical composition
In another aspect, there is provided a pharmaceutical composition comprising an antibody or fragment as described herein and optionally a pharmaceutically acceptable carrier. The term pharmaceutical composition
as used herein refers to a composition that is used to treat a companion animal, that is for veterinary use, i.e. a veterinary composition. In preferred embodiments the animal that is treated is a dog.
The pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier. Antibodies, protein or construct or the pharmaceutical composition can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitreal, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.
Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical or subcutaneous administration. Preferably, the compositions are administered parenterally.
The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form. The term "carrier" refers to a diluent, adjuvant or excipient, with which a drug antibody conjugate of the present invention is administered. Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered to an animal, the antibody of the present invention or compositions and pharmaceutically acceptable carriers are sterile. Water is a preferred carrier when the drug antibody conjugates of the present invention are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
The pharmaceutical composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension. The liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or sub-cutaneously. When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
As a solid composition for oral administration, the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition typically contains one or more inert diluents. In addition, one or more of the following can be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like;
lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule (e. g. a gelatin capsule), it can contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol, cyclodextrin or a fatty oil.
The composition can be in the form of a liquid, e. g. an elixir, syrup, solution, emulsion or suspension. The liquid can be useful for oral administration or for delivery by injection. When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
Compositions can take the form of one or more dosage units. In specific embodiments, it can be desirable to administer the composition locally to the area in need of treatment, or by intravenous injection or infusion.
Methods of treating disease
The invention further extends to methods for the treatment of a disease, administration of a pharmaceutical composition or formulation described herein or the antibody or antigen binding portion of the invention. Also envisaged is a pharmaceutical composition or formulation described herein or a binding molecule or fusion protein that comprises an antibody or antigen binding portion thereof as described herein for use in the treatment of disease.
In particular, the invention relates to a method of treating a condition mediated by B-cells in a canine subject in need thereof comprising administering an effective amount of the antibody or antigen-binding portion thereof as described herein.
An aspect of the invention is also an antibody or antigen-binding portion thereof or the pharmaceutical composition as described herein for use in the treatment of a condition mediated by B-cells in a canine subject.
For example, the antibody or antigen-binding portion thereof may be used to deplete canine blood and / or tissues of B cell lymphoma cells. The condition mediated by B-cells is selected from a B cell lymphoma, (e.g., diffuse large cell B cell lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, follicular lymphoma, mucosa- associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantel cell lymphoma, Burkitt's lymphoma, mediastinal large B cell lymphoma, Waldenstrom macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis), leukemia or an immune mediated disease. The immune mediated disease may be an autoimmune disease. Example may include, but are not limited to, autoimmune hemolytic anemia, immune-mediated thrombocytopenia, autoimmune blistering diseases, immune- mediated arthritis and atopic dermatitis, rheumatoid arthritis,
systemic lupus erythematosus (SLE), Sjogren's syndrome, vasculitis, multiple sclerosis, Graves' disease, idiopathic thrombocytopenia, dermatomyositis, immune mediated thrombocytopenia, polymyocytosis, pemphigus, immune mediated hemolytic anemia and bullous pemphigoid.
The amount of the therapeutic that is effective/active in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
Typically, the amount is at least about 0.01 % of an antibody or fragment thereof of the present invention by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1 % to about 80% by weight of the composition. Preferred oral compositions can comprise from about 4% to about 50% of the antibody or fragment thereof of the present invention by weight of the composition.
Preferred compositions of the present invention are prepared so that a parenteral dosage unit contains from about 0.01 % to about 2% by weight of the antibody or fragment thereof of the present invention.
For administration by injection, such as intravenous or sub-cutaneous injection, the composition can comprise from about typically about 0.01 mg/kg to about 250 mg/kg, for example 0.1 mg/kg to about 250 mg/kg of the subject’s body weight, for example, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, and more preferably about 1 mg/kg to about 10 mg/kg of the animal's body weight, although less than 0.1 mg/kg is also envisaged. In one embodiment, the composition is administered at a dose of about 0.5 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 0.5 to 5 mg/kg, about 0.5 to 2.5 mg/kg, about 0.5 to 2.0 mg/kg or about 2 or 3 mg/kg. In one embodiment, the composition is administered at a dose of 2 to 50mg/ml. In one embodiment, the composition is administered at a dose of 0.5mg/ml to 2.5 mg/ml, or 0.5mg/ml to 5mg/ml. The dosing schedule can vary from e.g., once a week to once every 2, 3, 4 weeks, or up to 8 weeks between doses. In one embodiment, the composition is administered at a dose of 0.5mg/ml to 2.5 mg/ml every three to four weeks, e.g. 0.5 mg/ml or 2.5 mg/ml every three to four weeks. Suitably the dose is chosen so as to give prolonged depletion of CD20 positive cells to allow a three to four week interval between doses. Multiple doses may be administered, suitably up to about 6 or more repeat doses.
In one embodiment, post-treatment, the subject has at least 7 days, or at least 14 days, or at least 21 days, or at least 28 days, or at least 40 days, or at least 50 days, or at least 60 days disease progression-free. In
one embodiment, post-treatment, the subject has at least 7 days, or at least 14 days, or at least 21 days, or at least 28 days, or at least 40 days, or at least 50 days, or at least 60 days disease progression-free.
In one embodiment, the number of days of survival, the number of disease free days, or the number of disease-progression free days is at least 2 months, or at least 3 months, or at least 4 months, e.g. at least 5 months, such as at least 6 months.
In one embodiment, the number of days of survival, the number of disease free days, or the number of disease-progression free days is at least 9 months, 200 days, 300 days or 3 years or more. In one embodiment, it is least one, two, three or more years. The invention provides methods of treating or preventing CD20-mediated diseases or disorders in a companion animal, e.g., a dog, comprising administering an effective amount of an antibody or fragment of the present invention to the animal in need thereof.
As used herein, "treat", "treating" or "treatment" means inhibiting or relieving a disease or disorder. For example, treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease. The terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., canine patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment. In treatment of B cell lymphomas, for example, ameliorating symptoms can be assessed by measuring lymph nodes after treatment and observing a reduction in lymph node size as an indication of successful treatment.
The term "subject" or "patient" refers to a dog, which is the object of treatment, observation, or experiment. For the avoidance of doubt, the treatment of humans is excluded.
The molecules or pharmaceutical composition of the invention may be administered as the sole active ingredient or in combination with one or more other therapeutic agent, for example a cancer therapy. A therapeutic agent is a compound or molecule which is useful in the treatment of a disease. Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, boron compounds, photoactive agents or dyes, radioisotopes, immunosuppressant or an immunological modulating agent, such as a cytokine or a chemokine. In one example, the molecules or pharmaceutical composition of the invention may be administered in combination with a multi-agent, CHOP-based chemotherapy protocol incorporating several injectable and oral drugs (Lasparaginase, vincristine, Cytoxan, prednisone, and doxorubicin), given on a more-or-less weekly basis for a period of several months. Administration may be at the same time, prior or after administration of the compound of the invention.
The invention also relates to a method of inhibiting tumor growth or metastasis comprising contacting a tumor cell with an effective amount of the antibody or antigen-binding portion thereof or a pharmaceutical composition as described herein. The method can be in vitro, in vivo or ex vivo.
The invention also relates to a method of killing a tumor cell expressing CD20, comprising contacting the cell with an antibody or pharmaceutical composition as described herein, such that killing of the cell expressing CD20 occurs. The tumor cell is a canine tumor cell. The method can be in vitro, in vivo or ex vivo.
Methods for eliminating cells expressing canine CD20 using an antibody or pharmaceutical composition as described herein are also provided. The method can be in vitro, in vivo or ex vivo.
Kit
In another aspect, the invention provides a kit for the treatment or prevention of a disease for example as listed herein or an immune response and/or for detecting CD20 for diagnosis, prognosis or monitoring disease comprising an antibody of the invention and optionally instructions for use. Such a kit may contain other components, packaging, instructions, or material to aid in the detection of CD20 protein. The kit may include a labelled antibody that binds to CD20 or a binding molecule comprising an antibody that binds to CD20 and one or more compounds for detecting the label.
Methods of making the antibodies
An antibody described herein can be obtained from a transgenic mammal, for example a rodent, that expresses canine antibodies upon stimulation with an CD20 antigen. Such rodents are described in W020018/189520 and W02020/074874.
Thus, an antibody or fragment described herein can be obtained from a mammal, for example a rodent, for example a transgenic animal, that expresses antibodies upon stimulation with a canine CD20 antigen. The transgenic rodent, for example a mouse, may have a reduced capacity to express endogenous antibody genes. Thus, in one embodiment, the rodent has a reduced capacity to express endogenous light and/or heavy chain antibody genes. The rodent, for example a mouse, may therefore comprise modifications to disrupt expression of endogenous kappa and lambda light and/or heavy chain antibody genes so that no functional mouse light and/or heavy chains are produced, for example as further explained below. Such transgenic rodents are described in the art and this is further explained in the examples below.
Also within the scope of the invention is a method for producing canine antibodies capable of binding CD20 said method comprising a) immunising a transgenic rodent, e.g. a mouse, with an CD20 antigen wherein said rodent expresses a nucleic acid construct comprising unrearranged canine V, D and J genes, b) isolating canine antibodies.
Also within the scope of the invention is a method for producing antibodies capable of binding canine CD20 said method comprising a) immunising a transgenic rodent, e.g. a mouse, with an CD20 antigen wherein said rodent expresses a nucleic acid construct comprising unrearranged canine V, D and J genes, b) generating a library of sequences comprising heavy chain and light chain sequences from said rodent, e.g. a mouse and c) isolating antibodies comprising heavy chain and light chain sequences from said libraries.
Further steps may include identifying an antibody that binds to CD20, for example by using functional assays as shown in the examples.
Methods for preparing or generating the polypeptides, nucleic acids, host cells, products and compositions described herein using in vitro expression libraries can comprise the steps of: a) providing a set, collection or library of nucleic acid sequences encoding amino acid sequences; and b) screening said set, collection or library for amino acid sequences that can bind to / have affinity for CD20 and c) isolating the amino acid sequence(s) that can bind to / have affinity for CD20
In the above method, the set, collection or library of amino acid sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening. Suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) amino acid sequences will be clear to the person skilled in the art (see for example Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press; 1st edition (October 28, 1996) Brian K. Kay, Jill Winter, John McCafferty). Libraries, for example phage libraries, are generated by isolating a cell or tissue expressing an antigen-specific antibody or fragment thereof, cloning the sequence encoding the antibody or fragment thereof mRNA derived from the isolated cell or tissue and displaying the encoded protein using a library. The sequences can be expressed in bacterial, yeast or other expression systems.
Another aspect also relates to an isolated antibody obtained or obtainable by a method described above.
Other methods and uses
In another aspect, the antibody or antigen-binding portion thereof as described herein is used for non- therapeutic purposes, such as diagnostic tests and assays. The invention thus also relates to a method for detecting a canine cell expressing canine CD20 or detecting a canine CD20 protein in a biological sample from a canine subject, comprising contacting a biological sample with the antibody or antigen-binding portion thereof as described herein wherein said antibody or antigen-binding portion thereof is linked to a detectable label. The biological sample may be a biopsy, tissue, blood, serum, plasma, or lymphatic fluid sample.
In certain embodiments, the method may include comparing the amount of binding in the test biological sample to the amount of binding in a control biological sample, wherein increased binding to the test biological sample relative to the control biological sample may indicate the presence of one or more lymphoma cells in the test biological sample. In some embodiments, the biological sample is canine blood or a needle aspirate. These methods are also provided in an in vivo and / or in vitro format.
Modifications of antibodies for diagnostic purposes are well known in the art. For example, antibodies may be modified with a ligand group such as biotin, or a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme. Compounds of the invention can be used for diagnostic purposes and e.g. labelled using conventional techniques. Suitable detectable labels include but are not limited to fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners.
In another aspect, the antibody or antigen-binding portion thereof as described herein is used in the isolation and / or identification of cells expressing canine CD20 or cells that contain a cell surface protein that reacts with these binding agents (e.g., B cells, B lymphoma cells, canine CD20).
The antibody or antigen-binding portion thereof as described herein can also be used in an assay to determine the level of CD20 expression. The level of expression may then be correlated with base (e.g., control) levels to determine whether a particular disease is present within the patient, the patient's prognosis, or whether a particular treatment regimen is effective.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. While the foregoing disclosure provides a general description of the subject matter encompassed within the scope of the present disclosure, including methods, as well as the best mode thereof, of making and using this disclosure, the following examples are provided to further enable those skilled in the art to practice this disclosure. However, those skilled in the art will appreciate that the specifics of these examples should not be read as limiting on the invention, the scope of which should be apprehended from the claims and equivalents thereof appended to this disclosure. Various further aspects and embodiments of the present disclosure will be apparent to those skilled in the art in view of the present disclosure.
All documents mentioned in this specification are incorporated herein by reference in their entirety, including references to gene accession numbers, scientific publications and references to patent publications.
"and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, "A and/or B" is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein. Unless context dictates otherwise, the descriptions and definitions of the features set out above are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments which are described.
The invention is further illustrated in the following non-limiting examples.
EXAMPLES
Example 1: Cloning canine CD20
A search of the CAMFAM_3.1 boxer reference genome was conducted using the UCSC Genome Browser. The genomic sequence for CD20 (MS4A1) was downloaded along with mRNA sequence AB210085.1. Using this sequence data, primers were designed to enable amplification of CD20 from cDNA with added sequence to allow for seamless cloning. This allowed for confirmation of the CD20 sequence in dog blood and seamless cloning into a piggyBac cloning vector.
Isolation of canine CD20 mRNA and generation ofcDNA
Beagle whole blood was supplied by Envigo RMS (Alconbury, Huntingdon, UK) and PBMCs were isolated using a Ficoll gradient. Briefly, 10 ml whole blood was diluted with 25 ml phosphate buffered saline (PBS) and layered onto 15 ml Ficoll Paque Plus (Sigma Aldrich) before centrifuging at 800rcffor 10 min, room temp, with slow acceleration and no brake. The interphase disk was collected into PBS. Total RNA was isolated from PBMCs with the QIAGEN RNeasy Mini Kit (Qiagen, Hilden, DE) and standard procedures, with an on- column DNAse digestion. cDNA generation was undertaken using the Superscript™ IV First-Strand Synthesis System following standard procedures and anchored oligo dT primers (ThermoFisher, Massachusetts, US).
The nucleotide and amino acid sequence of full length canine CD20 for cellular expression is shown below: NUCLEOTIDE:
ATGACAACACCCAGAAATTCAATGAGTGGAACTCTCCCGGTAGATCCTATGAAAAGCCCTACTGCCAT
GTATCCTGTTCAAAAAATAATTCCCAAAAGGATGCCTTCAGTGGTGGGCCCTACACAAAACTTCTTCAT
GAGGGAATCTAAGACACTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTAGGCAGC
CTCCTGATGATTCACACGGATGTCTATGCGCCCATCTGTATAACTATGTGGTACCCTCTCTGGGGAGG
CATTATGTTCATCATTTCTGGATCACTCCTGGCAGCAGCGGACAAAAACCCCAGGAAGAGTTTGGTCA
AAGGAAAAATGATAATGAACTCATTGAGCCTCTTTGCTGCTATTTCTGGAATAATTTTTTTGATCATGGA
CATATTTAATATTACCATTTCCCATTTTTTTAAAATGGAGAATTTGAATCTTATTAAAGCTCCCATGCCAT
ATGTTGACATACACAACTGTGACCCAGCTAACCCCTCTGAGAAAAACTCTTTATCTATACAATATTGTG
GCAGCATACGATCTGTTTTCTTGGGCGTTTTTGCTGTGATGGTGATCTTTACCTTTTTCCAGAAACTTG
T G ACAGCT GGCATTGTT GAGAAT G AAT GG AAAAAACTGTGCTCT AAACCT AAAT CT GAT GT AGTT GTTC
TGTT AGCT GCT GAAGAAAAAAAAG AACAGCCGATT G AAACAACAG AAG AAATGGTT G AGCT G ACTGAA
ATAG CTT C CC AAC C AAAG AAAG AAG AAG AC ATT G AAATT ATT C C AGTCC AAG AAG AAG AAG AGG AACT
GGAAATAAACTTTGCAGAACCTCCCCAGGAGCAGGAATCTTCACCAATAGAAAACGACAGCATCCCTT AA (SEQ ID NO: 1)
PROTEIN:
MTTPRNSMSGTLPVDPMKSPTAMYPVQKIIPKRMPSVVGPTQNFFMRESKTLGAVQIMNGLFHIALGSLLM IHTDVYAPICITMWYPLWGGIMFIISGSLLAAADKNPRKSLVKGKMIMNSLSLFAAISGIIFLIMDIFNITISHFFK MENLNLIKAPMPYVDIHNCDPANPSEKNSLSIQYCGSIRSVFLGVFAVMVIFTFFQKLVTAGIVENEWKKLCS KPKSDVVVLLAAEEKKEQPIETTEEMVELTEIASQPKKEEDIEIIPVQEEEEELEINFAEPPQEQESSPIENDSI P (SEQ ID NO: 2)
Example 2: Expressing canine CD20
Human embryonic kidney (HEK) 293 cells were grown on 90 mm round tissue culture plates as monolayers in DMEM/F12 (Life Technologies) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich) at 37°C, with 5% CO2. HEK293 cells were co-transfected with CD20 cDNA and PiggyBac transposase using polyethyleneimine (PEI MAX: 40 kDa, Polysciences Inc., Eppelheim, Germany). 30 pi of PEI MAX (1 mg ml 1), 5 pg cDNA and 1 ml DMEM/ F12 were incubated for 10 min at room temperature, added dropwise to a 90mm plate of 70 - 80% confluent HEK293 cells, and incubated for 2 days before use. Stably transfected cells were selected 48hrs later using a suitable antibiotic.
Mouse embryonic fibroblasts (MEF) were grown on 90 mm round tissue culture plates as monolayers in DMEM-high glucose (Life Technologies) supplemented with 10% FBS, 1 mM Sodium pyruvate (Sigma- Aldrich), 0.5mM b-mercaptoethanol (Gibco) and 1% MEM non-essential amino acids (Sigma-Aldrich) at 37°C, with 5% CO2. Cells were transfected with CD20 cDNA and PiggyBac transposase using Lipofectamine LTX with PLUS™ reagent (ThermoFisher Scientific) according to the manufacturer’s recommended instructions. Stably transfected cells were selected 48hrs later using a suitable antibiotic.
MDCK II (Madin-Darby canine kidney) cells were grown on surface treated tissue culture flasks (T25/ T75/ T175) as monolayers in DMEM-high glucose (Life Technologies) supplemented with 10% FBS, and 1% MEM non-essential amino acids (Sigma-Aldrich) at 37°C, with 5% C02. MDCK II cells were co-transfected with wild-type or mutant canine CD20 cDNA and piggyBac transposase using Lipofectamine™ LTX reagent with PLUS™ reagent (ThermoFisher Scientific) by following the recommended protocol.
Example 3: Immunisation of mouse model using DNA and MEF
Ky9™ mice, substantially as described in WO2018/189520 and W02020/074874, for example, were immunised. The transgenic mice have been modified by insertion of the dog immunoglobulin variable gene repertoire into the corresponding loci of the mouse genome. This allows for the production of antibodies that comprise a variable antibody region originating from the expression of canine DNA in the mouse, in
combination with a mouse constant region (for heavy chain and kappa chain) or a dog constant region (for lambda chain). Information concerning, or the nucleic acid comprising, the variable region of such chimeric antibody chains may be used to generate fully canine antibodies.
For DNA immunisation, prime and boost regime using hydrodynamic tail vein injection (HTVI) was performed and tissues harvested. For cell-based immunisation, a prime and boost regime using MEF cells stably expressing CD20 was performed and tissues harvested. A further immunisation regime was performed using HTVI DNA immunisation for the prime combined with CD20-expressing MEF cell boosters.
Determination of serum titres:
Mice were bled prior to immunisation and 10 days after each subsequent boost. Sera were separated from clotted blood by centrifugation in microvette 200 Z-gel tubes (Starstedt AG & Co. KG, Germany) and antibody titres against canine CD20 were evaluated by flow cytometry. Sera were serially diluted 1 :10 in FACS buffer (PBS + 3 % FBS) and added to cells stably-expressing canine CD20, or canine CD20 negative control cells. Mouse antibodies to canine CD20 were detected with either BB700 conjugated (BD Horizon Brilliant™ Blue 700, BD Biosciences) or FITC-conjugated secondary monoclonal antibodies against isotypes lgG1 , lgG2a, lgG2b (BD OptiBuild™, Becton Dickinson). Data were acquired using a BD Accuri C6 Flow Cytometer (Becton Dickinson, NJ, USA) or Beckman Coulter CytoFLEX. The pre-immunisation sera were used to determine background. Antibody titres were determined as the highest dilution that showed positive signal above background. Figure 1 shows antibody titres of 5 immunised Ky9 mice.
Example 4: Isolation of antibody producing cells, antibody sequencing, selection and sequence modification
Tissue isolation: Spleens, lymph nodes and bone marrow were harvested from mice. Splenocytes were prepared by cutting the spleen into pieces and mashing them through a 40 pm cell strainer (Falcon) while rinsing with RPMI-1640 (Lonza, Basel, CH) + 10% FBS on ice. A similar process was used for lymphocytes from lymph nodes with spleen and lymph node cells generally being pooled. Bone marrow was collected from femur and tibia by flushing the marrow with RPMI-1640 using a 25-gauge needle, through a 40 pm cell strainer pre-wetted with RPMI-1640. All cell types were pelleted at 300g for 5 min and either directly used for flow sorting or resuspended in FBS + 10% dimethyl sulfoxide (DMSO) before being frozen at -150°C.
Cell Sorting : Generally, antigen-specific splenic B cells can be captured by labelled antigen protein probes (eg. extra cellular domain) or antigen-VLPs because they dominantly express transmembrane antibodies on the cell surface. On the other hand, antigen-specific plasmablast or plasma cells are thought to be less easily labelled by protein probes or VLPs because of their dominant expression of secreted antibodies. Therefore, plasmablasts and plasma cells isolated from the spleen lymph nodes sample or bone marrow were proceeded to the next step of antibody sequence recovery without using antigen probes to isolate the antigen- specific subset of these populations. Cell surface co-expression of CD138 and CD267 (TACI) was used to identify the population of plasmablasts and plasma cells. For bulk sorting of plasmablasts and plasma cells
for 10X Genomics Chromium Single Cell Immune Profiling, a CD138 plasma cell enrichment kit (Miltenyi biotech UK) was used to enrich these rare cells. Prior to antigen-specific cell sorting from spleen and lymph node cells, B cell enrichment was undertaken using a mouse pan-B cell isolation kit according to the manufacturer’s instructions (StemCell Technologies UK) or using an in-house biotinylated antibody cocktail and streptavidin rapidspheres (StemCell Technologies UK) according to the manufacturer’s instructions.
Markers including CD19, IgM, IgA, IgD, CD138 and CD267 (TACI) are then used to identify isotype-switched B cells enriched in cells that are responding to the immunisation. Within this population, antigen-specific cells can be captured by staining with labelled protein probes or VLPs that express target antigen upon their surface and flow sorting. VLPs are generated from HEK cells stably transfected with CD20, and the retrovirus gag protein fused to EGFP; the gag expression enables VLP budding from cells, and EGFP labels the VLPs for fluorescence-detection. Surface antigens on VLPs are directly expressed from recombinant cells without any step of purification or modification, and are presented in a native form. Other mammalian cell lines, such as Chinese Hamster Ovary cells (CHO) or mouse embryonic fibroblasts (MEF) can also be used for VLP production. Markers to identify unwanted cell populations and dead cells (F4/80; Ly-6C/G; CD8a; CD4; CD11 c; 7AAD or zombie-NIR/FVD EF780) are included in all staining panels to exclude these cells from the sorting procedure.
Next Generation Sequencing and candidate selection:
Sorted cells are prepared for antibody profiling using the 10X Genomics Chromium Single Cell Immune Profiling system and the V(D)J Kit (10X Genomics) according to the manufacturer’s instructions. For 10X, various lllumina platform instruments are used according to the instructions from 10X Genomics. The sequences are analysed using custom tools based on the pRESTO /Change-O (Yale University) / IgBlast (NCBI, USA)/Enclone (10X Genomics) software to predict the germline sequence and hypermutation.
The variable immunoglobulin region comprises a VDJ region of an immunoglobulin nucleotide sequence for heavy genes and a VJ region of an immunoglobulin nucleotide sequence for IgK and IgA. Within a clonal family there are subfamilies with shared mutations within their V(D)J segments that arise during immunoglobulin gene recombination and somatic hypermutation. Different clonal families that display unique V(D)J segment usage usually exhibit different binding characteristics. During recombination and hypermutation, cells whose antibodies have a higher affinity for an antigen are selected. The affinity usually increases with further mutations; for example, a clustered family is shown in Figure 6 of WO2015/040401 .
A clonal family is generally defined by related immunoglobulin heavy chain and light chain V(D)J sequences of two or more clonal cells. Related immunoglobulin V(D)J sequences can be identified by theirshared usage of V and J gene segments. An example of the analysis of antibody sequences of sorted Ag-specific single B- cells is shown in Figure 5 of WO2015/040401 , and shows antibody sequences that are arranged by heavy- chain V-gene family usage, and clustered to generate the displayed phylogenetic trees. From phylogenetic trees such as these, candidate clones are selected.
For instance, anti-canine CD20 mAbs PMX001 , PMX002, PMX003, PMX004 and PMX005 are all encoded by the same heavy chain V-gene (CIGHV3-5), heavy chain J-gene (clGHJ4, with germline sequence given in SEQ ID NO: 75), light chain V-gene (clGLV3-3) and light chain J-gene (clGLJ3, with germline sequence given in SEQ ID NO: 77). PMX001 variable region sequences were first identified from a canine CD20 immunised Ky9 mouse. It has a heavy chain variable region nucleotide sequence (SEQ ID NO: 3) that encodes for the corresponding amino acid sequence (SEQ ID NO: 4) and a light chain variable region nucleotide sequence (SEQ ID NO: 5) that encodes for the corresponding amino acid sequence (SEQ ID NO: 6). There are 2 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 3 amino acid changes in light chain variable sequence as compared to the germline sequence (SEQ ID NO: 76). The CDR1 (SEQ ID NO: 7), CDR2 (SEQ ID NO: 8) and CDR3 (SEQ ID NO: 9) of the heavy chain variable region and the CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the light chain variable region are predicted using IMGT V-QUEST (http://www.imgt.org/IMGT_vquest/input). The CDR3 regions of the heavy chain and the light chain of PMX mAbs are 5aa and 9aa in length, respectively.
Hit expansion of PMX001 mAb was later performed in all the canine CD20 immunised mice, and candidates that share the same VJ gene usage and CDR3 length for both heavy and light chains were selected for further screening. Further mutations may occur in the sequences compared to PMX001 mAb. For instance, PMX002, PMX003, PMX004 and PMX005 mAbs were selected from other immunisation cohorts and hence different mice from where PMX001 mAb was identified. It shows the convergent selection of successful gene rearrangement.
PMX002 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 13) that encodes for the corresponding amino acid sequence (SEQ ID NO: 14) and a light chain variable region nucleotide sequence (SEQ ID NO: 15) that encodes for the corresponding amino acid sequence (SEQ ID NO: 16). There are 10 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDR1 (SEQ ID NO: 17), CDR2 (SEQ ID NO: 18) and CDR3 (SEQ ID NO: 19) of the heavy chain variable region and the CDR1 (SEQ ID NO: 20), CDR2 (SEQ ID NO: 21) and CDR3 (SEQ ID NO: 22) of the light chain variable region are predicted using IMGT V-QUEST.
PMX003mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 23) that encodes for the corresponding amino acid sequence (SEQ ID NO: 24) and a light chain variable region nucleotide sequence (SEQ ID NO: 25) that encodes for the corresponding amino acid sequence (SEQ ID NO: 26). There are 5 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and 1 amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDR1 (SEQ ID NO: 27), CDR2 (SEQ ID NO: 28) and CDR3 (SEQ ID NO: 29) of the heavy chain variable region and the CDR1 (SEQ ID NO: 30), CDR2 (SEQ ID NO: 31) and CDR3 (SEQ ID NO: 32) of the light chain variable region are predicted using IMGT V-QUEST.
PMX004 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 33) that encodes for the corresponding amino acid sequence (SEQ ID NO: 34) and a light chain variable region nucleotide sequence (SEQ ID NO: 35) that encodes for the corresponding amino acid sequence (SEQ ID NO: 36). There are 12 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDR1 (SEQ ID NO: 37), CDR2 (SEQ ID NO: 38) and CDR3 (SEQ ID NO: 39) of the heavy chain variable region and the CDR1 (SEQ ID NO: 40), CDR2 (SEQ ID NO: 41) and CDR3 (SEQ ID NO: 42) of the light chain variable region are predicted using IMGT V-QUEST.
PMX005 mAb has a heavy chain variable region nucleotide sequence (SEQ ID NO: 43) that encodes for the corresponding amino acid sequence (SEQ ID NO: 44) and a light chain variable region nucleotide sequence (SEQ ID NO: 45) that encodes for the corresponding amino acid sequence (SEQ ID NO: 46). There are 4 amino acid changes in the heavy chain variable sequence as compared to germline sequence (SEQ ID NO: 74) and no amino acid change in light chain variable sequence (SEQ ID NO: 76). The CDR1 (SEQ ID NO: 47), CDR2 (SEQ ID NO: 48) and CDR3 (SEQ ID NO: 49) of the heavy chain variable region and the CDR1 (SEQ ID NO: 50), CDR2 (SEQ ID NO: 51) and CDR3 (SEQ ID NO: 52) of the light chain variable region are predicted using IMGT V-QUEST.
Figure 2 shows an alignment of PMX antibody sequences.
Sequence modification
The framework region 1 (FR1) of the light chain of PMX003 (SEQ ID NO: 26) contains the NVT sequon, which is a consensus sequence for asparagine-linked glycosylation of proteins. To remove the glycans bound to this site, the NVT sequon in the FR1 of PMX003 mAb was mutated to QVT for PMX006 mAb, AVT for PMX007 mAb, EVT for PMX008 mAb, NVA for PMX009 mAb, SVT for PMX010 mAb and TVT for PMX011 mAb.
The resulted light chain variable region amino acid sequences of PMX006 mAb (SEQ ID NO: 53), PMX007 mAb (SEQ ID NO: 54), PMX008 mAb (SEQ ID NO: 55), PMX009 mAb (SEQ ID NO: 56), PMX010 mAb (SEQ ID NO: 57), PMX011 mAb (SEQ ID NO: 58) and the FR1 sequences of PMX003 (SEQ ID NO: 59), PMX006 mAb (SEQ ID NO: 60), PMX007 mAb (SEQ ID NO: 61), PMX008 mAb (SEQ ID NO: 62), PMX009 mAb (SEQ ID NO: 63), PMX010 mAb (SEQ ID NO: 64), PMX011 mAb (SEQ ID NO: 65) are listed in the Sequences Table.
The framework region 1 (FR1) of the light chain of PMX066 (SEQ ID NO: 81), PMX0067 (SEQ ID NO: 91), PMX068 (SEQ ID NO: 101), PMX0069 (SEQ ID NO: 111), PMX071 (SEQ ID NO: 131), PMX072 (SEQ ID NO: 141), PMX073 (SEQ ID NO: 151), PMX074 (SEQ ID NO: 161), PMX076 (SEQ ID NO: 181), PMX077 (SEQ ID NO: 191), PMX078 (SEQ ID NO: 201), PMX079 (SEQ ID NO: 211), PMX081 (SEQ ID NO: 231),
contains the NVT sequon. To remove the glycans bound to this site, the NVT sequon in the FR1 of PMX066, PMX0067, PMX068, PMX0069, PMX071 , PMX072, PMX073, PMX074, PMX076, PMX077, PMX078, PMX079, PMX081 mAb was mutated to SVT to generate the resulting light chain variable region amino acid sequences PMX112 (SEQ ID NO: 238), PMX113 (SEQ ID NO: 239), PMX114 (SEQ ID NO: 240), PMX115 (SEQ ID NO: 241), PMX116 (SEQ ID NO: 242), PMX117 (SEQ ID NO: 243), PMX118 (SEQ ID NO: 244), PMX119 (SEQ ID NO: 245), PMX120 (SEQ ID NO: 246), PMX121 (SEQ ID NO: 247), PMX122 (SEQ ID NO: 248), PMX123 (SEQ ID NO: 249) and PMX124 (SEQ ID NO: 250) respectively. The sequences are listed in Table 2. A number of the antibodies comprise naturally occurring sequence motifs which do not result in glycan being bound to the antibody. For example, PMX070 and PMX075 comprise the sequence motif SVT in FR1 of the light chain, PMX080 comprises the sequence motif TVT in FR1 of the light chain.
Example 5: Generation of monoclonal antibodies from single cells
The heavy chain and light chain V(D)J sequence of selected candidate clones are synthesised and cloned into expression vectors containing the genomic sequences of the dog IgG constant region, and the dog IGK or IGL constant regions, respectively. For instance, PMX001 to PMX005 variable sequences were cloned into the vectors that encode the dog IGGB (SEQ ID NO: 66) and dog IGLC5 constant regions (SEQ ID NO: 67). The expression vectors encoding the heavy chain and light chain were co-transfected into a suitable mammalian cell line such as CHO cells to obtain stable expression. Fully canine sequence antibodies were thus generated.
To facilitate the expression in CHO cells, codon-optimisation can be performed, for example, on the nucleotide sequences of the heavy chain variable region (SEQ ID NO: 68) and light chain variable region (SEQ ID NO: 69) of PMX003 mAb. Campath leader (SEQ ID NO: 70) (see US 8,362.208 B2)l can be introduced to replace the native leader (SEQ ID NO: 71 for heavy chain, SEQ ID NO: 72 for light chain) of PMX001 to PMX005 mAbs.
Monoclonal antibodies 1 E4 and 4E1-7 were also expressed. 1 E4 nucleotide sequence was obtained from WO2013063186. 4E1-7 amino acid sequence was obtained from Mizuno et al. Scientific Reports, 10, Article 11476 (2020) (https://doi.org/10.1038/s41598-020-68470-9). The variable regions of both antibodies were cloned into vectors that encode the dog IGGB (SEQ ID NO: 66) and dog IGK (SEQ ID NO: 73) constant regions. Rituximab-cIGGB control mAb was generated by synthesizing the variable region sequences (see US 5,736,137) and cloned into vectors that encode dog IGGB (SEQ ID NO: 66) and dog IGLC5 (SEQ ID NO: 67) constant regions.
The core fucose on the N-linked glycans bound to the Fc portion of antibodies could affect the binding of Fc receptors to the Fc region of the antibodies and therefore reduce the ADCC activities. To enhance the ADCC killing activities, Fut8 knockout (KO) CHO cells were generated in a pooled format, by deleting exon 2 of Fut8 coding gene as described in Yamane-Ohnuki et al., Biotechnol Bioeng. 2004 Sep 5;87(5):614- 22. https://pubmed.ncbi.nlm.nih.gov/15352059/). The KO cells were phenotypically selected using LCA staining.
For antibody production, 6 c 106 selected CHO cells or Fut8 knockout CHO cells were seeded in 3 ml culture media and incubated at 32°C, 8% CO2 with shaking at 200 rpm. 4 % HyClone Cell Boost 7a supplement + 0.4 % HyClone Cell Boost 7b supplement + 1 % glucose was added to the media on days 1 , 4, 7 and 10. Culture supernatants were collected on day 12 and the IgG concentration was determined using surface plasmon resonance (Biacore 8K, Cytiva Life Sciences).
Example 6: Binding assays
Flow cytometry-based assay:
HEK293 cells or MDCK II cells were stably transfected with a vector encoding the full length of canine CD20 cDNA. Binding of antibodies to these cells were assessed using flow cytometry. In brief, 1-2 x105 canine CD20-expressing cells were incubated with candidate mAbs for 1 hour at +4°C, at a fixed concentration of 1 pg/ml or 10 pg/ml for binding assays and a range of concentrations (12-point 1 :2 serial dilution antibodies starting at 30 pg/ml i.e. 200nM) for affinity determination, followed by incubation with 5 pg/ml of FITC- conjugated anti-canine IgG secondary antibody (Bethyl Laboratories) for 1 hour at +4°C. Cells incubated with anti-canine IgG FITC secondary antibody and without primary anti-canine CD20 antibody, or with isotype control primary antibody, were used as negative controls. The data were acquired on either a Beckman Coulter CytoFLEX or a BD Accuri C6 Plus flow cytometer and analysed using FlowJo software. For affinity determination, stained cells were washed and fixed with 1% paraformaldehyde/ 3%FBS/ PBS for 15 min after incubation with candidate antibodies and were fixed again for 24 h after incubation with secondary antibody before data acquisition on the flow cytometer. Graphs using mean fluorescence intensity (MFI) values of the FITC channel vs concentration of antibody were plotted in GraphPad Prism (Figure 3D). Apparent affinity (Kd) of binding of candidate antibodies to cell surface canine CD20 was determined as the concentration when 50% of CD20-expressing cells were stained, i.e. EC50 of binding, using an equation for log(agonist) vs response - variable slope (four parameters).
Results of binding assays are shown in Figure 3 A-C. These show that PMX antibodies had a stronger binding capacity to canine CD20 than test antibodies 1 E4 and 4E1-7 at a single point of concentration (10 ug/ml), apart from PMX002 which was equivalent to 4E1-7 antibody.
ELISA-based assay:
The large loop of the extracellular domain (ECD) of canine CD20 protein, as described below, is expressed in CHO cells and secreted into the extracellular media under the control of the CAG promoter, before purification using a protein A column.
CD20 ECD protein is coated to the assay plate. Antibodies are added at a range of concentrations and the binding capacity determined using ELISA.
SPR-based assay:
Affinity (Kd) of anti-canine CD20 mAbs can be measured by SPR, using a recombinant mouse Fc tagged CD20 extracellular domain.
The recombinant extracellular domain (ECD) (large loop) of CD20 named dCD20LL-Fc (see WO2013/063186, page 37, SEQ ID NO:62) is expressed in secreted form with a murine lgG2a Fc tag from stable CHO cells and purified from clarified supernatant using protein A chromatography. An apparent K corresponding to the bivalent avidity of the interaction is derived by amine coupling 100-150 RU of dCD20LL- Fc onto flow cell 2 of a CM5 chip with NHS/EDC activation/deactivation applied to flow cell 1 . Three-fold dilutions from 200 nM to 0.1 nM concentrations of candidate IgG are made in HBS-EP+ buffer and injected over the chip surface for 180 s at 30 pL/min. Dissociation is monitored for 600 s at 30 pL/min before regenerating the surface with a 60s pulse of 10 mM glycine-HCI pH 2.0. A monovalent Kd corresponding to the monovalent affinity is derived by repeating the protocol above using candidate antibody Fab fragment generated by papain (or SpeB) digestion of the full-length IgG. Experiments are conducted in HBS-EP+ running buffer at 25°C. All SPR experiments are carried out on a Biacore 8K instrument and data analysed by fitting the data to a 1 :1 binding model using Biacore Insight Evaluation software.
Example 7: Functional assays
Complement Dependent Cytotoxicity (CDC) Activity
CLBL-1 canine lymphoma tumour cell line (University of Veterinary Medicine Vienna) that natively expresses canine CD20 was used as the target cell line for a CDC assay.10,000 CLBL-1 cells per well of 96-well plate (white with clear bottom) were incubated with a titration (11 -point 1 :3 dilution starting at 10 pg/ml) of anticanine CD20 antibody and canine complement preserved serum (BiolVT) at a final dilution of 1 :4, for 2 hours at 37°C, 5% C02. The assay was set up using media (RPMI + 1% L-glutamine + 20% fetal bovine serum) made using heat inactivated serum so that canine complement preserved serum would be the only source of complement. Rituximab-cIGGB chimeric antibody was used as the negative, isotype control.
Live cells were then quantified using CellTitre-Glo® Luminescent Cell Viability Assay (Promega) following the assay protocol. This assay uses the ATP content of live cells as an indication of cell viability. Luminescence was measured on a CLARIOstar (BMG Labtech). Data were analyzed using MARS software (BMG Labtech) and the number of live cells remaining was used to calculate the percentage of killing in the presence of antibodies using Microsoft Excel, using wells without antibody as baseline. Graphs were plotted in GraphPad Prism.
Figure 4 shows CDC activity was observed with PMX003 in both native and a-fucosylated form. No CDC activity was observed for the native and a-fucosylated form of 1 E4 and 4E1-7 test antibodies under the same experimental settings using canine complement preserved serum. Table 4 summarises the CDC activity for antibodies PMX066 to PMX081 .
Antibody Dependent Cellular Cytotoxicity (ADCC) Activity
Canine cell line, such as MDCK II cell line (ATCC), was stably transfected with a construct encoding for the canine CD20 protein and a construct expressing a fluorescent protein (e.g. GFP). Either MDCK II cell line expressing the fluorescent protein, but not antigen, or an isotype control antibody was used as negative control for the experiment.
Canine peripheral blood mononuclear cells (PBMCs, Envigo) were used as a source of effector cells. PBMCs were isolated from freshly drawn whole blood, with sodium heparin anticoagulant, using Ficoll-Paque plus (Cytiva, GE17-1440-02) density gradient centrifugation by following the recommended protocol. PBMCs were resuspended in media (PBMC media = RPMI + 10% heat inactivated foetal bovine serum + 1% penicillin- streptomycin + 1% non-essential amino acids + 1% L-glutamine + 1% sodium pyruvate + 2% HEPES) supplemented with 50 ng/ml of recombinant canine IL-2 (R&D systems) and incubated for 24 hours at 37°C before being used in ADCC assay.
To assess ADCC activity, 10,000 MDCK II cells were co-cultured with PBMCs at an effector: target ratio of 35:1 and a titration of antibodies (11-point 1 :3 dilution starting at 10 pg/ml antibody), for 24 h at 37°C, in a 1 :1 mix of MDCK II media (DMEM + 1% L-glutamine + 10% fetal bovine serum) and PBMC media. Rituximab- cIGGB was used as the negative (isotype) control antibody.
GFP signal, which is proportional to the number of live cells per well, was used as a measure of the number of live cells remaining in the well at the end of the 24h incubation. GFP signal was measured on a CLARIOstar (BMG Labtech). Data was analysed using MARS software (BMG Labtech) and percentage of killing in the presence of antibodies was calculated using Microsoft Excel, using wells without antibody as baseline. Graphs were plotted with GraphPad Prism.
Figure 5 shows ADCC activity was observed in the presence of PMX antibodies. PMX003 antibody shows a stronger ADCC activity than test antibodies 1 E4 and 4E1-7, in both native and afucosylated form. Table 4 summarises the ADCC activity observed for antibodies PMX066 to PMX081 .
Antibody Dependent Cellular Phagocytosis (ADCP) Activity
A suitable method for measuring ADCP activity is described in Ito et al. Leuk Lymphoma. 2015 January; 56(1): 219-225.
Direct killing activity / Apoptosis assay
Direct killing may be measured as described in Mizuno et al. Scientific Reports, 10, Article 11476 (2020).
Example 8: Ex vivo - whole blood assay
To assess the B cell depletion efficiency in ex vivo dog models, 100 pi of freshly drawn dog whole blood was collected with heparin and diluted with 200 pi of RPMI1640 + 10% heat inactivated fetal bovine serum + 1% penicillin/streptomycin/L-glutamine + 1% non-essential amino acids + 1% sodium pyruvate + 2% HEPES buffer. The diluted blood was incubated with or without 10 pg/ml of anti-canine CD20 antibodies for 2 hours, 24 hours and 96 hours at 37°C. After incubation, samples were incubated with Versalyse solution (Beckman Coulter) for 15 minutes at room temperature to lyse red blood cells (RBCs). After washing, the samples were stained with anti-canine CD21 antibody and anti-canine CD8 antibody (both from BioRad), and the number of CD21 + B cells and CD8+ T cells were analysed on CytoFLEX Flow Cytometer (Beckman Coulter). The percentage of B cell depletion was calculated based on the decrease of the ratio of CD21 + B cells to CD8+ T cells as compared to no antibody control. Results in Figure 6A-B show that PMX003 mAb led to a more efficient killing of B cells in whole canine blood as compared to 1 E4 and 4E1-7 mAbs. Table 4 summarises the ex vivo specific B cell depletion activity observed for antibodies PMX066 to PMX081 .
Example 9: In vivo assays
Tumour mouse model
A syngeneic tumour mouse model is generated to evaluate the in vivo tumour killing efficiency of anti-canine CD20 antibodies. The genomic sequences of mouse 129Sv ES cells are modified to replace the mouse CD20 coding region with dog CD20 coding region by homologous recombineering. The targeting vector contains the genomic DNA sequence of dog CD20 coding region flanked by 4-4.5kb of mouse genomic sequences on both sides. After microinjection and germline transmission, the thus-generated mice are bred with Balb/c mice to produce mCD20/dCD20 heterozygous progenies of mixed genetic background.
The mouse lymphoma cell line A20 of Balb/c genetic background is also modified to express dog CD20. The mouse CD20 coding region is replaced by dog CD20 coding sequence by transfecting the A20 cell line with linearized ES cell targeting vector.
To assess the mouse tumour killing efficiency, 1 million dog CD20 knock-in A20 cells (in 100 mI of PBS) are subcutaneously transplanted to mCD20/dCD20 heterozygous mice (6-8 weeks old). Anti-canine CD20- mlGG2a chimeric antibodies (150 pg in 500 mI of PBS) or PBS only are intraperitoneally injected once on Day 0. The size of the tumour is measured every day and the mice are euthanized when the humane endpoints are reached.
In vivo dog studies
In dog study 1 , twelve healthy male beagles (three dogs per test group), 2-3 years old and weighing 8-11 kg, were bred at Avogadro LS, France. All of them were verified to be free of disease or other clinical abnormalities prior to the study. The native format of PMX003 antibody was produced in CHO cells and was administered to two test groups, with one group receiving 0.5mg/kg antibody and the other receiving
2.5mg/kg antibody. The a-fucosylated version of PMX003 antibody was produced by expressing it in Fut8 KO CHO cells and it was administered to one test group at 0.5 mg/kg. The control group received isotype control, rituximab-cIGGB, at 2.5mg/kg. All antibodies were administered on day 0 as a single dose intravenous infusion over 30 minutes. The percentage of CD21+ B cells was monitored and analysed on the following days post antibody administration: day 0 (pre-dose), 1 , 2, 5, 7, 15, 27 and 43. 0.5ml freshly drawn blood with K3EDTA anticoagulant was fixed with 1 ml 1x RBC Lysis/ Fixation Solution (BioLegend) for 30 minutes at room temperature in the dark and then diluted with 18 ml of 1x PBS. The fixed and diluted blood samples were kept at +4°C throughout storage and shipping to the UK. Sample analysis was performed within 48 hours from blood draw. For each sample, the cells were pelleted at 400g for 5 min, the cell pellets were resuspended in 0.5 ml buffer and 50 pi cells were used for staining of each technical replicate. For each replicate, cells were stained with AF647 conjugated anti-canine CD21 antibody (BioRad, 1 :10) and PE conjugated anti-canine CD8 antibody (BioRad, 1 :50). Data was acquired using Beckman Coulter CytoFLEX by setting the threshold on DAPI to exclude debris and non-nucleated cells. Percentage of CD21 + B cells and CD8+ T cells in the lymphocyte population was analysed using FlowJo software. B cell depletion was determined by comparing the percentage of CD21+ B cells on the day of assessment post antibody administration to the percentage on day 0 (baseline) for each dog. The percentage of CD8+ T cells was also evaluated and served as the internal control. Figure 7A-B shows the results of B cell depletion in healthy beagles administered PMX and control antibodies. Depletion was observed when PMX003 was administered in native and a-fucosylated form. The a-fucosylated form was more effective than the native form. PMX003 showed B cell killing at a much lower dose than that observed in a dog study using 1E4 (Rue et al. Veterinary Immunology and Immunopathology 164(2015), 148-159. In addition, B cell depletion was maintained at a low level for at least 15 days which is longer than observed in a dog study for 4E1-7 (Mizuno et al.).
In dog study 2, fifteen healthy male beagles (three dogs per test group), 2-3 years old and weighing 8-11 kg, were bred at Avogadro LS, France. All of them were verified to be free of disease or other clinical abnormalities prior to the study. The native format of PMX070 and PMX115 antibody was produced in CHO cells and was administered to two test groups per antibody, with one group receiving 0.5mg/kg antibody and the other receiving 2mg/kg antibody. The control group received isotype control, rituximab-cIGGB, at 2mg/kg. All antibodies were administered on day 0 as a single dose intravenous infusion over 30 minutes. The percentage of CD21 + B cells was monitored and analysed on the following days post antibody administration: day 0 (pre-dose), 1 , 4, 7, 14, 21 and 28. 1 ml freshly drawn blood with K3EDTA anticoagulant was fixed with 2ml 1x RBC Lysis/ Fixation Solution (BioLegend) for 30 minutes at room temperature in the dark and then diluted with 12 ml of 1x PBS. The fixed and diluted blood samples were kept at +4°C throughout storage and shipping to the UK. Sample analysis was performed between 48-72 hours from blood draw. For each sample, the cells were pelleted at 400g for 5 min, the cell pellets were resuspended in 1 ml buffer and 50 pi cells were used for staining of each technical replicate. For each replicate, cells were stained with AF647 conjugated anti-canine CD21 antibody (BioRad, 1 : 10) and PE conjugated anti-canine CD8 antibody (BioRad, 1 :50). Data was acquired using Beckman Coulter CytoFLEX by setting the threshold on DAPI to exclude debris and non- nucleated cells. Percentage of CD21+ B cells and CD8+ T cells in the lymphocyte population was analysed using FlowJo software. B cell depletion was determined by comparing the percentage of CD21+ B cells on
the day of assessment post antibody administration to the percentage on day 0 (baseline) for each dog. The percentage of CD8+ T cells was also evaluated and served as the internal control. Figure 7C shows the results of B cell depletion in healthy beagles administered PMX and control antibodies. Depletion was observed for PMX070 and PMX115 at 0.5mg/kg and 2mg/kg doses, and was comparable to the depletion observed with the a-fucosylated form of PMX003.
For pharmacokinetic analysis, the plasma concentration of the mAb drug was monitored and analysed at the following times post antibody administration: Pre-dose, T2h, T6h, T24h, T48h, T72h, T120h, T168h, T360h, D27 and D43 in dog study 1 and pre-dose, T2h, T6h, T24h, D4, D7, D14, D21 and D28 in dog study 2. Fresh blood with lithium heparin anticoagulant was placed on ice immediately after blood draw. The blood tubes were centrifuged at 2500g for 10 min at +5°C. The plasma was collected into polypropylene tubes and kept on ice until storage at -20°C. The plasma was kept frozen till analysis by ELISA. The concentration of mAb is assessed by ELISA using anti-idiotype polyclonal antibodies against PMX mAb as capture antibodies and anti-canine Fc-HRP (Sigma) or anti-canine Fc-biotin (Sigma) plus streptavidin-HRP (BioLegend) as detection antibody. Anti-idiotype polyclonal or monoclonal antibodies against PMX mAb are raised at GenScript by immunisation of rabbits with PMX Fab fragments, hybridoma cell line generation and selection of anti-idiotype antibodies that bind to PMX mAb followed by removal of any cross-reactive antibodies that bind isotype control antibody.
For immunogenicity assessment, the concentration of anti-drug antibodies (ADA) in the frozen plasma is assessed by ELISA after acid dissociation of any preformed complexes between candidate PMX antibodies and anti-drug antibodies. Chimeric versions of candidate antibodies, for example PMX-mouseFc or PMX- humanFc, are generated and a fraction is labelled with biotin. Presence and concentration of anti-drug antibodies is determined using a sandwich ELISA assay format where the unlabelled chimeric antibody is used as a capture reagent and the biotin labelled chimeric antibody along with streptavidin-HRP is used for detection. The anti-idiotype polyclonal antibodies generated for the pharmacokinetic assay above is used as a positive control and to generate a standard curve.
Example 10: Epitope Mapping
Epitope mapping was conducted to identify the site on canine CD20 antigen that the antibodies specifically bind to. Using site-directed mutagenesis, dog-human chimeric CD20-expressing vectors were generated by dividing the extracellular domain of canine CD20 into 9 regions and replacing each region in the dog sequence with the equivalent location in human sequence (Figure 8A). The same strategy was used to generate dog-mouse chimeric CD20 (Figure 8B). Mutated full length cDNA were expressed in MDCK cells as described in Example 2. By comparing the binding of PMX003, PMX115 and PMX070 to these chimeric mutants with the binding to wildtype CD20, the sequence ITISHFFKMENLNLIKAPM (SEQ ID NO. 303) was identified as the epitope of PMX003, PMX115 and PMX070, as the mutation at this position led to a reduced binding in flow cytometric analysis (Figure 9). “ENLNLIKAPM” (SEQ ID NO. 303, amino acid No. 150-159 in Seq ID NO: 2) was identified as the core epitope within that sequence. This epitope is different from
“DIHNCD” which was described as the epitope of the benchmark 1 E4 antibody. Another strategy to investigate the epitope is by alanine scanning, in which single alanine mutations are generated at every residue in the small loop and every other residue in the large loop (Figure 8C).
Example 11 Developabilitv criteria
There are several aspects of antibody characterisation including: 1) Transient expression level during small- scale antibody production which correlates to the eventual stable expression level which affects COGS (cost of goods sold). 2) Thermal stability which correlates to a number of properties, including propensity to aggregate, and compatibility with higher concentration formulations. Thermal stability can be reflected by Tm1 value, which is the temperature when 50% of the proteins are unfolded, and Tagg, which is the aggregation temperature. The Tm1 and Tagg values of the lead antibodies were measured using the UNcle protein stability screening platform (Unchained Labs). 3) Size and purity. Fragmentation and aggregation may lead to issues with efficacy or immunogenicity in vivo. The size of the antibodies was determined on non-reduced and reduced SDS-PAGE gel. HPLC-SEC indicated that each candidate product is made up of over 95% monomers. The diameter of the particles was detected using the UNcle machine which allowed us to detect potential issues of aggregation. The developability parameters of PMX003, PMX066, PMX067, PMX069, PMX070, PMX071 , PMX072, PMX073, PMX074, PMX075, PMX076, PMX077, PMX078,
PMX079, PMX080, PMX081 , PMX112, PMX115, PMX122 and PMX124 antibodies were displayed in Table 5.
Example 12 Analysis of deqlvcosylated antibodies
In addition to the above, a prediction of sequence liabilities was conducted using in silico sequence analysis. An N-linked glycosylation motif (NVT) was identified in the framework region 1 (FR1) of the light chain in PMX003 mAb and also in another 12 mAbs from the lead panel (except PMX070, PMX075 and PMX080). To reduce liabilities by preventing glycosylation at this position the NVT sequon in light chain FR1 of PMX003 was mutated to QVT (PMX006), AVT (PMX007), EVT (PMX008), NVA (PMX009), SVT (PMX010) and TVT (PMX011). De-glycosylation was observed by comparing the size of the light chain of the mutant antibodies with the original PMX003 mAb on a reduced SDS-PAGE gel. Following this, a binding and functional assessment was performed in order to evaluate the impact of these mutations. Flow-cytometry analysis revealed that the binding capacity to canine CD20-expressing cells remained unchanged, apart from QVT and AVT mutants which were slightly reduced (Figure 3B). Similarly, the killing potency in in vitro ADCC assay (Figure 5D and 5E) , and ex vivo whole blood assay (Figure 6C) was not significantly influenced by these mutations. Therefore, it is possible to modify the NVT motif for de-glycosylation without compromising the binding and functional activities.
Table 2: SEQUENCES
Table 3. VH and VL gene usage
Table 4. Summary of functional data for antibodies
Table 5 Developability profile
* average of 3 production batches
Claims
1 . An isolated canine antibody or antigen-binding portion thereof which binds canine CD20 wherein said antibody comprises a) a HC CDR1 sequence comprising or consisting of SEQ ID No. 27 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 27, b) a HC CDR2 sequence comprising or consisting of SEQ ID No. 28 or an amino acid sequence which has 1 , 2, 3 or 4 amino acid differences compared to SEQ ID No. 28, c) a HC CDR3 sequence comprising or consisting of SEQ ID No. 29 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 29, d) a LC CDR1 sequence comprising or consisting of SEQ ID No. 30 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 30, e) a LC CDR2 sequence comprising or consisting of SEQ ID No. 31 or an amino acid sequence which has 1 amino acid difference compared to SEQ ID No. 31 and f) a LC CDR3 sequence comprising or consisting of SEQ ID No. 32 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID No. 32.
2. The antibody or antigen-binding portion thereof according to claim 1 wherein said antibody or antigen-binding portion thereof has i) a HC CDR1 sequence comprising or consisting of SEQ ID No. 7, a HC CDR2 sequence comprising or consisting of SEQ ID No. 8, a HC CDR3 sequence comprising or consisting of SEQ ID No. 9, a LC CDR1 sequence comprising or consisting of SEQ ID No. 10, a LC CDR2 sequence comprising or consisting of SEQ ID No. 11 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 12, ii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 17, a HC CDR2 sequence comprising or consisting of SEQ ID No. 18, a HC CDR3 sequence comprising or consisting of SEQ ID No. 19, a LC CDR1 sequence comprising SEQ ID No. 20, a LC CDR2 sequence comprising or consisting of SEQ ID No. 21 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 22, iii) a HC CDR1 sequence comprising SEQ ID No. 37, a HC CDR2 sequence comprising SEQ ID No. 38, a HC CDR3 sequence comprising SEQ ID No. 39, a LC CDR1 sequence comprising SEQ ID No. 40, a LC CDR2 sequence comprising SEQ ID No. 41 and a LC CDR3 sequence comprising SEQ ID No. 42, iv) a HC CDR1 sequence comprising or consisting of SEQ ID No. 47, a HC CDR2 sequence comprising or consisting of SEQ ID No. 48, a HC CDR3 sequence comprising or consisting of SEQ ID No. 49, a LC CDR1 sequence comprising or consisting of SEQ ID No. 50, a LC CDR2
sequence comprising or consisting of SEQ ID No. 51 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 52, v) a HC CDR1 sequence comprising or consisting of SEQ ID No. 82, a HC CDR2 sequence comprising or consisting of SEQ ID No. 83, a HC CDR3 sequence comprising or consisting of SEQ ID No. 84, a LC CDR1 sequence comprising or consisting of SEQ ID No. 85, a LC CDR2 sequence comprising or consisting of SEQ ID No. 86 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 87, vi) a HC CDR1 sequence comprising or consisting of SEQ ID No. 92, a HC CDR2 sequence comprising or consisting of SEQ ID No. 93, a HC CDR3 sequence comprising or consisting of SEQ ID No. 94, a LC CDR1 sequence comprising or consisting of SEQ ID No. 95, a LC CDR2 sequence comprising or consisting of SEQ ID No. 96 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 97, vii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 102, a HC CDR2 sequence comprising or consisting of SEQ ID No. 103, a HC CDR3 sequence comprising or consisting of SEQ ID No. 104, a LC CDR1 sequence comprising or consisting of SEQ ID No. 105, a LC CDR2 sequence comprising or consisting of SEQ ID No. 106 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 107, viii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 112, a HC CDR2 sequence comprising or consisting of SEQ ID No. 113, a HC CDR3 sequence comprising or consisting of SEQ ID No. 114, a LC CDR1 sequence comprising or consisting of SEQ ID No. 115, a LC CDR2 sequence comprising or consisting of SEQ ID No. 116 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 117, ix) a HC CDR1 sequence comprising or consisting of SEQ ID No. 122, a HC CDR2 sequence comprising or consisting of SEQ ID No. 123, a HC CDR3 sequence comprising or consisting of SEQ ID No. 124, a LC CDR1 sequence comprising or consisting of SEQ ID No. 125, a LC CDR2 sequence comprising or consisting of SEQ ID No. 126 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 127, x) a HC CDR1 sequence comprising or consisting of SEQ ID No. 132, a HC CDR2 sequence comprising or consisting of SEQ ID No. 133, a HC CDR3 sequence comprising or consisting of SEQ ID No. 134, a LC CDR1 sequence comprising or consisting of SEQ ID No. 135, a LC CDR2 sequence comprising or consisting of SEQ ID No. 136 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 137, xi) a HC CDR1 sequence comprising or consisting of SEQ ID No. 142, a HC CDR2 sequence comprising or consisting of SEQ ID No. 143, a HC CDR3 sequence comprising or consisting of SEQ ID No. 144, a LC CDR1 sequence comprising or consisting of SEQ ID No. 145, a LC CDR2 sequence comprising or consisting of SEQ ID No. 146 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 147, xii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 152, a HC CDR2 sequence comprising or consisting of SEQ ID No. 153, a HC CDR3 sequence comprising or consisting of
SEQ ID No. 154, a LC CDR1 sequence comprising or consisting of SEQ ID No. 155, a LC CDR2 sequence comprising or consisting of SEQ ID No. 156 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 157, xii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 162, a HC CDR2 sequence comprising or consisting of SEQ ID No. 163, a HC CDR3 sequence comprising or consisting of SEQ ID No. 164, a LC CDR1 sequence comprising or consisting of SEQ ID No. 165, a LC CDR2 sequence comprising or consisting of SEQ ID No. 166 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 167, xiii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 172, a HC CDR2 sequence comprising or consisting of SEQ ID No. 173, a HC CDR3 sequence comprising or consisting of SEQ ID No. 174, a LC CDR1 sequence comprising or consisting of SEQ ID No. 175, a LC CDR2 sequence comprising or consisting of SEQ ID No. 176 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 177, xiv) a HC CDR1 sequence comprising or consisting of SEQ ID No. 182, a HC CDR2 sequence comprising or consisting of SEQ ID No. 183, a HC CDR3 sequence comprising or consisting of SEQ ID No. 184, a LC CDR1 sequence comprising or consisting of SEQ ID No. 185, a LC CDR2 sequence comprising or consisting of SEQ ID No. 186 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 187, xv) a HC CDR1 sequence comprising or consisting of SEQ ID No. 192, a HC CDR2 sequence comprising or consisting of SEQ ID No. 193, a HC CDR3 sequence comprising or consisting of SEQ ID No. 194, a LC CDR1 sequence comprising or consisting of SEQ ID No. 195, a LC CDR2 sequence comprising or consisting of SEQ ID No. 196 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 197, xvi) a HC CDR1 sequence comprising or consisting of SEQ ID No. 202, a HC CDR2 sequence comprising or consisting of SEQ ID No. 203, a HC CDR3 sequence comprising or consisting of SEQ ID No. 204, a LC CDR1 sequence comprising or consisting of SEQ ID No. 205, a LC CDR2 sequence comprising or consisting of SEQ ID No. 206 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 207, xvii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 212, a HC CDR2 sequence comprising or consisting of SEQ ID No. 213, a HC CDR3 sequence comprising or consisting of SEQ ID No. 214, a LC CDR1 sequence comprising or consisting of SEQ ID No. 215, a LC CDR2 sequence comprising or consisting of SEQ ID No. 216 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 217, xviii) a HC CDR1 sequence comprising or consisting of SEQ ID No. 222, a HC CDR2 sequence comprising or consisting of SEQ ID No. 223, a HC CDR3 sequence comprising or consisting of SEQ ID No. 224, a LC CDR1 sequence comprising or consisting of SEQ ID No. 225, a LC CDR2 sequence comprising or consisting of SEQ ID No. 226 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 227,
xix) a HC CDR1 sequence comprising or consisting of SEQ ID No. 232, a HC CDR2 sequence comprising or consisting of SEQ ID No. 233, a HC CDR3 sequence comprising or consisting of SEQ ID No. 234, a LC CDR1 sequence comprising or consisting of SEQ ID No. 235, a LC CDR2 sequence comprising or consisting of SEQ ID No. 236 and a LC CDR3 sequence comprising or consisting of SEQ ID No. 237.
3. The antibody or antigen-binding portion thereof according to a preceding claim wherein said antibody or antigen-binding portion thereof comprises a HC variable region sequence comprising SEQ ID NO. 24 or a sequence with at least 75%, 80%, 85% or 90% sequence identity thereto and a LC variable region sequence comprising SEQ ID NO. 26 or a sequence with at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity thereto for example a LC variable region sequence comprising SEQ ID NO. 53, 54, 55, 56, 57 or 58.
4. The antibody or antigen-binding portion thereof according to claim 3 wherein said antibody or antigen-binding portion thereof has a) a HC variable region sequence comprising SEQ ID NO. 4 and a LC variable region sequence comprising SEQ ID NO. 6; b) a HC variable region sequence comprising SEQ ID NO. 14 and a LC variable region sequence comprising SEQ ID NO. 16; c) a HC variable region sequence comprising SEQ ID NO. 34 and a LC variable region sequence comprising SEQ ID NO. 36; d) a HC variable region sequence comprising SEQ ID NO. 44 and a LC variable region sequence comprising SEQ ID NO. 46; e) a HC variable region sequence comprising SEQ ID NO. 79 and a LC variable region sequence comprising SEQ ID NO. 81 or a LC variable region sequence comprising SEQ ID NO. 238; f) a HC variable region sequence comprising SEQ ID NO. 89 and a LC variable region sequence comprising SEQ ID NO. 91 or a LC variable region sequence comprising SEQ ID NO. 239; g) a HC variable region sequence comprising SEQ ID NO. 99 and a LC variable region sequence comprising SEQ ID NO. 101 or a LC variable region sequence comprising SEQ ID NO. 240; h) a HC variable region sequence comprising SEQ ID NO. 109 and a LC variable region sequence comprising SEQ ID NO. 111 or a LC variable region sequence comprising SEQ ID NO. 241 ; i) a HC variable region sequence comprising SEQ ID NO. 119 and a LC variable region sequence comprising SEQ ID NO. 121 ; j) a HC variable region sequence comprising SEQ ID NO. 129 and a LC variable region sequence comprising SEQ ID NO. 131 or a LC variable region sequence comprising SEQ ID NO. 242;
k) a HC variable region sequence comprising SEQ ID NO. 139 and a LC variable region sequence comprising SEQ ID NO. 141 or a LC variable region sequence comprising SEQ ID NO. 243;
L) a HC variable region sequence comprising SEQ ID NO. 149 and a LC variable region sequence comprising SEQ ID NO. 151 or a LC variable region sequence comprising SEQ ID NO. 244; m) a HC variable region sequence comprising SEQ ID NO. 159 and a LC variable region sequence comprising SEQ ID NO. 161 or a LC variable region sequence comprising SEQ ID NO. 245; n) a HC variable region sequence comprising SEQ ID NO. 169 and a LC variable region sequence comprising SEQ ID NO. 171 ; o) a HC variable region sequence comprising SEQ ID NO. 179 and a LC variable region sequence comprising SEQ ID NO. 181 or a LC variable region sequence comprising SEQ ID NO. 246; p) a HC variable region sequence comprising SEQ ID NO. 189 and a LC variable region sequence comprising SEQ ID NO. 191 or a LC variable region sequence comprising SEQ ID NO. 247; q) a HC variable region sequence comprising SEQ ID NO. 199 and a LC variable region sequence comprising SEQ ID NO. 201 a LC variable region sequence comprising SEQ ID NO. 248; r) a HC variable region sequence comprising SEQ ID NO. 209 and a LC variable region sequence comprising SEQ ID NO. 211 a LC variable region sequence comprising SEQ ID NO. 249; s) a HC variable region sequence comprising SEQ ID NO. 219 and a LC variable region sequence comprising SEQ ID NO. 221 ; or t) a HC variable region sequence comprising SEQ ID NO. 229 and a LC variable region sequence comprising SEQ ID NO. 231 a LC variable region sequence comprising SEQ ID NO. 250.
5. The antibody or antigen-binding portion thereof according to a preceding claim wherein said antigen-binding portion thereof is an scFv, Fv, heavy chain or single domain antibody.
6. An isolated canine antibody or antigen-binding portion thereof that binds to canine CD20 competing with an antibody or antigen-binding portion thereof according to a preceding claim.
7. The antibody or antigen-binding portion thereof according to a preceding claim wherein said antibody or antigen-binding portion thereof is conjugated to a therapeutic moiety.
8. The antibody or antigen-binding portion thereof according to claim 7 wherein said therapeutic moiety is a second antibody or antigen-binding portion thereof.
9. The antibody or antigen-binding portion thereof according to claim 8 wherein said second antibody or antigen-binding portion thereof binds to a different target.
10. The antibody or antigen-binding portion thereof according to a preceding claim wherein said antibody or antigen-binding portion thereof is conjugated to a further moiety selected from a half life extending moiety, label, cytotoxin, liposome, nanoparticle or radioisotope.
11. The antibody or antigen-binding portion thereof according to a preceding claim wherein said antibody or antigen-binding portion thereof is a-fucosylated.
12. A pharmaceutical composition comprising an antibody or antigen-binding portion thereof according to a preceding claim.
13. The antibody or antigen-binding portion thereof according to any of claims 1 to 11 or the pharmaceutical composition according to claim 12 for use in the treatment of disease.
14. A method of treating a condition mediated by B-cells in a canine subject in need thereof comprising administering an effective amount of the antibody or antigen-binding portion thereof of any of claims 1 to 11 or a pharmaceutical composition according to claim 12.
15. The antibody or antigen-binding portion thereof or the pharmaceutical composition according to claim 13 or the method of claim 14 wherein the disease is a disease mediated by B-cells, for example a B cell lymphoma, leukemia or an immune mediated disease.
16. The antibody or antigen-binding portion thereof or the pharmaceutical composition according to claim 13 or 15 or the method of claim 14 or 15 further comprising separately administering another therapeutic agent to the subject.
17. The antibody or antigen-binding portion thereof or the pharmaceutical composition according to claim 16 or the method of claim 16 wherein the therapeutic agent is a cytotoxic agent or a radiotoxic agent, an immunosuppressant or an immunological modulating agent, such as a cytokine or a chemokine.
18. A nucleic acid sequence that encodes an antibody or antibody antigen-binding portion thereof according to any of claims 1 to 11 .
19. The nucleic acid sequence according to claim 18 comprising a sequence selected from SEQ ID
NOs. 3, 5, 13, 15, 23, 25, 33, 35, 43, 45, 78, 80, 88, 90, 98, 100, 108, 110, 118, 120, 128, 130,
138, 140, 148, 150, 158, 160, 168, 170, 178, 180, 188, 190, 198, 200, 208, 210, 218, 220, 228,
230, 251 , 252, 253, 254, 255, 256, 257, 258, 259, 260, 261 , 262, 263, 264, 265, 266, 267, 268,
269, 270,271 , 272, 273, 274, 275, 276, 277, 278, 279, 280, 281 , 282, 283, 284, 285, 286, 287,
288, 289, 290, 291 , 292, 293, 294, 295, 296, 297, 298, 299, 300 or 301 .
20. A vector comprising a nucleic acid sequence according to any of claims 18 to 19.
21 . A host cell comprising the nucleic acid sequence according to any of claims 18 to 19 or a vector of claim 20.
22. A kit comprising an antibody or antigen-binding portion thereof according to any of claims 1 to 11 or a pharmaceutical composition according to claim 12.
23. The kit according to claim 22 further comprising a reagent for the detection of the antibody or antigen-binding portion thereof.
24. A method for making a canine antibody that binds CD20 comprising culturing the isolated host cell of claim 21 and recovering said antibody.
25. A method for making a canine antibody that binds CD20 comprising the steps of a) immunising a transgenic mouse that expresses a nucleic acid construct comprising canine heavy chain V genes and canine light chain V genes with CD20 antigen, b) generating a library of antibodies from said mouse and c) isolating an antibody from said library.
26. A method for detecting a CD20 protein or an extracellular domain of a CD20 protein in a biological sample from a canine subject, comprising contacting a biological sample with the antibody or antigen-binding portion thereof of any of claims 1 to 11 wherein said antibody or antigen-binding portion thereof is linked to a detectable label.
27. The method of claim 26, wherein the biological sample is a biopsy, tissue, blood, serum, plasma, or lymphatic fluid sample.
28. A method of inhibiting tumor growth or metastasis comprising contacting a tumor cell with an effective amount of the antibody or antigen-binding portion thereof according to any of claims 1 to 11 or pharmaceutical composition according to claim 12.
29. A method of killing a tumor cell expressing CD20, comprising contacting the cell with the antibody of any one of claims 1 to 11 or pharmaceutical composition according to claims 12, such that killing of the cell expressing CD20 occurs.
30. The method of claim 28 wherein the tumor cell is a canine tumor cell.
31. An antibody or antigen binding portion thereof wherein the epitope comprises one or more amino residues e.g. 1 to 10, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9 or 10, of the following amino residues or consists of the following amino residues ENLNLIKAPM (SEQ ID NO. 303, amino acid No. ISO- 159 in Seq ID NO: 2).
32. An antibody or antigen binding portion thereof according to claim 31 binds an epitope that comprises one or more amino residues, e.g. 1 to 19, e.g. 1 , 2, 3, 4, 5 ,6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18 or 19, of the following amino residues or consists of the following amino residues ITISHFFKMENLNLIKAPM (SEQ ID NO. 302, amino acid No. 141-159 in Seq ID NO: 2).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2108677.2A GB202108677D0 (en) | 2021-06-17 | 2021-06-17 | Therapeutic antibodies |
GBGB2202635.5A GB202202635D0 (en) | 2022-02-25 | 2022-02-25 | Therapeutic antibodies |
PCT/GB2022/051559 WO2022263864A1 (en) | 2021-06-17 | 2022-06-17 | Anti canine cd20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4355782A1 true EP4355782A1 (en) | 2024-04-24 |
Family
ID=82482910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22740459.7A Pending EP4355782A1 (en) | 2021-06-17 | 2022-06-17 | Anti canine cd20 antibodies |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4355782A1 (en) |
KR (1) | KR20240021959A (en) |
AU (1) | AU2022294198A1 (en) |
BR (1) | BR112023026592A2 (en) |
CA (1) | CA3224517A1 (en) |
WO (1) | WO2022263864A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US9228008B2 (en) * | 2004-05-28 | 2016-01-05 | Idexx Laboratories, Inc. | Canine anti-CD20 antibodies |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
US20140294819A1 (en) * | 2011-10-13 | 2014-10-02 | Nvip Pty Ltd | Canine/feline cd20 binding epitope and compositions for binding thereto |
AU2012328819B2 (en) | 2011-10-26 | 2017-08-03 | Elanco Tiergesundheit Ag | Monoclonal antibodies and methods of use |
GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
EA039434B1 (en) * | 2016-02-18 | 2022-01-27 | Эланко Юэс Инк. | Chimeric canine anti-cd20 antibody |
GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
-
2022
- 2022-06-17 WO PCT/GB2022/051559 patent/WO2022263864A1/en active Application Filing
- 2022-06-17 CA CA3224517A patent/CA3224517A1/en active Pending
- 2022-06-17 BR BR112023026592A patent/BR112023026592A2/en unknown
- 2022-06-17 EP EP22740459.7A patent/EP4355782A1/en active Pending
- 2022-06-17 AU AU2022294198A patent/AU2022294198A1/en active Pending
- 2022-06-17 KR KR1020247001684A patent/KR20240021959A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20240021959A (en) | 2024-02-19 |
BR112023026592A2 (en) | 2024-03-05 |
AU2022294198A1 (en) | 2023-12-21 |
CA3224517A1 (en) | 2022-12-22 |
WO2022263864A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7142618B2 (en) | caninized antibody | |
WO2020098734A1 (en) | Anti-tigit antibody and use thereof | |
JP2022024054A (en) | Novel monoclonal antibodies to cytotoxic t lymphocyte-associated protein 4 (ctla-4) | |
KR20190028534A (en) | Bispecific antigen binding molecules that bind to anti-GPRC5D antibodies, GPRC5D and CD3, and their uses | |
CN112912397A (en) | anti-CD 3 antibodies and uses thereof | |
TW201726166A (en) | Antibody agents specific for human CD19 and uses thereof | |
US20240043530A1 (en) | PVRIG Binding Protein And Its Medical Uses | |
CN111744013B (en) | Methods and pharmaceutical combinations for treating diseases using anti-TIGIT antibodies in combination with PD-1 inhibitors | |
JP2018532401A (en) | Novel anti-mesothelin antibodies and compositions containing them | |
US20220242968A1 (en) | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof | |
TWI830151B (en) | TRISPECIFIC ANTIBODY AGAINST GPRC5DxBCMAxCD3 AND USE THEREOF | |
KR20230169944A (en) | MAGE-A4 peptide-MHC antigen binding protein | |
WO2022263864A1 (en) | Anti canine cd20 antibodies | |
CN115996951A (en) | anti-CD 103 antibodies | |
KR20220004979A (en) | Engineered IGA Antibodies and Methods of Use | |
US20240018255A1 (en) | ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF | |
WO2024051804A1 (en) | Anti-ilt4 antibody and pharmaceutical use thereof | |
CN117677637A (en) | Anti-canine CD20 antibodies | |
TW202413414A (en) | Anti-ilt4 antibody and the pharmaceutical use thereof | |
TW202346337A (en) | Ilt3 and cd3 binding agents and methods of use thereof | |
EA045935B1 (en) | ANTIBODIES TO CD3 AND THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20240109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |